A systematic review, psychometric analysis and qualitative assessment of Generic Preference-Based Measures of Health in Mental Health Populations and the estimation of mapping functions from widely used specific measures by Brazier, J. et al.
This is a repository copy of A systematic review, psychometric analysis and qualitative 
assessment of Generic Preference-Based Measures of Health in Mental Health 
Populations and the estimation of mapping functions from widely used specific measures.




Brazier, J. orcid.org/0000-0001-8645-4780, Connell, J. orcid.org/0000-0003-4609-3911, 
Papaioannou, D. et al. (11 more authors) (2014) A systematic review, psychometric 
analysis and qualitative assessment of Generic Preference-Based Measures of Health in 
Mental Health Populations and the estimation of mapping functions from widely used 
specific measures. Health Technology Assessment, 18 (34). ISSN 1366-5278 
https://doi.org/10.3310/hta18340
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Brazier et al.
under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and 
extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of
advertising. Applications for commercial reproduction should be addressed to: NIHR 
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies 





Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 18 ISSUE 34 MAY 2014
ISSN 1366-5278
DOI 10.3310/hta18340
A systematic review, psychometric analysis and 
qualitative assessment of generic preference-based 
measures of health in mental health populations  
and the estimation of mapping functions from  
widely used specific measures
John Brazier, Janice Connell, Diana Papaioannou, Clara Mukuria,  
Brendan Mulhern, Tessa Peasgood, Myfawnwy Lloyd Jones,  
Suzy Paisley, Alicia O’Cathain, Michael Barkham, Martin Knapp,  
Sarah Byford, Simon Gilbody and Glenys Parry

A systematic review, psychometric
analysis and qualitative assessment of
generic preference-based measures of
health in mental health populations and
the estimation of mapping functions from
widely used specific measures
John Brazier,1* Janice Connell,1 Diana Papaioannou,1
Clara Mukuria,1 Brendan Mulhern,1 Tessa Peasgood,1
Myfawnwy Lloyd Jones,1 Suzy Paisley,1
Alicia O’Cathain,1 Michael Barkham,2 Martin Knapp,3
Sarah Byford,3 Simon Gilbody4 and Glenys Parry1
1Health Economics and Decision Science, School of Health and Related Research
(ScHARR), University of Sheffield, Sheffield, UK
2Centre for Psychological Services Research, University of Sheffield, Sheffield, UK
3Centre for the Economics of Mental and Physical Health, King’s College London,
London, UK
4Department of Health Sciences, University of York, York, UK
*Corresponding author
Declared competing interests of authors: John Brazier was a developer of the SF-6D and
Michael Barkham was a developer of the CORE-OM.
Disclaimer: This report contains transcripts of interviews conducted in the course of the research and




This report should be referenced as follows:
Brazier J, Connell J, Papaioannou D, Mukuria C, Mulhern B, Peasgood T, et al. A systematic
review, psychometric analysis and qualitative assessment of generic preference-based measures of
health in mental health populations and the estimation of mapping functions from widely used
specific measures. Health Technol Assess 2014;18(34).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA MRP–MRC
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Five-year impact factor: 5.804
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is
assessed for inclusion in the Database of Abstracts of Reviews of Effects.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: nihredit@southampton.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme or,
commissioned/managed through the Methodology research programme (MRP), and (2) they are of a sufficiently high scientific quality as
assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to
minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: www.hta.ac.uk/
This report
This issue of the Health Technology Assessment journal series contains a project commissioned/managed by the Methodology research
programme (MRP). The Medical Research Council (MRC) is working with NIHR to deliver the single joint health strategy and the MRP was
launched in 2008 as part of the delivery model. MRC is lead funding partner for MRP and part of this programme is the joint MRC–NIHR
funding panel ‘The Methodology Research Programme Panel’
To strengthen the evidence base for health research, the MRP oversees and implements the evolving strategy for high quality methodological
research. In addition to the MRC and NIHR funding partners, the MRP takes into account the needs of other stakeholders including the
devolved administrations, industry R&D, and regulatory/advisory agencies and other public bodies. The MRP funds investigator-led and needs-
led research proposals from across the UK. In addition to the standard MRC and RCUK terms and conditions, projects commissioned/managed
by the MRP are expected to provide a detailed report on the research findings and may publish the findings in the HTA journal, if supported
by NIHR funds.
The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors
and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments
on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the HTA
programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, the MRC, NETSCC,
the HTA programme or the Department of Health.
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Brazier et al. under the terms of a commissioning
contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and
study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement
is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre,
Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR  
Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK
NIHR Journals Library Editors
Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical 
School, UK
Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group),  
Queen’s University Management School, Queen’s University Belfast, UK
Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School,  
University of Warwick, UK
Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK
Dr Peter Davidson Director of NETSCC, HTA, UK
Ms Tara Lamont Scientific Advisor, NETSCC, UK
Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society,  
Newcastle University, UK
Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK
Professor Jane Norman Professor of Maternal and Fetal Health, University of Edinburgh, UK
Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts Professorial Research Associate, University College London, UK
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: nihredit@southampton.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
A systematic review, psychometric analysis and qualitative
assessment of generic preference-based measures of
health in mental health populations and the estimation of
mapping functions from widely used specific measures
John Brazier,1* Janice Connell,1 Diana Papaioannou,1 Clara Mukuria,1
Brendan Mulhern,1 Tessa Peasgood,1 Myfawnwy Lloyd Jones,1
Suzy Paisley,1 Alicia O’Cathain,1 Michael Barkham,2 Martin Knapp,3
Sarah Byford,3 Simon Gilbody4 and Glenys Parry1
1Health Economics and Decision Science, School of Health and Related Research (ScHARR),
University of Sheffield, Sheffield, UK
2Centre for Psychological Services Research, University of Sheffield, Sheffield, UK
3Centre for the Economics of Mental and Physical Health, King’s College London, London, UK
4Department of Health Sciences, University of York, York, UK
*Corresponding author
Background: Generic preference-based measures of health like the EQ-5D and SF-6D® are increasingly
being used in economic evaluation and outcome assessment. However, there are concerns as to whether
or not these generic measures are appropriate for use in people with mental health problems.
Objectives: The EQ-5D and SF-36® (including its derivatives the SF-12® and SF-6D) were assessed using
the psychometric criteria of validity and responsiveness using quantitative and qualitative methods.
Another aim was to estimate mapping functions between the EQ-5D and SF-6D and condition-specific
measures, where appropriate.
Design: Four studies were undertaken to examine the appropriateness of the measures: (1) a systematic
review of quantitative evidence on validity and responsiveness; (2) a further quantitative assessment of
these criteria using existing data sets; (3) a review of qualitative research on the quality of life of people
with mental health problems; and (4) qualitative semistructured interviews of people with a full range of
problems. A fifth study estimated mapping functions between mental health-specific measures and the
EQ-5D and SF-6D.
Setting: A choice of venue was offered for the interviews including the participant’s own home, a room
at the university or a centre frequently used by mental health services.
Participants: The interviews were undertaken with 19 people with a broad range of mental health
problems at varying levels of severity.
Main outcome measures: The reviews included the EQ-5D and SF-36 (and the SF-12 and SF-6D). The
psychometric analysis included the Hospital Anxiety and Depression Scale (HADS), Clinical Outcomes in
Routine Evaluation – Outcome Measure (CORE-OM), Generalised Anxiety Disorder Assessment (GAD-7),
General Health Questionnaire (GHQ-12) and Patient Health Questionnaire (PHQ-9).
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Results: (1) and (2) The EQ-5D and SF-36 achieved an adequate level of performance in depression, and
to some extent in anxiety and personality disorder. Results from the psychometric analyses in schizophrenia
and bipolar disorder have been more mixed. (3) A framework analysis of 13 studies identified six major
themes. (4) The interview data fitted the themes from the review well and resulted in minor modifications
to the themes. The final set of themes comprised: well-being and ill-being; control, autonomy and choice;
self-perception; belonging; activity; hope and hopelessness; and physical health.
Conclusions: The EQ-5D and SF-36 achieved mixed results in the quantitative testing against psychometric
criteria. The qualitative analysis suggests this is because they provide a very limited coverage of themes
identified by people with mental health problems. Recommendations for future work include the
development of new preference-based measures in mental health that are based on, or substantially
revise, an existing measure.
Funding: The Medical Research Council.
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There has been an increasing use of the EQ-5D and SF-36® (and its derivative the SF-6D®) in the
economic evaluation of health-care interventions. These generic measures can produce health-state utility
values on a scale from 0 to 1 in order to calculate quality-adjusted life-years (QALYs). These QALY
calculations are used by policy-makers [e.g. the National Institute for Health and Care Excellence (NICE)] to
assess the cost-effectiveness of interventions in terms of their cost per QALY gained. Generic measures of
health are also being used to assess the outcome of care in routine practice (e.g. the NHS Patient Reported
Outcome Measures programme). There are concerns that generic measures have been primarily designed
for physical health problems and miss important aspects of the impact of mental health problems on the
quality of people’s lives. Another concern is that even where generic measures are found to be
appropriate, they are often not used in clinical studies.
Aims and objectives
This project examines in detail the appropriateness of the EQ-5D and the SF-36 and its derivatives in
populations with mental health problems in terms of their validity (construct and content) and
responsiveness. This research considers groups of people with mental health problems, including those
with common mental health problems (e.g. mild to moderate depression, anxiety, obsessive compulsive
disorder and panic disorders), severe and complex non-psychotic disorders (e.g. personality disorder), and
schizophrenia and other psychotic disorders. For those conditions where the EQ-5D and/or SF-36 is found
to be valid, a further aim is to estimate functions to predict their scores from mental health-specific
measures commonly used in clinical trials and other studies (also known as mapping or cross- walking).
Methods and results
The validity of the EQ-5D and SF-36 (including its derivatives, the SF-12® and SF-6D) was examined using
the psychometric criteria of validity and responsiveness. Validity is the extent to which an instrument
measures the concept of interest, and in this case it is the extent to which EQ-5D and SF-36 (and its
derivatives) reflect the impact of mental health problems on people’s health-related quality of life,
whether or not they use services. Construct and content validity are assessed in this research. Construct
validity is assessed in terms of the ability of these measures to reflect known-group differences
(or discriminant validity) and converge with other indicators of the concept (convergent validity).
Responsiveness is the ability to reflect change in the population over time. Evidence on construct validity
was obtained through the reviewing of published evidence and original analysis of seven existing data sets.
Content validity assesses the degree to which the items of the measures represent the domains of interest,
in terms of the impact of mental health problems on the quality of people’s lives. Qualitative evidence on
content validity was obtained from a systematic review of the literature and analyses of interviews of people
with mental health problems.
In all, four studies were undertaken to examine the appropriateness of the measures, and a fifth study to
estimate mapping functions between EQ-5D and SF-6D and commonly used mental health-specific measures.
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Study 1: a systematic review of the validity and responsiveness
of the EQ-5D, SF-36, SF-12 and SF-6D
The aim of this study was to assess research evidence on the validity and responsiveness of the SF-36,
SF-12, SF-6D and EQ-5D in mental health conditions.
Methods
Systematic reviews were undertaken in five mental health conditions. Ten databases were searched from
inception to August 2009. Studies were appraised and data extracted. A narrative synthesis was performed
on known-group validity, convergent validity (strength of association with related measures such as
symptoms or functioning) and responsiveness (e.g. changes in scores in responders/non-responders to
treatment and correlation with changes in related measures).
Results
For schizophrenia, the majority of evidence related to the SF-36 (25 studies) and EQ-5D (nine studies).
Both measures demonstrated known-group differences but this was mostly limited to differences between
individuals with schizophrenia and the general population. Contradictory results were found in studies
measuring convergent validity and responsiveness using clinical measures of symptom severity. For bipolar
disorder, 23 studies were identified, almost exclusively on the SF-36, which was able to detect known
differences in symptom severity and correlated strongly with clinical measures of depression, though
weakly with measures of mania. For personality disorders, the majority of studies (six out of nine) related
to the EQ-5D, which reflected known-group differences and responsiveness. For depression and anxiety,
23 EQ-5D and eight SF-6D studies were identified. Both measures demonstrated good convergent validity
and responsiveness for depression; however, the results on known-group differences may be driven by the
presence of comorbid depression in patients with anxiety disorders.
Study 2: assessing the validity and responsiveness of the EQ-5D
and SF-6D using existing data sets
The purpose of Study 2 was to generate further evidence on the validity and responsiveness of the EQ-5D
and SF-6D in anxiety, depression and schizophrenia samples by undertaking secondary analysis of available
data sets.
Methods
Psychometric performance of the generic preference-based measures was assessed in comparison with
mental health-specific measures using samples taken from seven patient data sets (total sample size = 5748
patients). For anxiety and depression, the EQ-5D was assessed in comparison with the Hospital Anxiety and
Depression Scale (HADS), and the SF-6D was assessed in comparison with the Clinical Outcomes in Routine
Evaluation – Outcome Measure (CORE-OM). For the schizophrenia samples, the EQ-5D and SF-6D were
both assessed using the Brief Psychiatric Rating Scale – Expanded (BPRS-E) and Positive and Negative
Syndrome Scale (PANSS). Tests of acceptability (in terms of missing data and response rates), construct
validity and responsiveness were carried out.
Results
Results support the findings from the review that both the EQ-5D and SF-6D are valid in common mental
health disorders, particularly in depression but also in anxiety to a lesser extent. There was evidence that
both measures were acceptable to respondents, are moderately correlated with the condition-specific
instruments used, and can significantly discriminate between severity groups. Both measures also displayed
a moderate level of responsiveness to change. The results in schizophrenia were less clear. The EQ-5D
score appears able to reflect some symptoms of schizophrenia but evidence for the convergent validity of
the SF-6D was limited. Both measures were able to discriminate between severity groups, but neither
measure appeared responsive to change.
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Study 3: estimating mapping functions between mental
health-specific measures and the EQ-5D and SF-6D
The aim of this study was to provide mapping functions to predict EQ-5D or SF-6D values from
condition-specific measures used in common mental health conditions, where the generic measures
were found to be valid in Studies 1 and 2.
Methods
Using data from four studies (n = 286, n = 475, n = 394 and n = 213 patients respectively) available
to the authors of this report, mapping functions were estimated by regression between the EQ-5D and the
HADS, and between the SF-6D and the HADS, General Health Questionnaire (GHQ-12), Patient Health
Questionnaire (PHQ-9), Generalised Anxiety Disorder Assessment (GAD-7) and CORE-OM. EQ-5D and SF-6D
scores and dimension-level response were used as independent variables. For each mental health-specific
measure, total scores, dimension scores and item response were entered as dependent variables. For
models with dimension scores and item-level responses, additive models were fitted to the data, with
interactions and squared terms explored for models with dimension scores. For the EQ-5D and SF-6D
scores, ordinary least squares regression was used to estimate the models, and Tobit models were explored
for the EQ-5D (owing to the presence of a large proportion of responders scoring 1). Multinomial models
were also fitted to the models with dimension-level response as independent variables. The performance of
the models was examined using R2 (where appropriate), Bayesian information criterion, root-mean-square
error and the ability to predict scores across severity groups.
Results
The results indicated that commonly used condition-specific measures for depression and anxiety are not
good predictors of EQ-5D and SF-6D scores. The HADS was found to predict EQ-5D scores poorly in
two data sets; it substantially overpredicted at the worst severity and underpredicted at the lowest severity.
The HADS and other measures, notably the CORE-OM, were better able to predict the SF-6D, though the
mapping functions continued to suffer from some degree of over- and underprediction towards the ends
of the ranges.
Study 4: a synthesis of qualitative research on the quality of life
of people with mental health problems
The aim of study 4 was to find out from people with mental health problems how their problems impact
on their quality of life, using a review of the qualitative literature. This review provided the basis for the
topic guide used in semistructured in-depth interviews and an initial framework for their analyses.
Methods
Our research firstly involved a systematic review of qualitative studies undertaken with people with mental
health problems. Studies were only included where they reported the views of people with mental health
problems and supported these with participant quotes. Participants had to be either diagnosed or
attending an establishment for people with mental health problems. Extensive searching was undertaken
using an iterative approach up to April 2012. Framework analysis was used to allow the identification of
common and variable patterns of themes within and across different studies. The searching and reviewing
was undertaken by two researchers. A multidisciplinary team met regularly, in addition to meetings with
clinicians and a user representative to discuss and challenge the inclusion and exclusion criteria, thematic
framework, and conceptual interpretations and conclusions.
Results
A framework analysis of 13 studies revealed six major themes: well-being and ill-being; control, autonomy
and choice; self-perception; belonging; activity; and hope. In particular, it underlined the complexity of
the measurement of quality of life in people with mental health problems and the difficulty in separating
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the symptoms of mental health from other aspects of life quality. One of the strongest themes was the
importance of a sense of belonging, derived from good quality relationships. However, relationships and
activity can also have a negative impact. A limitation of the review was that available studies focused on
quality of life of people with severe and enduring mental health problems, particularly schizophrenia rather
than affective disorder. This is addressed in the interview study.
Study 5: results from qualitative semistructured interviews of
people with mental health problems
The purpose of the fifth study was to examine further the domains of quality of life that are important to
people with mental health problems through interviews, and to confirm or otherwise add to the themes
found in the review. To address one of the limitations of the literature review, care was taken to recruit
people with a full range of problems including those with mild to moderate affective problems.
Methods
Qualitative semistructured interviews were conducted with 19 people with a broad range of mental health
problems at varying levels of severity. Participants were recruited through the local Improving Access to
Psychological Therapies (IAPT) service for milder depression and anxiety, and through two community
mental health teams who identified those with more severe problems, including complex non-psychotic
disorders and psychotic disorders. The interviews were analysed thematically using framework analysis.
The themes from the review made up the initial themes of the framework.
Results
Despite widening the types and severity of mental health problems studied, our interview data fitted well
with the themes from the review. Any differences tended to be within the themes and related to the
degree of impact of the themes on different levels of severity, chronicity and diagnosis. With some
exceptions, those with severe chronic difficulties were more likely to talk about losses and things that took
quality away from life, whereas those with moderate or relatively short-lived problems spoke of the things
that added quality to life. It was also found that depression had a greater impact on quality of life than
other problems such as anxiety, though coping mechanisms could have a detrimental effect on other areas
of life (e.g. avoidance). The only change made to the themes was that physical health was found to be
more important among the interviewees than suggested by the review, so this was added as a seventh
theme, as opposed to a minor sub-theme as in the review. Another important finding was a conflict
between the short-term stress and effort required for a fuller life (e.g. work or social activity) and the
longer-term benefits.
The content of the EQ-5D and SF-6D has been reviewed against the seven themes identified in the
qualitative research and the need to cover both positive and negative aspects. In summary, the EQ-5D
covers little of the content of these seven themes because of its focus on physical health. Only physical
health is covered, and, to some extent, activity, which is included in a rather crude way through usual
activities. The EQ-5D covers ill-being in terms of depression and anxiety but not well-being. The SF-36
covers more, through having a multi-item dimension on mental health and a vitality dimension that
includes more aspects of well-being and ill-being, and some aspects of social functioning. On the other
hand, like the EQ-5D, it fails to include the psychological responses of people with mental health problems
to occupational and social activities such as stress, self-perception and control, autonomy and choice, and
hope and hopelessness. These generic measures do not contain a sufficient proportion of the domains
identified by people with mental health problems in the qualitative research.
SCIENTIFIC SUMMARY
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Conclusions
The EQ-5D and SF-36 achieve an adequate level of performance in terms of the classical psychometric
tests for validity and responsiveness in depression and, to some extent, in anxiety and personality disorder.
The results of the mapping work, however, raise some concerns as to whether or not the EQ-5D in
particular is able to fully reflect the specific impact of common mental health problems. Results from the
psychometric analyses were more mixed in schizophrenia and bipolar disorder, with a suggestion that the
EQ-5D and SF-36 may be reflecting depression rather than other consequences of these conditions.
Although important issues were identified within the quantitative evidence, it was unclear why the evidence
appears so mixed in relation to the EQ-5D and SF-36. This was the rationale for undertaking the qualitative
research as this provides evidence on the content validity of these measures in people with mental health
problems. This found that the generic measures did not cover many of the theories identified in the
qualitative research.
Although this project has been comprehensive in the way it has adopted a multimethod approach and
sought to use the best available evidence, it does have a number of limitations. Many of the quantitative
studies reviewed were limited in terms of size and coverage for conditions. The studies are normally
designed for other purposes, and the measures used to assess construct validity and responsiveness were
often clinical measures of symptoms that may not provide a good indicator of the concepts of interest.
Although the qualitative work was intended to provide a more in-depth picture of the problem, the
population of people with mental health problems in the qualitative research was not comprehensive
despite an extensive review of the literature and an attempt to recruit across the spectrum of conditions for
the interviews. Furthermore, the samples were influenced by the clinicians used to help recruit participants.
Future research recommendations
l Further testing of construct validity and responsiveness of these generic measures should be
undertaken using a larger number of data sets.
l The analysis of content validity should be extended to existing condition-specific outcome measures
used in mental health research. This is important for guiding the choice of mental health measures for
use in research.
l There is a case for the development of a preference-based mental health measure. This could be an
enhanced version of an existing generic measure, created by adding extra dimensions (i.e. ‘bolt-ons’),
or a new specific mental health measure for calculating QALYs, which might include one or two
physical domains but would focus on the themes identified in this research.
l The qualitative research needs to be extended to those conditions not well represented (such as
obsessive compulsive disorder) and should involve participants recruited through different channels to
avoid the risk of selection bias that can result from a reliance on professionals.
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Chapter 1 Background and introduction
There has been a shift in mental health services from an emphasis on treatment focused on reducingsymptoms based on a narrow notion of health and disease, to a more holistic approach which takes into
consideration both well-being and functioning.1,2 Mental health services in the UK, for example, are now
including the routine assessment of patient-reported outcomes in psychological services [e.g. the Improving
Access to Psychological Therapies (IAPT) initiative and the Department of Health’s Patient Reported
Outcome Measures (PROMs) programme]. At the same time, there has been an increasing use of generic
measures of health, such as the EQ-5D, SF-36® (and its derivatives) and HUI3 in the economic evaluation of
health-care interventions. These generic preference-based measures produce health-state utility values on
a scale from 0 to 1 in order to calculate quality-adjusted life-years (QALYs). These QALY calculations are
used by policy-makers including the National Institute for Health and Care Excellence (NICE) to assess the
cost-effectiveness of interventions in terms of their cost per QALY gained.3–10 These generic measures of
health are designed for both physical and mental health problems; however, some argue that they are not
suitable for people with more severe mental health problems, including psychosis.11,12
In this report we present the findings of a research project examining the appropriateness of these
generic measures for assessing the impact of mental health problems on quality of life. This chapter begins
by describing the EQ-5D and SF-36 (and its derivative, the preference-based SF-6D® index). It goes on to
consider the different definitions of quality of life and the problems of measuring such a subjective
concept, in order to provide a broader context for the work being presented in this report. It then
considers how the key measurement concept of validity is approached in the literature before providing
an overview of the research undertaken for the report.
Generic preference-based measures
Many agencies around the world (e.g. NICE) recommend assessing the efficiency of new health-care
interventions in terms of their incremental (or extra) cost per QALY gained.4–10 The QALY combines survival
and health-related quality of life into a single measure of value. The number of QALYs is calculated by
multiplying survival in life-years by a value assigned to those years, which is known as a health-state utility
value. Full health has a value of 1 and states equivalent to being dead are given a value of 0, with states
worse than dead being negative.13 While the QALY was initially used mainly to assess the benefits of
life-saving treatments such as coronary artery bypass graft,14 over time it has been applied to assess the
benefits of interventions aimed primarily at improving quality of life rather than quantity, including
interventions for people with mental health conditions. The purpose of using a measure such as the QALY
is to inform comparisons not only between treatments, but also between programmes of care across
physical and mental health conditions.
This report appraises two generic preference-based measures used to generate values for health-related
quality of life (HRQoL) on the zero-to-one QALY scale, and considers whether or not they are appropriate
in people with mental health problems. The most commonly used measures for valuing health states in
order to generate QALYs are the generic preference-based measures of health, such as the EQ-5D,15
SF-6D,16 HUI317 and Quality of Well-Being Scale.18 Generic preference-based measures have two parts:
one is a classification for describing health across a set of dimensions or domains, and the second is an
algorithm for assigning values to each health state defined by the classification. The EQ-5D, for example,
has five dimensions, each with three levels that together define 243 possible health states. A respondent is
assigned a health state through their completion of a short questionnaire in which they indicate the level
best describing their health on each dimension. The scoring algorithm is provided by valuations obtained
from members of the general public using a valuation technique. In the case of the EQ-5D, the valuation
technique is called time trade-off (TTO), whereby respondents are asked how many years in full health are
equivalent to a longer period in an ill-health state.9 The focus for this report, however, is not the method
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of scoring per se, but the description of health used by these instruments, as this largely determines the
appropriateness of their use in mental health.
The EQ-5D has been selected as the most widely used preference-based measure and the one that is
preferred by NICE in health technology assessment submissions and the Department of Health PROMs
programme. The SF-36 and its derivatives (the SF-12® and the preference-based SF-6D) have also been
selected because the SF-36 is another widely used generic measure of health, and the SF-6D is accepted
by a number of other agencies around the world.3–10
EQ-5D
The EQ-5D questionnaire comprises five dimensions: mobility, self-care, usual activities, pain and anxiety/
depression (Table 1). These can be seen as a combination of physical functioning (mobility, self-care), mental
health (depression and anxiety), social functioning (which may be included in usual activities) and symptoms
(pain and discomfort). Respondents are asked to report their level of problems (no problems, some/moderate
problems or extreme problem/unable to do) on each dimension to provide a position on the EQ-5D health-state
classification system. Responses can be converted into one of 243 different health states [ranging from no
problems on any of the dimensions (11111) to severe problems on all five dimensions (33333)], each with its
own preference-based score. Preference-based scores are determined by eliciting strength of preference data,
that is, by establishing which health states are preferred from a sample of the general public. Preferences
are elicited using the TTO technique, which involves asking participants to consider the relative lengths of
time in full health (i.e. number of life-years) they would be willing to sacrifice to avoid poorer health states.
The scoring algorithm, or social tariff, for the UK is based on TTO responses of a random sample (n = 2997) of
non-institutionalised adults. Values are anchored by ‘1’ representing full health and ‘0’ representing the state
‘dead’, with states ‘worse than death’ bounded by ‘−1’. Utility values from the UK EQ-5D tariff range from
−0.59 to 1.15 The EQ-5D is often administered with the EQ visual analogue scale (EQ-VAS), which asks
respondents to indicate their health state on a rating scale from worst health imaginable to best imaginable.
TABLE 1 EQ-5D classification
Dimension Level Description
Mobility 1 No problems walking about
2 Some problems walking about
3 Confined to bed
Self-care 1 No problems with self-care
2 Some problems washing or dressing self
3 Unable to wash or dress self
Usual activities 1 No problems with performing usual activities (e.g. work, study, housework,
family or leisure activities)
2 Some problems with performing usual activities
3 Unable to perform usual activities
Pain/discomfort 1 No pain or discomfort
2 Moderate pain or discomfort
3 Extreme pain or discomfort
Anxiety/depression 1 Not anxious or depressed
2 Moderately anxious or depressed
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SF-36 and SF-12
The SF-36 is a generic health status profile measure consisting of eight dimensions of general health,
bodily pain, physical functioning, role-physical, mental health, vitality, social functioning and role-emotional
(Table 2).19,20 These eight dimensions produced separate scores by taking a simple summation of item
responses and applying a linear transformation to place them onto a 0 to 100 scale. There is also an
alternative normalised scoring system generating a mean normative score of 50, with 10 points
representing a standard deviation (SD) in a normal population. Physical and mental health component
summary scores (PCS and MCS) can also be generated from these dimension scores.10 The SF-1211 is a
shortened version of the SF-36, containing 12 SF-36 items, and also produces PCS and MCS scores. These
measures are two of the most widely used generic measures of health and have been validated in many
conditions and settings. However, the SF-36 and SF-12 cannot be used in their standard form in economic
evaluation because the scoring method is not preference-based and, therefore, cannot be used to
generate QALYs. Furthermore, they produce a profile of scores and cannot be combined with survival, so
they provide no single measure of effectiveness required for assessing cost-effectiveness. For this reason,
a preference-based measure called the SF-6D has been derived from the SF-36.
SF-6D
The SF-6D provides a means of translating the SF-36 or the SF-12 into a preference-based single index.16,21
The SF-6D reduces the eight dimensions of the SF-36 to six: physical functioning, role limitations, social
functioning, pain, mental health and vitality (Table 3). Each dimension has four, five or six levels, giving a
total of 18,000 possible health states. The values attached to each level and dimension generated by the
TABLE 2 Content of the SF-36
Dimension
No. of








10 Extent to which health limits physical activities such
as self-care, walking, climbing stairs, bending,
lifting, and moderate and vigorous exercises
3 ‘Yes limited a lot’





4 Extent to which physical health interferes with
work or other daily activities, including
accomplishing less than wanted, limitations
in the kind of activities, or difficulty in
performing activities
2 Yes/No
Bodily pain 2 Intensity of pain and effect of pain on normal
work, both inside and outside the home
5 and 6 ‘None’ to ‘very




5 Personal evaluation of health, including current
health, health outlook, and resistance to illness
5 ‘All of the time’ to
‘none of the time’
Vitality 4 Feeling energetic and full of life vs. feeling tired
and worn out
6 ‘All of the time’ to
‘none of the time’
Social
functioning
2 Extent to which physical health or emotional
problems interfere with normal social activities
5 ‘Not at all’ to
‘extremely’ and
‘All of the time’ to




3 Extent to which emotional problems interfere with
work or other daily activities, including decreased
time spent on activities, accomplishing less and not




5 General mental health, including depression,
anxiety, behavioural–emotional control, general
positive affect
6 ‘All of the time’ to
‘none of the time’
Taken from Brazier J, Deverill M, Harper R, Booth A. A review of the use of health status measures in economic evaluation.
Health Technol Assess 1999;3(9).20
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1 Your health does not limit you in vigorous activities
2 Your health limits you a little in vigorous activities
3 Your health limits you a little in moderate activities
4 Your health limits you a lot in moderate activities
5 Your health limits you a little in bathing and dressing
6 Your health limits you a lot in bathing and dressing
Role
limitations
1 You have no problems with your work or other regular daily activities as a result of your
physical health or any emotional problems
2 You are limited in the kind of work or other activities as a result of your physical health
3 You accomplish less than you would like as a result of emotional problems
4 You are limited in the kind of work or other activities as a result of your physical health and
accomplish less than you would like as a result of emotional problems
Social
functioning
1 Your health limits your social activities none of the time
2 Your health limits your social activities a little of the time
3 Your health limits your social activities some of the time
4 Your health limits your social activities most of the time
5 Your health limits your social activities all of the time
Pain 1 You have no pain
2 You have pain but it does not interfere with your normal work (both outside the home
and housework)
3 You have pain that interferes with your normal work (both outside the home and housework)
a little bit
4 You have pain that interferes with your normal work (both outside the home and housework)
moderately
5 You have pain that interferes with your normal work (both outside the home and housework)
quite a bit
6 You have pain that interferes with your normal work (both outside the home and housework)
extremely
Mental health 1 You feel tense or downhearted and low none of the time
2 You feel tense or downhearted and low a little of the time
3 You feel tense or downhearted and low some of the time
4 You feel tense or downhearted and low most of the time
5 You feel tense or downhearted and low all of the time
Vitality 1 You have a lot of energy all of the time
2 You have a lot of energy most of the time
3 You have a lot of energy some of the time
4 You have a lot of energy a little of the time
5 You have a lot of energy none of the time
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classification system were derived from standard gamble valuations for a sample of 249 of these health
states. Face-to-face interviews were conducted with a representative sample of 611 members of the UK
population.16 States were valued by asking respondents to choose between each of five SF-6D states
(imagining they remained in those states for the rest of their lives), versus a gamble between the best and
‘pits’ health states. Respondents were then asked to value the worst state in relation to immediate death.
The valuations for the SF-6D were derived from a linear random-effects model, and ranged from 0.29 to
1.0 (full health) (see www.shef.ac.uk/scharr/sections/heds/mvh/sf-6d).16
What is ‘quality of life’?
The question addressed in this report is whether the EQ-5D or SF-6D are able to reflect the way mental
health problems impact on the quality of people’s lives. Before addressing this question it is helpful to
consider more broadly the way quality of life can be defined. Quality of life has been described as an
amorphous concept for which there is no widely accepted theory or measurement instrument.22 The area
is bedevilled by the absence of any accepted gold standard. There are many different views or models of
quality of life and the more influential ones in health include: objective indicators, needs satisfaction,
subjective well-being, capabilities, psychological health and subjective health or HRQoL. These views are
not independent and often overlap. This section provides a brief description of these different accounts in
order to understand where EQ-5D and SF-36 fit into the literature, and to provide some background for
interpreting some of the findings presented from the qualitative research reported in Chapters 5 and 6.
Objective indicators
A tension exists in quality-of-life measurement over whether it should have a subjective or objective
orientation. A more objective approach may place its emphasis on income, living conditions, access to
resources, participation in occupational and social roles,23,24 or the presence or absence of a medical
condition or symptom. While objective measures have an important place in the broader quality-of-life
literature, within health there has been an increasing emphasis on the importance of the patient’s
perspective and this has been assumed to imply a move away from objective measures. This has been
partly because many of the commonly used objective indicators like income have been found to be only
weakly related to well-being. It is also because objective indicators, by their nature, take a top-down,
paternalistic approach, rather than reflecting what individuals might perceive to be important to their
quality of life. There has been a similar movement in health care, with a move away from using clinical
indicators to measure the outcome of health care towards a more user-focused approach using subjective
measures of health and well-being.
Needs satisfaction
There has been a tradition of defining quality of life in terms of the extent to which human needs are met.
This is based on Maslow’s25 hierarchy of needs necessary for human existence (e.g. food, drink and shelter,
social and belonging, status and self-esteem and self-actualisation). Once the basic needs for food, drink
and shelter are met, then human beings can look to fulfil higher needs such as control, autonomy,
pleasure and self-realisation.26,27 These have been found to correlate highly with life satisfaction. This
approach continues to be influential in the development of measures, including recent work on an
outcome measure for social care.28
Subjective well-being
It can be argued that in the developed world, where basic needs have been met, a focus on objective or
needs-based measures should be replaced by perceived well-being.29 Economists in the 19th century saw
utility as a cardinal indicator of happiness and this comes from the utilitarian Benthamite tradition
concerned with maximising the happiness of the greatest number.30 There has been something of a revival
in using happiness and other measures of well-being in public policy in psychology and economics, such as
through the work of Kahneman and others.31 In its modern formulation, subjective well-being is seen to
have two components. One is a hedonistic view based on how an individual feels in any given moment.
It has typically been assessed using simple items asking people to rate their current level of happiness.32
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The second is a more evaluative concept based on a reflection on how satisfied we are with our lives,
and this may include past and present happiness and future expectations, and embrace notions of
self-fulfilment, realisation or actualisation. This has typically been assessed using items that ask people to
rate how satisfied they are with their life and aspects of it.33
The revival of subjective well-being in economics has in part been a response to criticisms of measures of
benefit used by economists in economic evaluations such as the QALY. By the start of the 20th century,
mainstream economics had moved away from an experiential view of utility to one based on preference
satisfaction.34 This is best seen in the marketplace where individuals make choices between goods and
services on the basis of what they most desire. They are regarded as autonomous and perfectly informed
individuals who will choose the mix of goods and services that maximises their well-being. Where such
‘revealed’ preferences are not available, as is often the case for health, respondents are asked to state
strength of preference for different states of the world. This is a preference-based or decision-based notion
of utility. However, there is a large body of evidence that consumers do not necessarily know what will
maximise the well-being that they eventually experience.31 While this debate has not been important in the
general quality-of-life literature, it has been highly controversial in health economics since the EQ-5D and
SF-6D are scored using the preferences of the general public.35
Capabilities
The notion of capability was developed by Sen36 in response to what he regarded as the narrow
perspective of economists in the way they assessed value. He argues that subjective well-being and
preference-based utility both fail to consider all the factors that matter for informing public policy. Again,
this is an economics-focused debate, but one that has important implications later in this report for the
interpretation of qualitative data on what seems to matter to people with mental health problems
(see Chapters 5 and 6).
Sen36 offers a framework for moving from the purchase of goods and services (including health care) to
utility or well-being. He proposes that along the way individuals are transformed by the benefits of the
goods or service; for example, a bicycle will confer improved functioning in terms of mobility.36,37
Economics usually ignores the impact of what a person has on a person’s functioning, and focuses on
utility as reflected in their choices. Sen takes it one step further for policy-making, as he argues that public
policy is not concerned with functioning per se; so, in the case of the bike, public policy is concerned not
with whether or not the person chooses to use the bike, but simply the fact that they are able to function
in a particular way. This idea of capability offers someone the choice to be able to ‘do’ or to ‘be’. The
object of public policy is to provide opportunities and not to make people do one thing or another. Sen
accepts that for some basic capabilities this distinction between capability and functioning may not be
important as individuals have little choice, but in large areas of public policy it will be important to
separate out these concepts.36
Sen did not prescribe a particular set of capabilities or a way to operationalise the concept. There have
been attempts by others, with the most common being attempts by experts to construct a list of those
functionings they think are important, covering basic capabilities through to higher-level issues around
human rights and well-being.38 These tend to be more like the objective lists described earlier and there
has been little attempt to score them. In health economics, examples of capability measures include the
recently developed ICECAP-O and ICECAP-A, though these use stated preferences to generate the scores.
The items were developed from interviews with members of the general public, and attempts to capture
the idea of capability by using terms such as ‘I am able to be . . .’ or ‘I can have . . .’.39,40 Although there
may be doubts about whether or not this is truly a measure of capability (including the way it uses
preferences in the scoring), it is an important development in terms of going beyond health. This measure
will be considered again in the light of the findings of this research in Chapter 6.
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Psychological well-being
This is a broad category of constructs that covers aspects of personality that include morale, self-esteem
and self-concept, sense of coherence, self-efficacy, autonomy and control. This list often includes aspects
of subjective well-being, but we have presented them separately as they can be seen as mediating
variables rather than necessarily determining quality of life in their own right. Indeed, it has been proposed
that there should be a model of quality of life based on these psychological factors and the way they
explain variations in subjective well-being through cognitive mechanisms.41,42 They clearly have an
important role in the way people cope with and adapt to problems with their health. Knowledge of the
precise mechanisms and the support for different models, however, are limited. It is interesting to note
that these variables have also been found in measures of quality of life and capabilities as dimensions in
their own right.27,39,40
Health and health-related quality of life
There has been a separate tradition of measuring perceived health in health services research and health
economics, and the EQ-5D and SF-36 have come out of this tradition.43 Health can be seen as a part of
quality of life, and is usually seen as narrower than quality of life. However, some definitions of health are
very broad, such as the widely cited World Health Organization (WHO) statement, set out in its original
constitution, that health is: ‘A state of complete physical, mental and social well-being, and not merely the
absence of disease and infirmity’.44 This too is a rather amorphous construct. The field is made more
complicated by the idea of HRQoL, whereby the concern is not with health per se but those aspects of
quality of life that are related to a person’s health. Given the central role of health in many people’s lives,
this is likely to cover many different aspects of quality of life. A definition of HRQoL provided by
researchers, representing what many people in the field mean by HRQoL, is: ‘A person’s subjective
perception of the impact of health status, including disease and treatment, on physical, psychological and
social functioning and well-being’.45 This is also a broad definition, and as a result, the content of HRQoL
measures varies widely and is no less wide-ranging in coverage than many measure purporting to measure
quality of life; indeed, they are often wider.
Discussion of views of quality of life and their implications for this report
This section has demonstrated that there are many different and often competing views of quality of life:
objective versus subjective accounts; what people do and feel versus capability; well-being versus
psychological well-being (e.g. self-esteem, autonomy, choice and so forth); and narrow versus broader
notions. No measure can capture all these elements and ultimately there is a value judgement to be made
regarding what matters to policy-makers. It is also the case that these views are not entirely separable, so,
for example, needs satisfaction covers objective aspects alongside those concerned with psychological
well-being. In practice, measures often contain items from more than one of these views of quality of life.
The EQ-5D, for example, covers negative aspects of well-being (i.e. depression and anxiety) and objective
aspects such as mobility and self-care. Items of the SF-36 cover well-being (i.e. mental health and vitality),
objective aspects (i.e. physical function) and psychological health (i.e. general health perception).
The lack of an agreed view or clear definition means that any attempt to measure quality of life and
mental health-related quality of life is fraught with difficulty. This rules out the application of criterion
validation in this field, whereby a measure is compared to some accepted gold standard. This has been a
source of frustration for researchers and has led to some scepticism as to the value of trying to measure
quality of life.46 However, the primary aim of health services is to improve the quality (health related) and
quantity of life, so it is imperative for policy-relevant research to have measures of what matters in the lives
of people who use health services. The aim of this report is to examine the extent to which the EQ-5D and
SF-36 achieve this through the application of qualitative and quantitative methods.
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The appropriateness of the EQ-5D and SF-36 in mental health
Measures of health or HRQoL can be generic, or specific to a patient group defined in various ways
(e.g. by a medical condition). The EQ-5D and SF-36 are generic measures that are intended to reflect a
core set of domains relevant to all groups of patients (such as mobility, self-care or pain). The more specific
measures cover a narrower set of domains and tend to be more symptoms-orientated. Mental health
research has tended to be dominated by measures specific to mental health, such as the Patient Health
Questionnaire (PHQ-9), Generalised Anxiety Disorder Assessment (GAD-7), General Health Questionnaire
(GHQ-12), Beck Depression Inventory (BDI), Lancashire Quality of Life Scale, Health of the Nation Outcome
Scales (HoNOS), Clinical Outcomes in Routine Evaluation – Outcome Measure (CORE-OM), Camberwell
Assessment of Need (CAN) and many more. Generic measures of health are rarely used in mental health
research and this has been seen as a major limitation to conducting economic evaluations in mental
health.1 This has been either because these measures are not regarded as valid in the patient group or
investigators are keen to keep patient burden down and prefer to use a more specific measure.
There has been some scepticism about the appropriateness of the EQ-5D in mental health, given that it has
only one dimension specifically addressing mental health problems,11,47–49 though some have argued it is
appropriate in common mental health conditions like depression.50 Recent years have seen the development
of preference-based condition-specific measures,51 including one for common mental health problems.52
However, the pressure to use generic measures remains and has started to impact on the scales used in
clinical studies and, most recently in the UK, in routine patient-reported outcome measurement. The
appropriateness of a measure depends on meeting criteria such as reliability, validity and responsiveness.
This report is concerned with bringing together quantitative and qualitative evidence on these criteria.
Assessing appropriateness
This report brings together important new evidence on the appropriateness of the two most widely used
generic preference-based measures in mental health in the UK (the EQ-5D and SF-6D), and assesses
whether or not it is necessary to adapt them in some way, or consider developing a new preference-based
measure for mental health. It uses a combination of quantitative and qualitative evidence within the
psychometric framework to assess the validity of the measures in mental health populations.53,54
Validity
Validity is defined as the extent to which an instrument measures what it is intended to measure and is the
core criterion for assessing psychometric performance. The problem for assessing validity is that there is
not a gold standard for comparison, as the concept of quality of life, and, therefore, mental health-related
quality of life, is fundamentally subjective. Nonetheless, various indirect ways of establishing validity have
been developed in the health field and elsewhere, including content validity and construct validity.55,56
Content validity ‘refers to the degree to which the content of the items reflects the content of the
domains of interest’.57 There are quantitative methods for assessing content validity, based on the extent
of agreement between experts regarding the extent to which an item taps the domain. However, these
techniques presuppose that the domains are known, which may not always be the case. To address this
gap, researchers in the health field have increasingly been applying qualitative methods to obtain the
views of people with a given condition to develop and validate the content of the instrument.56 Indeed,
the U.S. Food and Drug Administration58 regards this as an essential step in the process of validating a
patient-reported outcome measure. Qualitative methods provide a depth of understanding that is rarely
possible with conventional psychometric techniques. We obtained evidence on the appropriate content of
a measure of the impact of mental health problems on quality of life by reviewing qualitative studies of
people with mental health problems using in-depth interviews and focus groups. The findings were further
tested by conducting in-depth interviews with mental health service users in order to obtain data on a
broader range of mental health problems and to refine the emerging themes.
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The more conventional approach to validation is to examine construct validation. This can be broken
down into two types of tests: discriminant or known-group differences validity and convergent validity.
Known-group validity requires data sets with indicators or measures of severity that can be used to define
the groups. It should be noted that the usefulness of these tests is limited by sample size (especially as
studies are usually not powered on a preference-based measure), the appropriateness of the clinical
groups defined, and exogenous factors that may influence quality of life. For instance, groups may be
defined by specific clinical symptoms such as mania, but whether or not these result in differences in
quality of life is less clear. In mental health there is also the problem of comorbidities, whereby differences
between groups may arise due to another condition (such as physical health problems or depression)
rather than the one being considered (e.g. schizophrenia).
The other subset of construct validity examined in this report, convergent validity, is defined as the extent
to which one measure correlates with another measure of what is purported to be a similar concept. This
can be the extent to which generic measures correlate with each other and/or with measures of mental
health, but again this depends on the extent to which the latter reflects genuine differences in
quality of life.
Responsiveness
Responsiveness is the ability of an instrument to measure clinically significant changes in health over time
and can be seen as another form of validity. Responsiveness is usually assessed statistically using measures
such as the ‘effect size’ (where the mean change in score is divided by either the SD at baseline or the
SD of the change). A common assumption in the assessment of responsiveness is that for a given health
change, the measure with the largest effect size is the better measure.59 Where the objective is to
minimise sample size, this makes sense and maximises the ability to detect significant differences. For
economic evaluation, this is less important and, instead, it is a case of establishing that the descriptive
content is able to detect change of significance to service users. Related to this is the concept of precision,
which is concerned with the ability of a measure to detect changes over the range experienced by patients
being assessed.53 This requires the items and levels of the domains to be well spread over the range
of the measure.
The problem for assessing validity and the related responsiveness is that it is rarely possible to prove that a
measure is valid or that it is not valid. The nature of the evidence is rarely that conclusive. It is more a
question of bringing together evidence, both quantitative and qualitative, that either supports or refutes
the claim of validity in comparison to other measures and indicators used in the field.
Outline of report
The aim of this research is to assess the appropriateness of the EQ-5D and the SF-36 (and its derivatives
the SF-12 and the preference-based SF-6D) in people with mental health problems, in terms of their
validity and responsiveness. These criteria are assessed using evidence from a range of different sources:
the literature, a number of existing data sets and interviews with users. This research considers all the main
groups of people with mental health problems, including those with common mental health problems
(e.g. mild to moderate depression, anxiety, obsessive compulsive disorder and panic disorders), severe
and complex non-psychotic disorders (e.g. personality disorder), and schizophrenia and other psychotic
disorders. The ways the groups are defined is to a large extent determined by the literature being
reviewed, the data available or, in the case of the interviews, by the way services for people with mental
health problems are organised. Although we must adopt diagnostic and service groupings in parts of the
report, such groupings are not mutually exclusive and, furthermore, many users have more than
one diagnosis.
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In all, there were four studies undertaken to examine the appropriateness of the measures, and a
fifth study to estimate mapping functions between the EQ-5D and SF-6D and commonly used mental
health-specific measures. Chapters 2 and 3 are concerned with the quantitative evidence on the construct
validity (i.e. known-group differences and convergent validity) and responsiveness, with Chapter 2
presenting a systematic review of the existing literature on the EQ-5D and SF-36 across the main mental
health conditions and Chapter 3 presenting new psychometric analyses of existing data sets. For those
situations where the EQ-5D and/or SF-6D were found to be acceptable in terms of their psychometric
properties, the next stage was to estimate mapping functions between those mental health-specific
measures widely used in clinical studies and the two generic measures. This is presented in Chapter 4.
Chapters 5 and 6 present qualitative evidence on the domains of quality of life that appear to be
important to people with mental health problems in order to shed light on the validity of the content of
these generic measures. Chapter 5 presents a review of previous qualitative research; although this
evidence was helpful in starting to identify key themes on the impact of mental health problems on quality
of life, it was limited in terms of the groups covered and by the topic guide used by the researchers.
Therefore, in-depth interviews were carried out with mental health service users and a thematic analysis
undertaken, and this is presented in Chapter 6 in order to provide the basis for reviewing the
appropriateness of content of the generic measures.
Chapter 7 presents a brief overview of the findings of each study before discussing the main findings of
this research, and presents the recommendations for further research and implications for policy.
BACKGROUND AND INTRODUCTION
10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Chapter 2 A systematic review of the validity and
responsiveness of the EQ-5D, SF-36, SF-12 and SF-6D
in mental health
This chapter examines the validity and responsiveness of two generic preference-based measures ofhealth (the EQ-5D and SF-6D) and two related generic non-preference-based measures (the SF-36 and
SF-12) in populations with mental health problems. The assessment is based on a systematic review of
studies reporting one or more of these measures alongside various condition-specific indicators of mental
health that can be used to assess validity using known-group comparisons and convergence, and
responsiveness to changes in health over time. It forms the first study presented in this report.
This review covers five mental health conditions: schizophrenia, bipolar disorder, personality disorders,
depression and anxiety. Four separate systematic reviews were undertaken from one common search of
the literature, with depression and anxiety reviewed together. This chapter presents the methods and an
overview of the findings. The detailed findings with tables of results by study are available in published
articles or in discussion paper form.60–62
Methods
Selecting review studies
Inclusion and exclusion criteria
Studies were eligible for inclusion if they contained HRQoL data obtained using one or more of the
instruments under study (SF-36, SF-12, SF-6D or EQ-5D) within the specified population of adults
(aged ≥ 18 years) suffering from one of the five conditions. HRQoL data could be from descriptive systems
(i.e. their items and dimensions) or health-state utility values generated by the EQ-5D or SF-6D, or the
EQ-VAS. Studies whose primary focus was on individuals with alcohol and/or drug dependency were
excluded whether or not those individuals had one of the five conditions. The outcomes had to include
data that allowed measurement of the construct validity (i.e. known groups, convergent or discriminant) or
the responsiveness of the HRQoL instrument(s). Responsiveness data had to be in the form of effect sizes,
standardised response means (SRMs) or correlation with change scores on symptom measures. Studies that
only provided data on other psychometric properties, such as reliability, face validity and content validity,
were not included.
Identification of studies
A literature search was performed to identify relevant research for all mental health conditions being
investigated within the wider review, using a database thesaurus and free text terms. Two sets of search
terms were combined: terms for each of the four HRQoL measures and terms for each mental health
condition (the search strategy is in Appendix 2). Ten databases were searched for published research from
inception: Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled
Trials (CENTRAL), NHS Economic Evaluation Database (NHS EED), Health Technology Database, Database
of Abstracts of Reviews of Effects (DARE), MEDLINE, PreMEDLINE, Cumulative Index to Nursing and Allied
Health Literature (CINAHL), EMBASE and Web of Science. Searches were limited to English language only
but not by any date restriction. All searches were initially conducted in August 2009, though updates were
undertaken for personality and bipolar disorders until March 2011, and for depression and anxiety until
December 2010. The reference lists of relevant studies were searched for further papers.
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Citations identified by the searching process were screened by one reviewer (DP or TP) using the inclusion
criteria. The full texts of papers were retrieved for any titles or abstracts that appeared to satisfy the
inclusion criteria, or for which inclusion or exclusion could not be definitely determined. The same inclusion
and exclusion criteria were used to assess full-text papers and any queries over inclusion were resolved by
discussion and consensus between two reviewers (DP and JB or TP and JB).
Data extraction
Data from all included trials were extracted using a form designed specifically for this review, and piloted
on a sample of papers. Data extracted included: country of publication, type of disorder, study sample
characteristics (numbers, age, sex), other measures used, mean scores on HRQoL measures, type and
method of validity assessment, type and method of responsiveness assessment, and validity and
responsiveness data. Extractions were performed by one reviewer (DP or TP). Where duplicate publications
reported on similar data, the most complete and recent data were extracted.
Quality assessment
There is no formal method for assessing the quality of these studies (i.e. there are no quality assessment
checklists), and thus we used the methods described by Fitzsimmons et al.63 to evaluate HRQoL data in
their systematic review on the use and validation of HRQoL instruments with older cancer patients. These
included examining whether or not tests of statistical significance were applied, differences between
treatment groups reported (where applicable, e.g. in known-group validity), clinical significance
discussed and missing data documented. We also report on response and completion rates where these
were provided.
Evidence synthesis and meta-analysis
Owing to the large degree of heterogeneity between studies (including types of study designs, HRQoL
measure, population characteristics and methods of determining construct validity and responsiveness),
it was not appropriate to perform meta-analysis. Analysis was by narrative synthesis and data were
tabulated. All analyses were performed based on the HRQoL measure, with data analysis grouped by type
of validity (convergent/discriminant or known groups) or responsiveness test used.
Defining validity and responsiveness
Validity and responsiveness were assessed using the definitions presented in Chapter 1. For convergent
validity, the strength of correlation between the two measures is calculated using statistical tests
(e.g. Pearson’s product moment correlation or Spearman’s rank correlation). We have used the
following categories for evidence of correlation: > 0.6 = very strong, ≥ 0.5 to < 0.6 = strong, < 0.5 to
≥ 0.3 =moderate, and < 0.3 = weak. Statistical significance is also attached to correlations (p < 0.05).
Responsiveness can be measured in a number of ways by effect size statistics64 standardised in different
ways, such as dividing through by the SD at baseline or SD of the change in scores over time (i.e. SRMs).
Within this review, Cohen’s65 categories for magnitude of effect size were used: ≥ 0.80 = large, < 0.80 and
≥ 0.50 =moderate, and 0.30 to < 0.50 = small. As pointed out in Chapter 1, these tests need to be used
with some care as there is no gold standard and the application of these tests sometimes uses indirect
indicators of the concept (e.g. symptoms rather than quality of life).
Study characteristics
The initial search for studies for the wider review retrieved 4115 unique citations across the five mental
health conditions (Figure 1). Of these, 3849 were excluded at the title and abstract stage and 266 were
examined in full text. From these, 154 studies were found that met the inclusion criteria. A further
12 studies were identified through reference list checking. Overall, the findings from 91 studies are
discussed in this chapter for the five conditions. SF-36 and SF-12 studies were not ultimately included in
the depression and anxiety review as a sufficiently large number of studies used the SF-6D to be able to
extrapolate to these longer versions of the measure. Figure 1 shows a flow diagram of study identification
and the characteristics of the studies reviewed by condition are presented in Appendix 2.
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Schizophrenia
Thirty-one studies were identified that provided data on the validity and/or responsiveness of the EQ-5D,
SF-36, SF-12 or SF-6D within individuals diagnosed with schizophrenia, schizophreniform disorder or
schizoaffective disorder (see Appendix 2, Table 32).48,66–95 Six studies were undertaken internationally
across more than one country.66–71 The numbers of participants in the studies with schizophrenia or related
conditions ranged from 15 to 2657. Participants included males and females with a mean age of
participants with a schizophrenia spectrum disorder, reported in 21 of the 33 studies, ranging between
20.3 and 57.9 years.48,68,70–73,75–80,82,84,86,88–91,94,95
All studies obtained HRQoL information from patients; seven of these studies compared patient HRQoL
values with published general population ‘normative’ values,70–76 three compared HRQoL values with
normal comparison participants that were recruited to the study77–79 and two used ‘norms’ from healthy
participants who had taken part in large surveys.80,96
Bipolar disorder
Twenty-two studies were identified that provided data on the validity and/or responsiveness of the generic
HRQoL measures in bipolar disorder (see Appendix 2, Table 33).74,97–117 Nineteen studies74,97,98,102–117
contained data on the SF-36, one study involved the SF-12101 and four studies98–101 contained data on the









































FIGURE 1 Flow diagram of study identification.
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The numbers of participants in the studies with bipolar disorder ranged from 30 to 1999. Participants
included men and women. The mean age of participants with a bipolar disorder, reported in 19 of the
22 studies,97–103,106–117 ranged between 29.3 and 60.2 years.
All studies obtained HRQoL information from patients; six of these studies compared patient HRQoL values
with ‘norms’ derived from published general population ‘normative’ values,48,76,80,81,96,118 three compared
HRQoL values with normal comparison subjects that were recruited to the study74,79,82 and one study used
‘norms’ from healthy subjects taking part in large surveys.83 Four studies investigated differences in HRQoL
between mood groups in bipolar disorder.75,84–86 Two of the four studies investigating the EQ-5D used
general population preferences for EQ-5D health states to generate EQ-5D index values.87,96
Personality disorder
In total, there were 10 studies reporting HRQoL data on patients with personality disorder.96,119–128
Six studies looked at the EQ-5D,120,124–128 two at the SF-36119,121 and two at the SF-12 (corresponding to
three articles).96,122,123 No studies were found investigating the validity or responsiveness of the SF-6D in
this patient group. Studies were undertaken in four countries. Nine96,119–128 of the 10 studies presented
data for different personality disorders together. One study looked exclusively at individuals with borderline
personality disorder. The numbers of individuals included within the studies that were diagnosed or
screened as having one or more personality disorders ranged from 48 to 1708. Participants included males
and females (proportions can be seen in Appendix 2, Table 34). The mean age of participants with
personality disorders, reported in 9 of the 10 studies, ranged between 29.4 and 45 years.96,119–121,124–128
Two studies120,127 investigated the known-group validity of the EQ-5D, one study127 investigated the
convergent validity of the EQ-5D and four studies124–126,128 investigated the responsiveness of the EQ-5D.
Two studies119,121 investigated the known-group validity of the SF-36 and two studies96,122,123 investigated
this property in the SF-12. One study119 investigated the responsiveness and convergent validity of the SF-36.
Depression and anxiety
Owing to the large number of studies reporting SF-36 and SF-12 data in this group, it was decided to
focus on EQ-5D and SF-6D data. SF-36 and SF-12 are not preference-based and have been included in the
other studies to give an indication of the likely performance of the derivative SF-6D. In all, there were
22 studies50,129–149 identified with data on the validity and/or responsiveness of the generic HRQoL
measures in depression and anxiety for EQ-5D and SF-6D. Fourteen studies50,129,136–139,142–149 had data on
the EQ-5D and seven130,131,133–135,140,141 contained data on the SF-6D. Studies were undertaken in at least
12 countries (a number covered Europe). The numbers of participants with depression and anxiety in
these studies ranged from 44 to 3815. Participants included men and women with a mean age between
39.2 and 49 years of age.
Six studies139,142,144,147–149 investigated the known-group validity of the EQ-5D across severity groups,
five studies129,136,137,143,145 reported convergent validity of the EQ-5D and 14 studies50,130–138,140,141,145,146
investigated the responsiveness of the EQ-5D. Two studies139,142 had known-groups differences in the
SF-6D, three132,134,137 had convergent validity and two136,145 had responsiveness.
Quality of included studies
Most studies reported tests for statistical significance of the properties measured for difference between
groups (e.g. known-group validity) and responsiveness to change over time. A minority of studies
considered what constituted a clinically significant difference in HRQoL scores, by either providing a
predefined value or discussing whether or not the results were clinically meaningful. There was little
discussion or inclusion, however, of clinical significance defined in terms of patient perception, and thus,
from the perspective of preference-based measures, the lack of patient preference undermines the concept
of clinical significance. Most studies did not report missing HRQoL data. This has implications for the
representativeness of these samples due to possible selection bias.
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Results
Detailed findings with tables of results on the validity and responsiveness have been reported
elsewhere.60–62 This section summarises the results using a simple classification of the evidence: ✓ indicates
results in support of validity or responsiveness and ✗ indicates an inconsistent or non-significant result.
The results on validity have been divided into known-group differences across severity groups typically
defined using symptoms, known differences against a normal case–control group and convergence with a
measure of the condition.
Schizophrenia
The majority of the evidence (25 studies) examined the validity and responsiveness of the SF-36.66,67,69–85,88,92–95
Although there appears to be strong evidence that the SF-36 is able to distinguish between general population
norms and scores of people with schizophrenia (known-group validity), the evidence for convergent validity
and responsiveness is less certain (Table 4). Similar findings exist for the EQ-5D, with mixed evidence for the
properties of convergent validity and responsiveness. Indeed, when strong associations were found between
individual EQ-5D health-state dimensions (e.g. anxiety/depression or self-care) and symptom or functioning
measures, this did not necessarily translate into comparable changes in overall EQ-5D index scores,
i.e. health-state utility values.48,90 There was some evidence that associations with measures of depression
were comparatively stronger than those with symptom measures of schizophrenia [e.g. the Positive and
Negative Syndrome Scale (PANSS)].71,88–90
When testing associations between measures for convergent validity (or change scores in responsiveness),
there are reasons to predict that stronger and more consistent correlations might exist between generic
HRQoL measures and functioning [e.g. Global Assessment of Functioning (GAF), Social and Occupational
Functioning Assessment Scale (SOFAS)] or mental health/schizophrenia-specific HRQoL [e.g. Quality of Life
Scale for Schizophrenia (QLS)] measures than purely symptom-based measures such as the PANSS. By their
very nature, symptom measures are measuring different concepts from HRQoL measures, so it might be
reasonable to predict that it is less likely that a strong correlation might exist. A re-examination of the
evidence, taking into account evidence for the type of measure used to assess convergent validity
(symptom vs. functioning or HRQoL measures, subjective vs. objective measures), produced mixed results.
Functioning and schizophrenia HRQoL measures did not fare much better than clinical and symptom-based
measures, with four studies indicating strong evidence for convergent validity,82–84,86 and four indicating
uncertain or no evidence of such a relationship.69,81,88,89
Bipolar disorder
There was positive evidence that the SF-36 is a valid and responsive measure in bipolar disorder when
individuals are in a depressed, euthymic or mixed state (Table 5). There was little evidence available on the
EQ-5D and SF-12 and none for the SF-6D. What evidence there is on the EQ-5D is mixed, with three tests
supporting the validity of the EQ-5D in this group and three against it across four studies.98–101
TABLE 4 Results for schizophrenia
Criterion EQ-5D SF-36 SF-12 SF-6D
KGV: severity ✓ ✓ None None
KGV: case–control None ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ None
Correlation ✓ ✓ ✓ ✗ ✗ ✓ ✗ ✓ ✓ ✗ ✓ ✓ ✓ ✓ ✗ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✗ ✗ ✗ ✗ None ✓
Responsiveness ✓ ✓ ✓ ✗ ✗ ✓ ✓ ✓ ✗ ✗ ✗ ✗ None ✗
KGV, known-group validity.
✓ indicates results in support of validity or responsiveness; ✗ indicates an inconsistent or non-significant result.
Each ✓ and ✗ represents an individual study.
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It is unclear if these generic measures are valid in manic or hypomanic individuals. Only 7 out of 22 SF-36
studies included individuals in a manic or hypomanic state,74,99,101,104,106,110,117 and these suggest it is not a
valid and responsive measure within this population. However, where studies examined convergent validity
with clinical measures of mania, the numbers of patients in the manic or hypomanic mood state were too
small to be meaningful. More generally, there is some concern around how to obtain reliable HRQoL
ratings within bipolar disorder individuals in manic or hypomanic states as this relies on self-report.
Depression and anxiety
The SF-6D and EQ-5D demonstrate good construct validity and responsiveness for patients with depression
(Table 6). They can both distinguish between groups that are known to vary according to severity of
depression, and across differences in quality of life of depressed patients. Both measures respond to
clinical and quality-of-life improvement and deterioration. Indeed, in many cases they are more responsive
than depression-specific measures (this may be due to the integrated nature of mental and physical health
problems and potential simultaneous improvement in comorbid conditions).
The performance of the EQ-5D for patients with anxiety is a little more mixed. The measures were found to
be more highly correlated with depression scales than with clinical anxiety scales in patients with anxiety.
The relationship between the EQ-5D and the SF-6D reflects that found for other conditions. The EQ-5D
shows a lower level of utility at the most severe end for depression, and the SF-6D shows equal or greater
detriment at the milder end. The SF-6D identifies utility loss in patients that report full health on the EQ-5D,
though patient averages for mild depression and anxiety are still able to show lower than normal
population utility using the EQ-5D.
Personality disorder
The EQ-5D appears responsive in individuals with personality disorders (Table 7). Data on other properties
such as convergent and known-group validity were very limited. There was also little evidence on the
SF-36 or SF-12 and none on the SF-6D. Nevertheless, the studies which did exist provided some positive
evidence that the measures are valid for use in personality disorders.100,102,107 An exception was Narud et al.,119
who found that most dimensions on the SF-36 were not able to detect changes in patients in the same way
as clinical measures. They concluded that this may be because some SF-36 dimensions are not relevant to
HRQoL, so that, even if patients change clinically, this does not translate to a change in HRQoL.
TABLE 5 Results for bipolar disorder
Criterion EQ-5D SF-36 SF-12 SF-6D
KGV: severity ✓ ✓ ✓ ✓ ✓ ✗ ✓✓ ✓ None
KGV: case–control ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ None None
Correlation ✓ ✗ ✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓ None
Responsiveness None ✓ ✓ ✓ ✓ ✗ None None
KGV, known-group validity.
✓ indicates results in support of validity or responsiveness; ✗ indicates an inconsistent or non-significant result.
Each ✓ and ✗ represents an individual study.
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Discussion
This review is the first to have comprehensively identified studies that report on the construct validity and
responsiveness of these four generic HRQoL measures, and to tabulate and give a narrative synthesis of
the findings. Overall, the evidence suggests that generic HRQoL measures are appropriate for patients with
depression and personality disorder, but it is more mixed in relation to anxiety, bipolar disorder
and schizophrenia.
The findings for depression are encouraging, but there is a concern that this may be driving the differences
between groups found for other conditions. For anxiety, the ability of generic preference-based measures
to distinguish between subgroups of patients with anxiety may be driven by aspects of depression within
anxiety disorder and the presence of comorbid depression. There was some evidence that associations with
measures of depression were comparatively stronger than those with symptom measures of schizophrenia
(e.g. the PANSS).71,88–90 This may indicate that: (a) the generic HRQoL measures were only able to detect
this component of HRQoL, or (b) depression is the only component of HRQoL within these groups of
patients that is important within the context of HRQoL measurement. The issue is whether schizophrenia
or anxiety has quality-of-life implications not adequately described by the five dimensions of the EQ-5D. It
is also difficult to predict how HRQoL is affected by the manic or hypomanic states from the perspective of
the individual with bipolar disorder. These non-depression consequences of these conditions are explored
later in this report through qualitative interviews with patients.
TABLE 7 Results for personality disorders
Criterion EQ-5D SF-36 SF-12 SF-6D
KGV: severity ✓ ✗ ✓ ✓ None
KGV: case–control ✓ ✓ ✓ None None
Correlation ✓ ✓ None None
Responsiveness ✓ ✓ ✓ ✓ None None
KGV, known-group validity.
✓ indicates results in support of validity or responsiveness; ✗ indicates an inconsistent or non-significant result.
Each ✓ and ✗ represents an individual study.
TABLE 6 Results for depression and anxiety
Criterion EQ-5D SF-6D
KGV: severity ✓ ✓ ✓ ✓ ✗ ✓ ✓ ✓ ✓
KGV: case–control None ✓ ✓
Correlation ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Responsiveness ✓ ✓ ✓ ✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
KGV, known-group validity.
✓ indicates results in support of validity or responsiveness; ✗ indicates an inconsistent or non-significant result.
Each ✓ and ✗ represents an individual study.
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The review has some limitations, resulting from the need to compromise on some elements of the review
process because of the large scope of the project. Although the search for studies was reasonably
comprehensive, it was limited to key databases and reference list checking of included studies, and study
selection was undertaken by one reviewer. Ideally, further searching could be undertaken in trial registries,
conference proceedings and by citation searching to make the search more comprehensive in terms of
process. Study quality assessment has been pragmatic and focused on the elements that contribute to
HRQoL analysis. The populations included in this review were heterogeneous in terms of the nature of
their conditions, particularly for conditions such as schizophrenia and personality disorder where there are
numerous subgroups, and not all studies provided detailed or uniform information on these characteristics.
Such clinical variables clearly have an impact on HRQoL, and thus these factors will have had an impact
upon the results of individual studies.
It is also difficult to draw any firm conclusions on the basis of this review, owing to the limited nature
of much of the evidence in terms of the number of studies, the size of some of the studies and the
heterogeneity within the conditions. There is very limited evidence of validity or responsiveness for
the SF-12 and SF-6D, and though these are derivatives of the SF-36, their more limited item coverage
(12 and 11, respectively) means that they may not perform as well. Therefore, further research needs to be
directed towards demonstrating these properties for these instruments. To improve the evidence base, the
next chapter will conduct further psychometric tests on existing data sets containing the EQ-5D and SF-6D.
More evidence is also required on the validity and responsiveness of generic measures for older people
with depression, as this group may be different from the younger adults typically found in published trials.
There is another general concern regarding whether or not it is reasonable to assess HRQoL when an
individual is in a particular state, such as a manic or hypomanic state, as he or she may view the effect that
the state had on his or her HRQoL very differently when not actually in that health state.
The findings are also limited by the measures used to establish validity and responsiveness. It is difficult to
determine, in theory, how strongly correlated generic HRQoL measures should be with symptom and/or
other clinical measures, and there is little guidance on what constitutes reasonable correlation. Indeed, it is
impossible to prove validity of HRQoL instruments, as no ‘gold standard’ exists. Also, as discussed
previously, where health dimensions and changes appear to have been missed by preference-based HRQoL
measures, these may not actually be important to patients or valued by the general population. The former
will be examined in the qualitative research reported in Chapters 5 and 6.
The dominance of physical health in the EQ-5D may explain why it is not sensitive to differences in
some mental health populations.48 Although this does not seem to have been a problem in depression, it
may account for the more mixed results in other conditions. There are also concerns that the descriptive
systems of the generic measures are too narrow in terms of the dimensions they cover. Some of the
questions raised are addressed later in this report using the findings of qualitative interviews of people
with mental health problems, who can provide some insight into the shortcomings of the content of the
descriptions contained in these generic measures (see Chapters 5 and 6).
Research needs to be directed towards developing robust methods of demonstrating validity and
responsiveness for generic HRQoL measures. For known-group validity, the evidence discriminating
between healthy and non-healthy individuals could be considered fairly crude; large differences should be
obviously apparent between such groups. Therefore, research is required to test instruments in terms of
the ability to reflect known-group differences using indicators of condition severity that are important to
patients. For convergent validity, this might mean consideration of which measures to choose for
assessment of strength of correlation, both by considering the type of measure (e.g. symptom functioning
or HRQoL) and the nature of the measure (subjective or objective). Studies need to be explicit at their
outset about the hypothesised associations when investigating validity and responsiveness. In addition,
wherever studies investigate the feasibility of administering generic HRQoL measures alongside construct
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validity and responsiveness using quantitative and qualitative methods within this disease area, this will
allow a greater overall understanding of which measures are useful within schizophrenia.
Conclusion
Despite the shortcomings identified in the evidence base, this review gives an overall picture of the validity
and responsiveness of the EQ-5D and SF measures across mental health populations. It has shown a mixed
picture, with the generic measures appearing to perform acceptably well in depression and personality
disorder, but less well in anxiety, schizophrenia and bipolar disorder. This has highlighted the need for
further quantitative research, and the insights that can be gained from people regarding the content
validity of the measures in terms of coverage of the dimensions of their life impacted upon by their mental
health problems. The following chapters report both quantitative and qualitative studies that further
investigate the validity of these measures.
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Chapter 3 Assessing the psychometric
performance of the EQ-5D and SF-6D using existing
data sets
The review of psychometric evidence reported in the last chapter found mixed evidence on theperformance of the EQ-5D and SF-36 (and its derivatives). The aim of the study reported in this chapter
was to use existing data to supplement the psychometric evidence on both the EQ-5D and the SF-6D in
samples of common mental health conditions, schizophrenia and personality disorder. The validity of the
instruments and their responsiveness to change over time were assessed in comparison with widely used
condition-specific outcome measures that have been validated for use in the mental health population,
using existing data sets sourced from a range of studies. These data sets included 3512 people with
common mental health problems (including depression and anxiety), 480 people with a mixed diagnosis
of moderately severe common mental health problems and personality disorders leading to self-harm,
and 1756 people with schizophrenia and other personality disorders. The analysis adds to the evidence
base regarding the psychometric performance of the EQ-5D and SF-6D in mental health populations,
providing information on the conditions in which the generic measures can be used and those for which
improvements to the existing instruments and/or new measures are required.
Methods
Measures used in data sets
The EQ-5D and SF-6D were compared to one widely used and validated condition-specific measure within
each data set. The measures used were restricted to those included in the data sets available. Table 8 displays
the measures used in the analysis. Details of the two generic preference-based measures are presented in
Chapter 1. The condition-specific measures are described below.
Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale (HADS)156 is a 14-item self-report measure that contains two
seven-item subscales: depression (HADS-D) and anxiety (HADS-A). The total score for each dimension is
21 (items are scored 0–3) with high scores indicative of increased levels of anxiety and depression (a score
of 8+ indicates a possible case, and a score of 11+ indicates a probable case). The overall score [Hospital
Anxiety and Depression Scale – Total score (HADS-T)] is also used as a measure of global functioning. The
HADS has been widely used across clinical groups and research settings,157 and there is evidence for its
psychometric validity in comparison with other mental health158,159 and generic measures.160 In this study,
HADS was used to assess the psychometric performance of the EQ-5D in two separate samples of people
with anxiety and depression.
Clinical Outcomes in Routine Evaluation – Outcome Measure
The CORE-OM161–165 is a self-reported measure developed in the UK for routine use in psychological
services at assessment and outcome. It comprises 34 items addressing domains of subjective well-being,
symptoms (anxiety, depression, physical problems, trauma), functioning (general functioning, close
relationships, social relationships) and risk (risk to self, risk to others). Items are scored on a 5-point,
0–4 scale. CORE clinical scores are computed as the mean of all completed items multiplied by
10 (range 0–40). This is so that clinically meaningful differences are represented by whole numbers.
The psychometric validity of the CORE-OM in comparison to other widely used measures of mental
health has been demonstrated.166,167 In this study, the CORE-OM was used to assess the psychometric
performance of the SF-6D in two separate samples of people with anxiety and depression.
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mean (SD) Female (%)
Common mental health conditions
Assessing Health Economics of
Antidepressants (AHEAD)150
RCT of the cost-effectiveness of
antidepressants (three time points).
Sample includes common mental





EQ-5D HADS 327 43.1 (15.4) 67.0
Psychological Interventions for Postnatal
Depression (PoNDER)151
Study of two psychologically informed





SF-6D CORE-OM 2640 31.5 (5.1) 100.0
IAPT cohort study152 Evaluation of the outcomes from two
IAPT demonstration sites. Sample





SF-6D CORE-OM 527 40.9 (14.2) 72.3
Common mental health and personality disorders
The POPMACT study153 RCT of MACT vs. TAU in recurrent
self-harm. Sample includes patient
with diagnoses of common mental
health conditions and personality
disorders leading to self-harm
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Schizophrenia
Quality of Life following Adherence
Therapy (QUATRO)154
Multicounty RCT of adherence therapy
in patients with a clinical diagnosis of
schizophrenia who needed continuing
antipsychotic medication for at least
1 year from assessment, and had






BPRS-E 409 41.5 (11.5) 59.9
Multicentre study of Art Therapy In
Schizophrenia: Systematic Evaluation
(MATISSE)155
RCT of group art therapy for




EQ-5D PANSS 417 41.0 (11.5) 33.3
Schizophrenia and personality disorders
Study of Cost-Effectiveness of Personality
disorder TREatment (SCEPTRE)120
Dutch study of adult patients with






932 35.1 (9.8) 68.1
BPRS-E, Brief Psychiatric Rating Scale – Expanded; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition; HADS, Hospital Anxiety and Depression Scale;


















































































































































































































































































































































































































































































Brief Psychiatric Rating Scale – Expanded
The Brief Psychiatric Rating Scale (BPRS)168 was developed to assess symptom change in psychiatric
inpatients and is one of the most widely used measures to assess psychotic and affective symptoms. The
current study used the expanded version, the Brief Psychiatric Rating Scale – Expanded (BPRS-E), which has
24 items developed for use in schizophrenia patients. The BPRS-E is administered using semistructured
interviews and each of the 24 items has a possible score of 1 (not present) to 7 (extremely severe). Total
scores range from 24 to 168 with higher scores indicating higher severity. The BPRS has been shown to be
highly sensitive to change in psychiatric patients.169 In this study, the BPRS-E was used to assess the
psychometric performance of both the EQ-5D and SF-6D in a sample of people with schizophrenia.
Positive and Negative Syndrome Scale
The PANSS was developed to evaluate positive, negative and other symptom dimensions in schizophrenia
by combining the 18 items of the BPRS with the 12 items of the Psychopathology Rating Schedule with
detailed instructions on completion by interview. It has 30 items which are scored from 1 (absent) to
7 (extreme) and result in 3 subscales: positive, negative and general psychopathology.170,171 The PANSS is
sensitive to changes in both positive and negative symptoms in patients.169 The PANSS was used to assess
the performance of the EQ-5D in a sample of people with schizophrenia.
Data sets
Identification of data sets
The systematic reviews reported in Chapter 2 examined the performance of generic preference-based
measures in depression, anxiety and schizophrenia, and these reviews identified 91 studies. Corresponding
authors of these studies were contacted and the data sets were requested for use in this study, and
publicly available data sets were sourced. In total, 12 data sets were received (13% of those requested),
and these were reviewed for acceptable condition-specific comparison measures or clinical indicators.
Three data sets were excluded as they focused on general population samples, and two were excluded as
they did not include a comparison measure of interest.
Seven data sets were selected for use in this study. Three included common mental health problem
samples [Assessing Health Economics of Antidepressants (AHEAD), Psychological Interventions for Postnatal
Depression (PoNDER) and IAPT]; one included mixed common mental health and personality disorder
diagnoses (POPMACT); two included schizophrenia samples [Quality of Life following Adherence Therapy
(QUATRO) and Multicentre study of Art Therapy In Schizophrenia: Systematic Evaluation (MATISSE)]; and
one included schizophrenia and personality disorder [Study of Cost-Effectiveness of Personality disorder
TREatment (SCEPTRE)] (see Table 8).
Common mental health problems data sets
The AHEAD study150 was a prospective randomised controlled trial (RCT) of the cost-effectiveness of
tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and lofepramine. The sample
(n = 327) consisted of patients recruited in a primary care setting who reported a range of common mental
health concerns including depression, mixed anxiety and depressive disorders (MADD) and a number of
phobias. The EQ-5D and HADS were collected at baseline and at six follow-up time points. In this study,
baseline and two follow-up time points (6 months and 12 months) have been considered.
The PoNDER trial,151 which assessed two psychologically informed interventions for women with postnatal
depression, was also selected. The sample used is those patients who completed the study at all time
points (n = 2640). SF-6D and CORE-OM data were collected at baseline, 6 months, 12 months and
18 months, with the first three time points considered in this study.
The IAPT152 cohort study (n = 527 patients), which examined access to psychological therapies and
associated outcomes for patients with mild to moderate depression and anxiety, was also selected. SF-6D
and CORE-OM were administered at baseline, 4 months and 8 months.
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Mixed common mental health and personality disorder diagnoses data set
The POPMACT study153,172 was a RCT of manual-assisted cognitive therapy versus treatment as usual in
recurrent self-harm. The baseline sample was used in this study and consisted of patients presenting with
recurrent deliberate self-harm (n = 480).
Schizophrenia data sets
The MATISSE study was a three-arm randomised trial of group art therapy for people with schizophrenia.155
Study participants (n = 409) were recruited from inpatient and community-based mental health and social
care services at four centres in England and Northern Ireland. Participants were > 18 years of age with a
clinical diagnosis of schizophrenia. Assessment was at baseline and at 12 and 24 months, and EQ-5D and
PANSS were collected at all time points. Analysis in this study focuses on baseline and 12 months.
The QUATRO study was a two-arm RCT of adherence therapy in patients with schizophrenia.154 Participants
(n = 417) were recruited from four countries (the Netherlands, Germany, England and Italy) and were
included if they had a clinical diagnosis of schizophrenia [based on International Classification of Diseases,
Tenth Edition (ICD-10) criteria], needed continuing antipsychotic medication for at least 1 year from
assessment, and had evidence of clinical instability in the year before assessment. EQ-5D and BPRS-E data
were collected at baseline and 12 months after randomisation, and these data were used in the analysis.
Schizophrenia and personality disorder data set
Study of Cost-Effectiveness of Personality disorder TREatment study120 participants (n = 932) were recruited
from a consecutive series of admissions to six mental health care institutes in the Netherlands offering
outpatient, day hospital and/or inpatient psychotherapy for adult patients with personality pathology and/
or personality disorders. Patients with clear signs of unreliable or incomplete data and those with serious
intellectual impairment were excluded. Overall, 88% had at least one personality disorder based on the
Dutch version of the Structure Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders
– Fourth Edition) Personality. The data set consists of EQ-5D baseline assessments and follow-up at 6, 12,
24 and 36 months. We used the UK EQ-5D tariff to allow for comparability with the other samples.
Analysis was limited to baseline and 12-month follow-up.
Demographic characteristics available across the data sets are displayed in Table 8. Table 9 displays the
scores for each sample on the measures used in the analysis for those who returned either the generic
preference-based measure or the condition-specific instrument. The POPMACT sample has lower EQ-5D
index scores than the AHEAD sample, and the mean HADS scores also indicate that the POPMACT sample
displays higher levels of anxiety and depression. SF-6D and CORE-OM scores indicate that the IAPT
sample displays lower levels of health than the PoNDER sample. For the schizophrenia and personality
disorders groups, baseline EQ-5D scores indicate that those in the MATISSE and QUATRO samples have
similar health levels, whereas those in the SCEPTRE sample display lower health as measured by the EQ-5D.
Analysis
Feasibility
The feasibility of administering the measures to respondents was assessed in terms of the level of
completion of each measure for respondents who participated at baseline. Baseline measures were used as
these were available for all of the data sets used. Completion is a highly simplistic measure of feasibility
from the patient’s perspective, but provides an indication of the acceptability of the instruments and the
items included using the level of missing data as a proxy. Completion rates of ≥ 95% are high.
The analysis was carried out for both the common mental health conditions group, where the measures
used were completed using self-report either at home or with an interviewer, and also for the schizophrenia
and personality disorders samples, where the measures were interviewer-administered but may still lead
to missing data due to item unacceptability. It is important to note that although the level of completion
acts as a useful proxy for the feasibility of the measure, the results need to be interpreted with caution.
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TABLE 9 Descriptive statistics and completion rates
Time point n (completing measure) Mean SD Completion (%)
Common mental health conditions – EQ-5D
AHEAD
EQ-5D Baseline 320 0.604 0.264 97.86
6 months 174 0.752 0.257
12 months 164 0.777 0.249
HADS-A Baseline 324 13.11 3.48 99.08
6 months 202 8.78 3.54
12 months 169 8.30 3.59
HADS-D Baseline 324 10.50 3.87 99.08
6 months 202 4.94 3.92
12 months 169 4.34 3.99
Common mental health conditions – SF-6D
IAPT
SF-6D Baseline 504 0.613 0.13 95.60
4 months 425 0.645 0.14
8 months 390 0.668 0.15
CORE-OM clinical score Baseline 494 20.06 7.81 93.74
4 months 409 16.58 8.53
8 months 403 15.09 8.83
PoNDER
SF-6D Baseline 2600 0.669 0.09 97.82
6 months 2614 0.822 0.14
12 months 1697 0.839 0.13
CORE-OM clinical score Baseline 2640 5.23 4.97 99.32
6 months 2641 4.73 4.91
12 months 1713 4.52 4.85
Common mental health and personality disorders
POPMACT
EQ-5D Baseline 476 0.503 0.320 99.20
HADS-A Baseline 479 14.13 3.94 99.80
HADS-D Baseline 478 11.22 4.58 99.58
Schizophrenia
SCEPTRE
EQ-5D Baseline 899 0.566 0.284 99.34
12 months 693 0.741 0.249
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This is because it is not always clear how many questionnaires respondents have completed before those
included in the study or the impact fatigue may have on the level of missing data, and also because of the
nature of data collection in trials where artificially high response rates are achieved.
Validity
Validity assesses how well an instrument measures what it was intended to measure, and is assessed in
comparison with other instruments and clinical indicators that have been validated for use in the area
(in this case mental health). In this study we will assess the validity of the measures by carrying out of
number of tests, including known-group validity and convergent validity.
Convergent validity
The convergence between the generic preference-based measures and the condition-specific instruments was
tested using Spearman’s correlation coefficients and locally weighted scatterplot smoothing techniques.173
Good correlations indicate that the preference-based measures can measure mental health-related factors that
are assessed by the validated condition-specific instruments. Correlations are assessed as: ≥ 0.7 = strong,
< 0.7 to ≥ 0.3 =moderate and < 0.3 =weak. Locally weighted scatterplot smoothing (LOWESS) is a form of
non-parametric regression that attempts to capture general patterns in the relationship between two measures
without making assumptions about the actual relationship between the variables, and demonstrates the
relationship between the measures across the scoring range. LOWESS plots a line on a scatterplot on the central
tendency between the two variables. This allows the visualisation of the relationship between the variables.
In the common mental health conditions group, the convergent validity of the EQ-5D was assessed in
comparison with the HADS-T, HADS-A and HADS-D, and the SF-6D was assessed in comparison with
the CORE-OM clinical and dimension scores. In the schizophrenia analysis, the EQ-5D was assessed in
comparison with the PANSS and the BPRS-E, and the SF-6D was assessed in comparison with the BPRS-E.
TABLE 9 Descriptive statistics and completion rates (continued )
Time point n (completing measure) Mean SD Completion (%)
MATISSE
EQ-5D Baseline 409 0.676 0.271 98.08
12 months 357 0.678 0.297
PANSS total score Baseline 411 79.45 24.19 98.56
12 months 334 76.15 27.11
QUATRO
EQ-5D Baseline 394 0.679 0.291 96.33
12 months 367 0.710 0.286
SF-6D Baseline 383 0.668 0.125 93.64
12 months 367 0.682 0.134
BPRS-E total Baseline 406 45.17 13.02 99.27
12 months 371 37.71 10.54
Schizophrenia and personality disorders
SCEPTRE
EQ-5D Baseline 899 0.566 0.284 99.34
12 months 693 0.741 0.249
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Known-group validity
For the common mental health conditions sample, the known-group validity of the EQ-5D was assessed
using HADS-A and HADS-D cut-off points indicating probable anxiety or depression (a score of ≥ 11), and
this analysis was carried out across both available data sets. For the SF-6D, known-group validity was
assessed using CORE-OM clinical cut-off points (where a score of > 10 indicates clinical concerns). For the
schizophrenia samples, known-group validity of the EQ-5D and SF-6D was assessed using BPRS-E cut-offs
(31 for ‘mildly ill’, 41 for ‘moderately ill’, 53 for ‘markedly ill’ and 70 for ‘extremely ill’), developed by
Leucht et al.,174 and PANSS175 cut-offs (58 for ‘mildly ill’, 75 for ‘moderately ill’, 95 for ‘markedly ill’ and
116 for ‘severely ill’). In the schizophrenia and personality disorder sample, the known-group validity
of the EQ-5D was tested using diagnostic categories based on the Structured Interview for DSM-IV
(defined as those with and without a personality disorder diagnosis, and also the number of personality
disorders diagnosed).
One-way ANOVA was used to assess the magnitude of differences in the generic preference-based
measure scores across the severity groups. Standardised effect sizes across severity subgroups were also
calculated as the difference in mean scores between two adjacent subgroups of study participants with
different levels of severity divided by the SD of scores for the milder of the two subgroups. Values between
0.2 and 0.5, 0.5 and 0.8, and ≥ 0.8 denote ranges containing small, medium and large effect sizes,
respectively, according to Cohen’s criteria.65 Values < 0.2 are usually regarded as not clinically significant.
However, care must be taken when comparing these between preference-based measures, because more
is not necessarily better in terms of effect sizes.54 These simply indicate whether or not the generic
preference-based measure reflects what appears to be an important difference.
Responsiveness
The responsiveness analysis reported here assessed the sensitivity to change of the EQ-5D and SF-6D in
comparison with the condition-specific measures. This included an analysis of both the floor and ceiling
effects and the magnitude of the change in score between two study time points. If a large proportion of
the sample is at the floor (lowest possible score) or ceiling (highest possible score) this impacts on the
ability of the measure to detect deterioration or improvements in health, respectively. Change is assessed
before and after an intervention. We accept that this is a crude indicator of change; however, for each
study there was evidence of improvement, on average, for patients between baseline and follow-up.
Where there has been an overall improvement, this should be reflected in a clinically significant change in
the generic preference-based measures. The magnitude of the change reflected in the measures between
the time points is assessed using the SRM statistic, which is calculated by dividing the mean change on the
measure by the SD of the change,176 and the effect size, which is calculated by dividing the mean change
in score by the SD at baseline. Effect sizes of 0.2 are defined as small, 0.5 as moderate, and 0.8 as large.65
Results
Feasibility
Common mental health conditions
The AHEAD150 data set demonstrates that both the EQ-5D and HADS had completion rates in the high
range (97.86–99.08%) at baseline for those participants who returned a questionnaire. Across the IAPT152
and PoNDER151 data sets, the completion rates for the SF-6D and CORE-OM for those who returned a
questionnaire at baseline were between 93.74% and 97.86%.
Common mental health and personality disorders
The EQ-5D and HADS were fully completed by more than 99% of the POPMACT153 sample who
were interviewed.
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Schizophrenia
Across the two data sets,154,155 the EQ-5D completion rates (for those taking part at baseline where the
measures were collected via interview) range between 96.33% and 98.08%. This is slightly higher than
the SF-6D which has a completion rate of 93.64%. The condition-specific PANSS and BPRS-E also have
high completion rates (98.56% and 99.27%, respectively; see Table 9).
Schizophrenia and personality disorders
The EQ-5D had high completion rates in the SCEPTRE120 sample (99.34%) but the low levels of missing
data may reflect those who were excluded for this reason.
Across the samples, the higher levels of completion among those who returned a questionnaire may act as
some form of proxy for the feasibility of using the questionnaires in mental health populations. However,
there are a number of caveats to this that are described in detail in the discussion.
Convergent validity
Common mental health conditions
The correlation between the EQ-5D and HADS-T, HADS-A and HADS-D indicated a moderate level of
convergence (Table 10). The SF-6D is correlated with the CORE-OM clinical score and the functioning,
well-being and symptoms domain scores in the moderate-to-strong range across both samples
(see Table 10). Correlation with the risk domain score is moderate for the IAPT sample and low for the
PoNDER sample. All correlations are significant (p < 0.01).
Figure 2 displays scatterplots of the relationships between the generic and condition-specific measures and
the LOWESS fit lines. The lines demonstrate that the relationship between the EQ-5D and HADS differs
across the severity scale (the concordance between the measures is better at the less severe end of the
scale). The relationship between the SF-6D and CORE-OM is more consistent across the severity scale, and
is similar for both the IAPT and PoNDER samples.
TABLE 10 Convergent validity of the EQ-5D and SF-6D in common mental health conditions and common mental
health conditions and personality disorder samples
Condition-specific measure
Common mental health conditions Mixed
AHEAD IAPT PoNDER POPMACT
EQ-5D index SF-6D index SF-6D index EQ-5D index
HADS-T −0.38* – – −0.49*
HADS-A −0.25* – – −0.39*
HADS-D −0.35* – – −0.45*
CORE-OM
Clinical score – −0.62* −0.56* –
Functioning score – −0.51* −0.49* –
Symptoms score – −0.65* −0.59* –
Well-being score – −0.56* −0.46* –
Risk score – −0.35* −0.18* –
* Significant at 0.01.
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Common mental health conditions and personality disorders
The correlation between the EQ-5D and HADS-T, HADS-A and HADS-D indicate a moderate level of
convergence (see Table 10). Again, the LOWESS fit line for the POPMACT data indicates that the
relationship between the EQ-5D and HADS differs across the severity scale, where the concordance
between the measures is higher at the less severe end of the scale.
Schizophrenia
The correlations between the EQ-5D and condition-specific measures vary across the two schizophrenia
samples. Correlations with the BPRS-E in the QUATRO sample154 are moderate for the total score and the
depression and positive symptom dimensions, whereas they are weak for the other dimensions (Table 11).
Correlations with the PANSS in the MATISSE sample155 are weak, indicating little convergence.
The correlations between the SF-6D and BPRS-E follow a similar pattern to those of the EQ-5D
although the correlations are smaller in magnitude, with weak correlations across most of the dimensions
apart from depression (see Table 11). There is, therefore, poor evidence of convergence for the SF-6D.
The LOWESS lines for the QUATRO sample (which completed both the EQ-5D and SF-6D) demonstrate a
tendency for the generic preference-based measure scores to increase as scores on the BPRS decrease
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FIGURE 2 Scatterplots and LOWESS lines for the common mental health conditions and mixed diagnosis data sets.
(a) AHEAD; (b) POPMACT; (c) IAPT; and (d) PoNDER.
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meaning that a score of 1 on the EQ-5D is associated with a wide range of BPRS scores. There is a trend
towards a linear relationship between the EQ-5D and PANSS, and again there is a large EQ-5D ceiling
effect whereby a score of 1 equates to a wide range of PANSS scores (Figure 3).
Discriminant validity
Common mental health conditions
EQ-5D index scores are significantly higher in the ‘no case’ group (a score of 0–8) than in the ‘probable
case’ group (a score of > 8) as measured by both the HADS-A and HADS-D for the AHEAD sample
(p = 0.002). In both the IAPT and PoNDER samples, the SF-6D index score is significantly higher in the
non-clinical population than in the clinical group, as measured by CORE-OM (both p < 0.001; Table 12).
Common mental health conditions and personality disorders
For the POPMACT sample, there is a similar pattern as for the AHEAD sample. The EQ-5D index scores
are significantly higher in the ‘no case’ group than in the ‘probable case’ group for both the HADS-A
(p < 0.001) and HADS-D (p < 0.001).
Schizophrenia
EQ-5D scores are significantly higher for those with a lower level of severity as measured by both the
BPRS-E (p < 0.001) and the PANSS (p = 0.003) in the two schizophrenia samples (Table 13). The effect sizes
across the severity subgroups are moderate in size for the BPRS-E and small for the PANSS, indicating that
there is evidence that the EQ-5D can discriminate between severity groups to some extent.
The SF-6D scores significantly discriminate between BPRS-E severity groups (p < 0.001), with scores in the
most severe group higher than those for the EQ-5D (see Table 13). Effect sizes indicate that the difference
between the mild and moderate severity groups is in the range defined as small.
Schizophrenia and personality disorders
The EQ-5D scores also vary with the number of diagnoses, with lower scores for those with one or more
personality disorders. However, these differences are not statistically significant (p = 0.202). There is a
significant difference in EQ-5D scores between samples with different types of personality disorder, but
this is difficult to interpret.
TABLE 11 Convergent validity of the EQ-5D and SF-6D in schizophrenia and personality disorders
Condition-specific measure
QUATRO MATISSE
EQ-5D index SF-6D index EQ-5D index
BPRS-E total −0.34* −0.31* –
BPRS-E disorganization −0.22* −0.17* –
BPRS-E depression −0.39* −0.38* –
BPRS-E negative symptoms −0.14* −0.13* –
BPRS-E positive symptoms −0.25* −0.22* –
PANSS total – – −0.15*
PANSS positive – – −0.14*
PANSS negative – – −0.03
PANSS general symptoms – – −0.21*
* Significant at 0.01.
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FIGURE 3 Scatterplots and LOWESS lines for the schizophrenia samples. (a) QUATRO (EQ-5D); (b) QUATRO (SF-6D);
and (c) MATISSE.
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TABLE 12 Discriminant validity of the EQ-5D and SF-6D in common mental health and mixed diagnosis conditions
Data and indicator Groups n Mean (SD)
Common mental health conditions – EQ-5D (AHEAD)
HADS-A caseness No case 98 0.671 (0.25)
Probable case 219 0.573 (0.27)
p-value 0.002
ES 0.37
HADS-D caseness No case 163 0.677 (0.24)
Probable case 154 0.525 (0.27)
p-value 0.000
ES 0.60
Common mental health conditions – SF-6D (IAPT)
CORE-OM clinical Non-clinical 53 0.740 (0.11)




CORE-OM clinical Non-clinical 2241 0.683 (0.08)
Clinical 399 0.595 (0.07)
p-value 0.000
ES 1.16
Common mental health and personality disorders – EQ-5D (POPMACT)
HADS-A caseness No case 84 0.718 (0.28)
Probable case 392 0.457 (0.31)
p-value 0.000
ES 0.88
HADS-D caseness No case 210 0.622 (0.30)
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TABLE 13 Discriminant validity of the EQ-5D and SF-6D in schizophrenia and other personality disorders
Variable Groups
EQ-5D SF-6D
n Mean (SD) ES n Mean (SD) ES
QUATRO
BPRS-E None/mild (24–31) 56 0.831 (0.16) 56 0.727 (0.09)
Moderate (32–41) 112 0.744 (0.23) 0.54a 112 0.682 (0.12) 0.47
Marked (42–53) 119 0.652 (0.28) 0.40a 119 0.664 (0.12) 0.16
Severe (> 53) 88 0.543 (0.36) 0.39 88 0.625 (0.13) 0.31
p = 0.000 p = 0.000
MATISSE
PANSS Normal/mild (30–58) 86 0.747 (0.24)
Moderate (59–75) 114 0.693 (0.23) 0.23
Marked (76–95) 112 0.660 (0.27) 0.14





No personality disorder 84 0.648 (0.24)
One personality disorder 248 0.606 (0.27) 0.18
Two personality
disorders
95 0.549 (0.30) 0.21
Three personality
disorders
42 0.493 (0.29) 0.18
Four or more
personality disorders
41 0.416 (0.27) 0.27
p = 0.202
Diagnosisb None 113 0.657 (0.23)
Borderline 41 0.581 (0.29) 0.32c
Avoidant 69 0.638 (0.25) 0.08c
Obsessive compulsive 55 0.578 (0.27) 0.34c
Depressive 60 0.525 (0.28) 0.56c
Not otherwise specified 142 0.616 (0.29) 0.17c
p = 0.042
ES, effect size.
a p < 0.05 in test of difference between adjacent severity groups.
b Sample of those with a single diagnosis.
c Effect size between adjacent severity groups.
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Responsiveness
Common mental health conditions
At baseline, the EQ-5D and HADS display no evidence of floor or ceiling effects. However, at follow-up
there is evidence of a large ceiling effect for the EQ-5D and a moderate ceiling effect for the HADS-D
(Table 14). The SRM for EQ-5D is in the moderate range and for the HADS is large. This demonstrates that
the HADS is more responsive in the AHEAD sample.






Mean change (SD) ES SRM t-testT0 T1 T0 T1
Common mental health conditions
EQ-5D – AHEAD (n = 164a)
EQ-5D 0.00 0.00 2.19 34.15 0.17 (0.38) 0.64 0.45 –
HADS-T 0.00 0.00 0.00 0.00 –10.74 (8.83) –1.85 –1.22 –
HADS-A 0.00 0.00 0.00 0.00 –4.81 (4.98) –0.70 –0.97 –
HADS-D 0.00 0.00 0.62 14.79 –5.93 (5.67) –0.68 –1.05 –
SF-6D – IAPT (n = 390a)
SF-6D 0.00 0.00 0.00 1.54 –0.06 (0.12) 0.46 0.50 –
CORE-OM clinical score 0.00 0.00 0.00 0.00 –4.71 (6.71) 0.60 –0.70 –
Functioning score 0.41 0.00 0.82 1.50 –0.37 (0.75) 0.44 –0.49 –
Symptoms score 1.22 1.24 0.20 0.50 –0.58 (0.84) 0.62 –0.70 –
Well-being score 7.46 2.72 0.81 3.95 –0.57 (0.97) 0.63 –0.59 –
Risk score 0.2 0.00 39.27 54.48 –0.18 (0.55) 0.22 –0.32 –
PoNDER (n = 1697a)
SF-6D 0.00 0.00 0.00 18.33 0.17 (0.13) 1.89 1.31 –
CORE-OM clinical score 0.00 0.00 3.48 7.82 –0.58 (4.69) –1.16 –0.12 –
Functioning score 0.00 0.06 12.35 17.24 –0.04 (0.57) –0.06 –0.07 –
Symptoms score 0.00 0.00 8.60 16.13 –0.10 (0.57) –0.17 –0.18 –
Well-being score 0.00 0.06 20.14 29.77 –0.10 (0.76) –0.13 –0.13 –
Risk score 0.04 0.00 90.23 89.55 –0.01 (0.20) –0.07 –0.05 –
Schizophrenia
QUATRO (n = 328a)
EQ-5D 0.0 0.0 16.8 20.7 0.035 (0.29) 0.12 0.12 0.026
SF-6D 0.0 0.3 0.6 0.9 0.014 (0.12) 0.12 0.12 0.027
BPRS-E 1.2 4.3 0.0 0.0 –7.60 (13.06) –0.58 –0.58 0.000
BPRS-E positive 17.1 26.8 0.0 0.0 –3.04 (5.70) –0.52 –0.53 0.000
BPRS-E negative 21.3 35.1 0.0 0.0 –1.37 (4.06) –0.33 –0.34 0.000
BPRS-E disorganisation 20.1 36.9 0.0 0.0 –1.62 (4.22) –0.42 –0.38 0.000
BPRS-E depression 0.0 15.9 0.0 0.0 –1.90 (5.41) –0.34 –0.35 0.000
continued
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The SF-6D displays some evidence of a ceiling effect for the PoNDER data (see Table 14). The SRM statistics
for the SF-6D and CORE-OM in the IAPT validation sample are in the moderate range. For the PoNDER
sample, the SF-6D SRM is in the large range, in contrast to the CORE-OM dimensions which are in the
small range. Therefore, there is evidence that the responsiveness of the SF-6D is in the same range as the
CORE-OM for depression, and that it is more responsive in postnatal depression.
Schizophrenia
The EQ-5D displays no evidence of floor effects at baseline but there is evidence of a large ceiling effect at
both baseline and follow-up time points in the QUATRO and MATISSE samples (see Table 14). Mean
change in the QUATRO sample is statistically significant, but the effect sizes and SRMs are < 0.2 (below
the clinically significant range). The BPRS-E has larger effect size and SRM statistics, which indicates
that the EQ-5D was less responsive in this sample. The SF-6D displays no evidence of floor or ceiling
effects in the QUATRO sample. Mean change on the SF-6D is smaller than the EQ-5D and the effect size
and SRM statistics were consistently < 0.2.
In the MATISSE sample, mean change for the EQ-5D is not statistically significant, leading to a small effect
size and SRM statistics. The PANSS demonstrates statistically significant mean change; however, the
effect sizes are in the low range. The small change demonstrated indicates that neither the EQ-5D nor
PANSS are responsive in the MATISSE schizophrenia sample.
Schizophrenia and personality disorders
In the SCEPTRE sample, the EQ-5D displays minimal floor and ceiling effects and shows good responsiveness,
with moderate effect sizes and SRMs at 12 months.






Mean change (SD) ES SRM t-testT0 T1 T0 T1
MATISSE (n = 321a)
EQ-5D 0.0 0.0 16.8 20.2 –0.005 (0.29) –0.02 –0.02 0.767
PANSS 0.0 0.0 0.0 0.0 –3.41 (20.85) –0.16 –0.14 0.004
PANSS positive 2.5 3.4 0.0 0.0 –0.93 (6.17) –0.15 –0.15 0.007
PANSS negative 2.2 4.0 0.0 0.3 –0.78 (6.48) –0.12 –0.11 0.031
PANSS general symptoms 0.3 0.0 0.0 0.0 –1.21 (10.65) –0.11 –0.10 0.042
Personality disorders
SCEPTRE (n = 679a)
EQ-5D 0.0 0.0 4.0 21.6 0.170 (0.29) 0.61 0.58 0.000
ES, effect size; T0, baseline; T1, follow-up.
a n corresponds to the number of patients who completed both measures at both time points.
Note: ES/SRM size – small = > 0.2, ≤ 0.5; moderate = > 0.5, < 0.8; large =≥ 0.8.
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Discussion
Seven data sets were used to examine the psychometric validity of the EQ-5D and SF-6D across a range of
mental health conditions in comparison to existing condition-specific measures. The findings add to the
growing literature relating to the validity of the instruments across mental health populations in the light
of a range of caveats to the findings (described below). The results suggest that the generic preference-
based measures are psychometrically valid for use in common mental health condition and mixed diagnosis
groups in comparison with widely used and validated measures of mental health (HADS and CORE-OM).
Furthermore, there is some evidence that the measures respond to change in health status over time. In
comparison, the evidence for the psychometric validity of the generic preference-based measures in the
schizophrenia and personality disorder patient groups is less clear. There is support for construct validity
across some related domains and some evidence for the discriminant ability of the measures, but
responsiveness to change in health status over time is low.
The psychometric validity of the EQ-5D and SF-6D in common mental health patient samples examined in
this study is consistent with previous empirical work reported in Chapter 2, which established the validity
of the instruments for use in mild depression and anxiety samples. The measures may be valid for use in
these populations because both descriptive systems include mental health-specific questions that are
relevant to depression and anxiety, and they may therefore have a level of sensitivity to the conditions and
some level of association with the widely used comparison measures. We have also established some
evidence that the psychometric performance of the EQ-5D is acceptable in a sample with common mental
health and personality disorder diagnoses who self-harm, and this group could be seen as a moderately
severe sample. There are some differences between the EQ-5D and SF-6D, but direct comparisons are
difficult because the analysis of each measure was carried out using different samples with different
characteristics. However, the evidence for both measures can be seen as complementary in establishing an
overall picture of the psychometric performance of the instruments. The growing evidence base regarding
the validity of the instruments means that the EQ-5D and SF-6D can be considered for use in the economic
evaluation of interventions for common mental health disorders with some level of confidence.
The review in Chapter 2 found limited and mixed evidence for the performance of generic preference-based
measures in schizophrenia. We have also found evidence for and against the validity of these measures in
schizophrenia and personality disorder samples with mixed evidence on the ability of the measures to
reflect schizophrenia-specific symptoms. There is evidence that the EQ-5D may be related to some
condition-specific domains (for example, depression) but not to others (such as positive symptoms), and
again this may be linked to the classification system which directly assesses anxiety and depression but is
not sensitive to other schizophrenia-specific domains. The results indicate that the EQ-5D has the ability
to discriminate across severity groups in schizophrenia, and also across different personality disorder
diagnoses. However, the large ceiling effects at baseline of the EQ-5D in the schizophrenia data sets may
impair its ability to detect change over time. Direct comparisons between the EQ-5D and SF-6D were only
possible for one of the data sets included in this study. The QUATRO study154 demonstrates that neither
instrument converges with the condition-specific measure (but this may not be expected), and neither
instrument responds to change over time at the same level that is reflected in the condition-specific
measures. The mixed evidence regarding the schizophrenia and personality disorder samples means that
the EQ-5D and SF-6D should be used with caution in these groups, and further research in other samples
to investigate psychometric performance in more detail is warranted.
Psychometric analysis of the preference-based measures is one method of assessing validity, and should be
considered alongside other types of evidence to establish a detailed picture of the performance of the
measures. For example, this work should be considered alongside systematic review evidence presented in
Chapter 2, and also qualitative work assessing the content validity and acceptability of the instruments
with mental health service users, presented in later chapters in this report. This allows for detailed insight
into the performance of the instruments and will inform future work to increase the sensitivity and validity
of measurement across a range of mental health conditions. A five-level version of the EQ-5D has been
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developed,177 and it is possible that this version may be more sensitive to different severity levels and
change across time. Further research could assess the validity of the five-level version in people with
mental health conditions.
This study has a number of limitations. We used the level of missing data as a form of proxy for the
feasibility of the measure in mental health populations, an approach which can be criticised as the external
pressures and expectations felt by respondents in trials to complete the measures is unclear. There are a
range of reasons why measures may be incomplete that do not specifically relate to the measure, including
fatigue, illness, lack of motivation, or the position of the questionnaires in the study; those appearing later
in the assessment protocol may have higher levels of missing data.
The inferences that can be drawn from the results are also limited by the data available to carry out the
analysis. The differing levels of performance in terms of construct validity, convergent validity and
responsiveness may reflect systematic variance attributable to different types of data used in this study, the
different patient populations and different study designs. Furthermore, only one data set included both
the EQ-5D and SF-6D. This means that the level of transferability to other mental health samples with similar
diagnoses but different characteristics is unclear, and full comparisons between the generic preference-based
measures are not possible. However, the results presented here across the different samples should be seen
as complementary, and part of the process of building an overall picture of the psychometric validity of the
instruments. Further work into the performance of the generic measures could repeat the analysis reported
here on different data sets using different condition-specific measures and indicators. It would also be useful
to directly compare the EQ-5D and SF-6D in samples where both have been completed.
In summary, we have reported the first work to pool data from a variety of sources to test the psychometric
performance of two widely used generic preference-based measures of HRQoL in populations with mental
health problems. The study adds to the evidence base regarding where generic preference-based measures
can be used in terms of applicable mental health populations. It also highlights possible areas where new
preference-based measures, or additions to existing measures, would improve the measurement of HRQoL
in mental health.
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Chapter 4 Mapping mental health
condition-specific measures to generic
preference-based measures
The previous chapter presented evidence on the validity of the generic preference-based measures, theEQ-5D and the SF-6D, for common mental health problems such as depression and anxiety. Mental
health condition-specific measures (e.g. the HADS and the CORE-OM) tend to be used in clinical studies of
mental health interventions rather than generic measures. Scores from these measures cannot be used for
cost-per-QALY analysis as they are not preference based. One potential solution to the unavailability of the
generic preference-based measure in studies is to map, or cross-walk, the condition-specific measures onto
the generic measure in order to obtain the generic scores. This involves estimating the relationship
between the non-preference-based condition-specific measure and a generic preference-based measure
using statistical association.178 This requires a degree of overlap between the descriptive systems of the
two measures and that the two measures are administered in the same population. The psychometric
analysis indicated that there was some correlation between depression and anxiety measures and generic
preference-based measures, which means that mapping may offer a solution to providing EQ-5D or SF-6D
scores. This chapter aims to develop and test mapping functions from the condition-specific measures for
depression and anxiety that would be used to generate scores where generic preference-based measures
had not been used.
Methods
Analysis focused on the baseline measures for the depression and anxiety data sets presented in the
previous chapter (AHEAD, POPMACT and IAPT) for those with non-missing items, and one additional data
set, Ethnic Minority Psychiatric Illness Rates in the Community (EMPIRIC),179 described below (see Data).
We focused on the two generic measures (target measures), the EQ-5D and SF-6D, as well as the
condition-specific measures used in Chapter 3, the HADS and CORE-OM (source measures). We included
other condition-specific measures that are commonly used in the assessment of depression and anxiety:
the PHQ-9, GAD-7 and GHQ-12, described below (see Measures). This section provides an overview of
the analysis followed by details of measures and mapping functions developed in each data set.
Analysis
Preliminary analysis was undertaken prior to mapping in order to identify which condition-specific
dimensions/items to use (model specification) and which technique to use to model the relationship
between these condition dimensions/items and the target generic measures (model type). Correlation
analysis exploring the relationship between generic scores/dimensions and condition-specific scores/items
was used to identify which dimensions and/or items would be expected to have a strong relationship with
the EQ-5D or SF-6D scores/dimensions and hence the appropriate model specification.180 Correlation
analyses were also used to determine whether or not any independent variables were highly correlated
and, therefore, not recommended for inclusion in the same regression model, at both the dimension and
item levels. We assessed the distribution of the scores of the generic measures to help inform the choice of
estimation technique.
Mapping functions can be generated using different specifications based on assumptions regarding
the relationship between generic measures and condition-specific measures. The simplest function is the
additive model, where our target measure, the EQ-5D or SF-6D score, is regressed on the total score of
the condition-specific measure of interest, for example the HADS total score. This is a limiting specification
as it assumes that the dimensions/items of the starting measure carry equal weight and that responses on
all items lie on the same interval scale.178 This assumption can be relaxed by using the dimensions or items
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from the starting measure instead. Dimension scores are treated as continuous variables whereas items are
modelled as dummy variables, i.e. there is a variable for each level in the item (all of the time, some of the
time, etc.), which has a value of 1 for those at that level and 0 for everyone else. The assumptions of
the additive model can be relaxed by adding interaction terms and squared terms for dimensions.178 This is
often limited to dimension level, especially where there are a large number of items with several levels
which can result in a large number of variables. Analysis may also be limited to statistically significant
items. Other variables can also be included, for example clinical and sociodemographic information. In this
study, we tested additive models with total scores and dimension scores and then tested the inclusion of
interaction and squared terms at the dimension level. We also analysed item-level models but did not test
for interactions or squared terms for these models. Sociodemographic information (age and sex) was
added to the best-fitting models for each condition-specific measure. Comparisons were made between
models that had all variables and those that only included variables that were significant at the 10% level.
We started by using ordinary least squares (OLS) regression to model the relationships, as this is the most
common model technique.178 However, OLS fails to take into account the bounded nature of generic
preference-based measures which have a maximum value of 1. It also fails to take into account the
distribution of some measures such as the EQ-5D, where there may be a large number of respondents at
a score of 1 with non-normal (bimodal or trimodal) distributions.178 The Tobit model can be used to take
into account the bounded nature of the preference-based measure values.180 The two-part model, which
models the probability of having a score of 1 and the generic preference-based measure score for those
not at 1 in two separate regressions, can also be used where there is a sufficient number of respondents
at 1 (full health).180 Assessment of the range and distribution of utility scores was used to determine
whether to use the Tobit or two-part model in the analysis and the models were used where appropriate.
More complex models can be developed whereby, rather than the target measure being the generic
measure score, separate regressions are undertaken on the dimensions of the generic preference-based
measure, referred to as response-level mapping in the literature.181 For example, for the EQ-5D, separate
regressions are carried out for the five dimensions (mobility, self-care, usual activities, pain and anxiety/
depression). Here, the condition-specific measure is used to model the probability of an individual being at
a particular level of the generic measure dimension, for example level 2 for mobility, self-care, etc. This
results in separate regressions for each dimension of the generic preference-based measure, which are
then used to classify individuals in each dimension. Existing tariffs are then used to generate the utility
scores. Multinomial or ordered logistic regressions are used to model these probabilities. We tested the
application of response-level mapping.
Regression coefficients were assessed based on expected relationship with generic preference-based
measure scores and dimensions as well as statistical significance using the Wald test (p≤ 0.1). Model
goodness of fit was measured using R2, adjusted R2, pseudo-R2 and Bayesian information criterion (BIC).
With R2 values, the higher the value, the better the model, and with BIC, the lower the value, the better
the model. The main concern when assessing mapping results is the accuracy of the predictions.180 Model
prediction properties were tested using the root-mean-square error (RMSE), a measure of the difference
between the observed and predicted generic scores. Smaller RMSE values indicate better-performing
models. We also compared RMSE alongside predicted means across the EQ-5D and SF-6D range as well as
using severity measures where group differences were expected. As the aim of the study was to develop
mapping functions that could be used in external studies, it was important to assess how well these
functions would work in an external data set within a similar patient population. Follow-up samples were
available for some of the data sets used. However, patient clinical characteristics may have changed at
follow-up because of interventions, and so generic and condition-specific measure scores may not be
comparable to baseline values. Validation was therefore undertaken for the best-fitting models by splitting
the baseline samples (75%/25%). The larger sample (75%) was used to estimate the model and the
smaller sample was used to validate this model.
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We undertook standard tests for the modelling techniques that we used. For OLS, we assessed whether or
not there was evidence of heteroscedasticity using White’s test. Multicollinearity was assessed using the collin
user-generated command in Stata 11 (StataCorp LP, College Station, TX, USA) and variables exhibiting
collinearity were excluded. Non-linearity was tested using fractional polynomials and squared terms were
tested where there was evidence of non-linearity. The omodel user-generated Stata command was used
to test for the proportional odds assumption when undertaking response-level mapping. Multinomial
regressions were used where this assumption was violated in any one of the dimension regressions, and
ordered logit regressions were used where this assumption held for all the regressions. Logit regressions
were used where there were dependent variables that had been collapsed to two levels because of small
proportions of individuals at the lowest levels; for example, very few individuals reporting level 3 in the
mobility dimension of the EQ-5D. Model specification was assessed using the link test. We report the
performance statistics for the best-fitting models for each condition-specific measure in the main report, and
performance statistics for other models are reported in Appendix 2. Stata 11 was used in all the analyses.
Measures
Generic preference-based measures
We used the two generic preference-based measures – the EQ-5D and the SF-6D described in Chapter 1.
The EQ-5D scores range from –0.594 to 1 and it has five dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression), each with three levels. The SF-6D scores range from 0.30 to 1
and it has six dimensions (physical functioning, role limitation, social functioning, pain, mental health and
vitality) with four to six levels. We mapped to both the scores and dimensions of the two measures where
they were available.
Condition-specific measures
We focused on the common condition-specific measures for depression and anxiety, some of which have
already been introduced in the previous chapter, as follows.
Hospital Anxiety and Depression Scale
The HADS156 has two dimensions: the HADS-D (seven items) and the HADS-A (seven items), with scores
from 0 to 21 as well as the total score. The dimension scores are used separately to identify depression and
anxiety, with high scores indicative of increased levels of symptoms, and these were used as independent
variables to predict EQ-5D and SF-6D scores (NB HADS items were not available in the data sets).
Patient Health Questionnaire
The PHQ-9 is the nine-item depression module of the Patient Health Questionnaire.182 It is a self-report
checklist which covers aspects related to depression. Items are completed on a four-point scale from 0 to 3
(‘not at all’, ‘several days’, ‘more than half the days’, and ‘nearly every day’) with higher scores indicating
depression. An additional item asks respondents to rate the impact of depression on their daily activities.
The PHQ-9 has been shown to be valid for use with patients and the general public to assess depression
and distinguish between levels of severity.183,184 The total score and the items (including the additional
item) were used to predict SF-6D scores.
Generalised Anxiety Disorder Assessment
The GAD-7 items describe the most prominent diagnostic features of the DSM-IV diagnostic criteria for
generalised anxiety disorder.185 On the GAD-7, subjects are asked how often, during the last 2 weeks, they
have been bothered by each of the seven core symptoms of generalised anxiety disorder as well as an
additional question on the impact of these symptoms on their activities. Response options are the same
as the PHQ-9 with higher scores indicating anxiety. The GAD-7 was shown to be a valid measure for
screening for generalised anxiety disorder and assessing severity levels.185,186 Total scores and all items
were used to predict SF-6D scores.
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Clinical Outcomes in Routine Evaluation – Outcome Measure
The CORE-OM165 dimensions of subjective well-being, symptoms (anxiety, depression, physical problems,
trauma), functioning (general functioning, close relationships, social relationships) and risk (risk to self, risk
to others), as well as the 34 items were used to predict SF-6D scores. Items are scored on a five-point,
0–4 scale (‘not at all’, ‘only occasionally’, ‘sometimes’, ‘often’, ‘all or most of the time’) and means are
computed for dimension and total scores, with higher scores indicating problems in those dimensions.
General Health Questionnaire
The GHQ-12 is a self-report measure of psychological morbidity, intended to detect ‘psychiatric disorders . . .
in community settings and non-psychiatric settings’.187 It is widely used in clinical practice, epidemiological
research and psychological research. It comprises six items that are positive descriptions of mood states
(e.g. ‘felt able to overcome difficulties’) and six that are negative descriptions of mood states (e.g. ‘felt like a
worthless person’). Total scores range from 0 to 12 and item levels range from 1 to 4, with higher scores
indicating psychological morbidity. The GHQ-12 has been validated for use in mental health populations.188
The total GHQ score and the items were used to predict SF-6D scores.
The condition-specific total and dimension scores increase with increasing severity and were therefore
expected to be negatively associated with generic measure scores and positively associated with generic
measure dimensions.
Data
We focused on two common mental health conditions data sets (AHEAD and IAPT) and one common
mental health conditions and personality disorders data set (POPMACT), described in detail in Chapter 3.
The PoNDER sample was not used as it focused on women with postnatal depression and mapping
functions developed from this sample may not be transferable to other, more general samples. We also
included an additional sample (EMPIRIC), described below.
Assessing Health Economics of Antidepressants
The AHEAD study,150 which focused on patients who reported a range of common mental health concerns
including depression, MADD and a number of phobias (n = 286) was used to map from the HADS to
the EQ-5D.
POPMACT
A second data set that contains the EQ-5D and HADS is the POPMACT study,189 which recruited patients
presenting with recurrent deliberate self-harm (n = 475). There are differences in AHEAD and POPMACT
populations in terms of HADS and EQ-5D scores and separate algorithms were therefore developed for the
two samples. HADS depression scale cut-offs identifying probable cases of depression (> 10) were used as
the measure of severity in assessing the predictive ability of the mapping functions in the AHEAD and
POPMACT samples.
Improving Access to Psychological Therapies
The IAPT cohort study,152 which focused on patients with mild/moderate depression and/or anxiety
(n = 394), was used to develop mapping algorithms between the PHQ-9, GAD-7, CORE-OM and SF-6D.
The PHQ-9 depression scale cut-offs identifying severity levels of depression were used to assess the
predictive performance for the mapping functions developed from these measures.
Ethnic Minority Psychiatric Illness Rates in the Community
The EMPIRIC study,179 which was used to estimate the prevalence of psychotic symptoms and risk factors
for reporting psychotic symptoms in a community-based sample of people from different ethnic groups,
was used to map between the GHQ-12 and the SF-6D. The study was a cross-sectional survey of
4281 adults aged 16–74 years living in private households in England. The analysis focuses on those
who had any depressive or anxiety episodes (n = 213). The Revised Clinical Interview Schedule (CIS-R),190
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which is used for identifying the presence of common mental health disorders, was used to assess the
performance of mapping functions.
Results
Preliminary analysis results
Range and distribution of scores
Descriptive statistics are reported in Table 15. Across all four samples, most of the generic scores did not
cover the full range of the measures, apart from in the POPMACT sample. None of the SF-6D scores were
at 1, and there were only a few individuals (7/286) at 1 in the EQ-5D in the AHEAD sample. Most of the
condition-specific measures cover the full range of scores.
The EQ-5D scores showed evidence of bimodal distributions whereas SF-6D scores were approximately
normally distributed across the samples (Figure 4). Distribution of EQ-5D dimension levels was skewed,
with < 5% of individuals in level 3 in all dimensions apart from the anxiety and depression dimension
(25%) in the AHEAD sample. In the POPMACT sample, the EQ-5D dimensions had < 1% in level 3 for
mobility and self-care. SF-6D dimension levels were evenly distributed in both IAPT and EMPIRIC samples.
Correlation analysis
Preliminary analysis of correlations between the generic preference-based measure and the condition-specific
measures as reported in Chapter 3 indicated that there was a moderate level of convergence between the
EQ-5D and the HADS, with negative correlations ranging from 0.25 to 0.49 across the AHEAD and
POPMACT samples. The correlations were smaller in the AHEAD sample, which may indicate that the HADS
will be a poor predictor of EQ-5D scores in this sample. Further correlation analysis (see Appendix 3, Table 36)
indicated that the HADS dimension scores and total scores were poorly correlated with most dimensions of
the EQ-5D, with positive correlation scores ranging from 0.01 to 0.21 in mobility, self-care and pain
dimensions across the two samples. Correlations with the usual activities dimensions ranged from 0.17 to
0.40, with high correlations in the POPMACT sample. The anxiety/depression dimension had moderate
correlations of 0.39 to 0.50 (see Appendix 3, Table 37). HADS dimensions were therefore expected to be
poor predictors of the EQ-5D dimensions. In contrast, the SF-6D scores had better correlations, ranging from
0.33 to 0.56, indicating that HADS dimensions could be better predictors of SF-6D scores. SF-6D dimensions
were not available so correlations were not tested.
Total scores of the PHQ-9, GAD-7 and CORE-OM total and dimension scores were moderately correlated
with SF-6D score (0.52 to 0.65), apart from the CORE-OM risk dimension which had a smaller correlation
(0.35) (see Appendix 3, Table 38). These measures were positively correlated with SF-6D dimensions with
the largest correlations in the SF-6D mental health dimension, whereas physical functioning and pain had
smaller correlations (< 0.4). Correlations between the SF-6D score and the PHQ-9 items ranged from 0.34
to 0.59; for the GAD-7 they ranged from 0.36 to 0.51. SF-6D dimension correlations with PHQ-9 items
were moderate to high in most dimensions apart from the pain dimension; the same was true for the
GAD-7 items, but correlations with the physical functioning dimension were also low. CORE-OM items in
the IAPT sample had moderate negative correlations with the SF-6D score. Item-level correlations mainly
ranged between 0.3 and 0.5. Correlations between SF-6D dimensions and CORE-OM items were also
positive and moderate for most of the items. This indicated that the PHQ-9, GAD-7 and CORE-OM could
be good predictors of SF-6D scores and dimensions apart from pain and physical functioning. Correlation
results for these three measures are reported in the appendices (see Appendix 3, Tables 39–42).
The GHQ-12 in the EMPIRIC sample had low correlations with the SF-6D at the total score and item level
(< 0.3) (see Appendix 3, Table 43). Correlations with SF-6D dimensions were also small. This indicated that
the GHQ-12 would be a poor predictor of SF-6D scores and dimensions.
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TABLE 15 EQ-5D, SF-6D and condition-specific measure summaries and descriptive statistics
Variables Mean SD Minimum Maximum
AHEAD (n = 286)
EQ-5D 0.62 0.26 −0.13 1
SF-6D 0.62 0.09 0.30 0.80
HADS-D 10.48 3.95 0 20
HADS-A 13.06 3.47 2 20
HADS-T 23.54 5.89 6 38
Age 42.5 15.32 17 91
Female n (%) 192 (67.1)
POPMACT (n = 475)
EQ-5D 0.50 0.32 –0.59 1
SF-6D – – – –
HADS-D 11.22 4.55 0 21
HADS-A 14.15 3.95 0 21
HADS-T 25.37 7.45 0 42
Age 32.0 11.23 16 66
Female n (%) 325 (68.4)
IAPT (n = 394)
SF-6D 0.62 0.13 0.30 0.93
CORE-OM T 19.84 7.77 0.88 37.94
CORE-OM W 2.57 0.93 0.00 4.00
CORE-OM S 2.37 0.92 0.08 4.00
CORE-OM F 2.10 0.85 0.00 4.00
CORE-OM R 0.60 0.79 0.00 4.00
PHQ-9 15.59 7.05 0.00 27.00
GAD-7 13.42 5.59 0.00 21.00
Age 40.0 13.9 16 89
Female n (%) 283 (71.8)
EMPIRIC (n = 213)
SF-6D 0.59 0.11 0.35 0.88
GHQ-12 16.97 7.33 2 36
Age 39.0 13.97 16 73
Female n (%) 127 (59.6)
CORE-OM F, CORE-OM functioning; CORE-OM R, CORE-OM risk; CORE-OM S, CORE-OM symptoms; CORE-OM T,
CORE-OM total; CORE-OM W, CORE-OM well-being.
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FIGURE 4 SF-6D and EQ-5D histograms. (a) SF-6D; and (b) EQ-5D.
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This initial analysis indicated that OLS regression analysis was likely to be the best approach for the SF-6D
scores; as there were no individuals with a score of 1, the Tobit model would not improve results and
two-part models could not be undertaken. The EQ-5D scores had a small percentage at full health in the
AHEAD and POPMACT samples, so Tobit models may result in some differences, and these were tested.
However, two-part models cannot be run where there are very few individuals in full health, as was the
case in these samples. Multinomial regressions for predicting EQ-5D and SF-6D dimensions could be
undertaken and, again, small numbers at lower levels for EQ-5D dimensions and poor correlations meant
that these models were not expected to generate large improvements over the OLS model. Table 16
provides an overview of the data sets and measures and the analysis that was undertaken. This includes the
dependent variables based on the available data, the independent variables which are the condition-specific
measures, the model type and the model selection information, based on the preliminary analysis results.
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CIS, Clinical Interview Schedule.
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Mapping results
In this section we report performance statistics of the best-fitting models for each source measure (HADS,
PHQ-9, GAD-7, CORE-OM and GHQ-12) and the two target measures (EQ-5D and SF-6D). Performance
statistics of the best-fitting models from the other models that were tested, and OLS regression results, are
reported in Appendix 3.
Hospital Anxiety and Depression Scale and EQ-5D
Ordinary least squares regressions were undertaken for the EQ-5D regressions with HADS dimensions and
total scores in the AHEAD and POPMACT samples. The best-fitting models were the total score model in
the AHEAD sample and the model with both anxiety and depression dimensions in the POPMACT sample.
Coefficients were negative as expected, indicating that as depression and anxiety increase, EQ-5D scores
fall. Figure 5 shows the predicted and observed scores for these two models; these have a weak
association, particularly on the ends of the scale. Interaction terms were not statistically significant and
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FIGURE 5 Predicted and observed EQ-5D – HADS. (a) HADS total score (AHEAD); and (b) HADS-A and
HADS-D (POPMACT).
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Summary goodness of fit and predictive measures are reported in Tables 17 (AHEAD) and 18 (POPMACT).
As OLS is used, the predicted mean value for the best-fitting models is the same as the observed values, but
the minimum and maximum scores indicate a smaller range of values. This reflects findings shown in
Figure 5 that these models overpredicted at the bottom end of the EQ-5D and underpredicted at the top
end. As expected, there was poor association between these predictors and the EQ-5D with small R2 values,
particularly in the AHEAD sample. In the AHEAD sample, age was statistically significant and improved
predictive performance (Table 17, model 2) based on BIC. However, the link test indicated that this model
was misspecified and the White test showed evidence of heteroscedasticity. Predictive performance was
poor, with a RMSE of 0.375 for EQ-5D scores < 0.3 and 0.193 for scores > 0.8 in the AHEAD sample.
Although not directly comparable, RMSE scores in the POPMACT sample exhibited a similar pattern, with
large RMSEs at the severe end (RMSE = 0.299 for EQ-5D values < 0). Predictions were slightly better at the
top end of observed EQ-5D scores for the POMACT sample (RMSE = 0.082 to 0.088). Age and sex were not
statistically significant in this sample. There was evidence that predicted EQ-5D scores could discriminate
between individuals with and without depression in both samples but the RMSEs were still large.
TABLE 17 Summary performance statistics: OLS regressions, EQ-5D onto HADS (AHEAD)
Independent variables Observed EQ-5D
Predicted EQ-5D
Model 1 Model 2
HADS-T HADS-T + age
Summary statistics
Mean 0.61 0.61 0.61
SD 0.262 0.104 0.115
Minimum –0.126 0.3571 0.3332
Maximum 1 0.9208 0.9173
Regression performance statistics
R2 0.156 0.193
Adjusted R2 0.153 0.187
RMSE 0.194 0.188
BIC 8 1
EQ-5D range n Mean EQ-5D Mean EQ-5D RMSE Mean EQ-5D RMSE
< 0.3 59 0.1816 0.5565 0.375 0.5495 0.368
0.3 to 0.599 34 0.4186 0.5421 0.129 0.5254 0.124
0.6 to 0.699 52 0.6709 0.6142 0.098 0.6002 0.099
0.7 to 0.799 34 0.7402 0.655 0.098 0.655 0.105
0.8 to 1 107 0.8408 0.6495 0.193 0.6655 0.179
HADS-D n Mean EQ-5D Mean EQ-5D RMSE Mean EQ-5D RMSE
Non-case/possible≤ 10 147 0.6931 0.6821 0.169 0.6816 0.160
Probable case > 10 139 0.5258 0.5374 0.221 0.5379 0.218
Regression results are reported in Appendix 3, Table 48.
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TABLE 18 Summary performance statistics: OLS regressions (POPMACT – EQ-5D)














EQ-5D range n Mean EQ-5D Mean EQ-5D RMSE
≤ 0 33 –0.1245 0.4021 0.299
0.001 to 0.199 60 0.1295 0.4423 0.117
0.2 to 0.299 64 0.263 0.4324 0.045
0.3 to 0.599 90 0.4242 0.4449 0.017
0.6 to 0.699 57 0.6699 0.532 0.037
0.7 to 0.799 45 0.7374 0.5421 0.062
0.8 to 0.899 103 0.8382 0.586 0.082
0.9 to 1 23 1 0.7295 0.088
HADS-D n Mean EQ-5D Mean EQ-5D RMSE
Non-case/possible≤ 10 210 0.622 0.6375 0.220
Probable case > 10 265 0.4104 0.3981 0.233
Regression results are reported in Appendix 3, Table 49.
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Tobit regressions were also undertaken. Summary statistics of the best-fitting model indicated that OLS
performed better than Tobit in terms of BIC for both samples, with little difference in terms of overall
RMSE (see Appendix 3, Tables 44 and 45). However, RMSE over the EQ-5D range showed that the
Tobit model performed slightly better at the severe end of the EQ-5D scale and worse at the top end.
Response-level mapping models were also tested for the two best-fitting OLS models: those with anxiety
and depression combined and with the total scores. As already noted, there were very few individuals at
level 3 in the five EQ-5D dimensions and dimension levels had to be collapsed in order to run these
models. This resulted in loss of information and poor predictive performance, especially at the severe end
of the EQ-5D scale, with RMSE > 0.5. The best-fitting response-mapping model performance statistics are
also reported in Appendix 3, Tables 44 and 45.
Hospital Anxiety and Depression Scale and SF-6D
Ordinary least squares regressions to predict the SF-6D from the HADS in the AHEAD sample indicated
that the best-fitting model based on BIC was the one with both the HADS-D and HADS-A dimension
scores. This model showed evidence of heteroscedasticity but no evidence of misspecification based on the
link test. The coefficients were negative, as expected. Plots of the predicted and observed SF-6D scores
indicated that the HADS was poor at predicting SF-6D scores, particularly at the severe end of the scale
(Figure 6). Minimum predicted SF-6D scores for Models 4 and 5 were much higher than the observed
SF-6D scores (Table 19), although RMSE for scores < 0.5 indicate that this might be an outlier as these
range between 0.141 and 0.134. There was also evidence of underpredicting at the top end of the SF-6D
scale. The R2 values were higher than those reported for the EQ-5D regressions, indicating better
association. As with predicted EQ-5D scores, predicted SF-6D scores are able to discriminate between
those with and without depression. Interaction and squared terms do not add to the model, although age
was statistically significant and added to the model (Table 19). Tobit models did not provide improvements
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FIGURE 6 Predicted and observed SF-6D – HADS (AHEAD).
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Patient Health Questionnaire and SF-6D
The best-fitting model from the PHQ-9 regressions based on the BIC was the item-level model with
significant items only; however, the full item-level model performed better in terms of predictive ability and
results from the latter model are therefore reported. The coefficients on most of the items were negative
and statistically significant. Items related to suicidal thoughts and ‘feeling bad about yourself’ were
positive, which is contrary to expectations as this indicates that reporting these symptoms is associated
with higher SF-6D scores. Figure 7 shows the predicted and observed SF-6D scores indicating some
association. R2 was high in the item-level models (Table 20, model 6). There was evidence of
overpredicting severe health problems and underpredicting for those in better health. RMSEs are similar
at both ends of the SF-6D scale. Predicted SF-6D scores are able to discriminate across patients with
depression with RMSEs < 0.1. As expected, Tobit models did not offer any advantage over the best-fitting
OLS model as there were no individuals at the top of the SF-6D scale (see Appendix 3, Table 46).
Response-level mapping models also performed poorly relative to OLS, with large RMSEs at the severe end
of the scale (see Appendix 3, Table 47). This was mainly because dimensions and items had to be
collapsed into smaller numbers of levels in order for the models to run.
TABLE 19 Summary performance statistics: OLS regressions (AHEAD – SF-6D)
Independent variables Observed SF-6D
Predicted SF-6D





Mean 0.6118 0.6118 0.6118
SD 0.089 0.049 0.051
Minimum 0.2968 0.5003 0.4942
Maximum 0.8037 0.766 0.7645
Regression performance statistics
R2 0.305 0.326
Adjusted R2 0.301 0.319
RMSE 0.059 0.057
BIC –660 –663
SF-6D range n Mean SF-6D Mean SF-6D RMSE Mean SF-6D RMSE
< 0.5 27 0.4478 0.5885 0.141 0.5816 0.134
0.5–0.599 82 0.5556 0.5963 0.050 0.5956 0.049
0.6–0.699 124 0.6496 0.6214 0.042 0.623 0.042
0.7–0.804 53 0.7379 0.6692 0.069 0.6702 0.068
HADS-D n Mean SF-6D Mean SF-6D RMSE Mean SF-6D RMSE
non-case/possible≤ 10 147 0.6584 0.6575 0.059 0.6574 0.058
Probable case >10 139 0.5793 0.5803 0.058 0.5804 0.057
Regression results are reported in Appendix 3, Table 50.
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FIGURE 7 Predicted and observed SF-6D – PHQ-9 and GAD-7 (IAPT). (a) PHQ-9 items; (b) GAD-7 items; and (c) PHQ-9
and GAD-7 items.
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TABLE 20 Summary performance statistics: OLS regressions (IAPT – SF-6D and PHQ-9, GAD-7)
Independent variables
Observed
SF-6D (n = 394)
Predicted SF-6D
Model 6 Model 7 Model 8




Mean 0.6193 0.6193 0.6193 0.6193
SD 0.126 0.091 0.078 0.093
Minimum 0.301 0.4242 0.4834 0.4079
Maximum 0.929 0.8595 0.8336 0.8719
Regression performance statistics
R2 0.516 0.383 0.538
Adjusted R2 0.476 0.342 0.487
RMSE 0.070 0.079 0.067










< 0.4 20 0.3610 0.4929 0.132 0.5319 0.171 0.4944 0.133
0.4–0.499 51 0.4690 0.5592 0.093 0.5699 0.101 0.5537 0.088
0.5–0.599 100 0.5587 0.5692 0.053 0.5871 0.056 0.5682 0.053
0.6–0.699 125 0.6386 0.6354 0.051 0.625 0.054 0.6344 0.048
0.7–0.799 60 0.7444 0.687 0.066 0.6747 0.079 0.6904 0.064










None/mild 90 0.7272 0.7273 0.073 0.6934 0.085 0.726 0.069
Moderate 84 0.6501 0.6475 0.071 0.6481 0.079 0.6498 0.068
Severe 220 0.5634 0.5643 0.068 0.578 0.076 0.564 0.066
Regression results are reported in Appendix 3, Tables 51–53.
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Generalised Anxiety Disorder Assessment and SF-6D
The GAD-7 OLS regression results indicated that there was poor association between this measure and
the SF-6D. The best-fitting model was the full-item model, but most of the items were not statistically
significant, and those that were are mainly negative, as expected. Figure 8 shows that there was poor
association between observed and predicted SF-6D scores. R2 values were smaller than those of the PHQ-9.
Maximum and minimum scores were lower and higher than those of the PHQ-9 (see Table 20, model 7).
RMSEs were therefore also larger. Despite evidence of poor predictive performance, predicted scores are
able to discriminate across depression severity groups. Similar to the PHQ-9 results, Tobit did not offer any
advantage over OLS and the response-level mapping performed poorly (see Appendix 3, Tables 46 and 47).
Patient Health Questionnaire-9 items and Generalised Anxiety
Disorder Assessment
We also assessed the use of both PHQ-9 and GAD-7 total scores and items to predict the SF-6D scores.
The measures assess depression and anxiety which can occur as comorbidities, and so using both measures
may capture more variation than each individual measure. Both measures are used in routine data
collection in the IAPT services, so may provide a better specification for predicting SF-6D scores for this
routine data. A number of items were excluded from the item-level models as there was a high degree of
collinearity. Items that were statistically significant were mainly negative and were from the PHQ-9, with
one item from the GAD. The best-fitting model based on BIC was the PHQ-9 significant item model, but
the full item model (excluding highly collinear items) performed better in predictive terms and this is
reported (model 8). This model shows no evidence of heteroscedasticity or misspecification, although there
is some evidence of collinearity. Combining these measures offered slight improvements in terms of
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FIGURE 8 Predicted and observed SF-6D – CORE-OM (IAPT). (a) CORE-OM items; and (b) CORE-OM significant items.
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Clinical Outcomes in Routine Evaluation – Outcome Measure and SF-6D
The OLS results for the dimension scores of the CORE-OM indicate that only the symptoms dimension
was statistically significant. As the CORE dimensions have a short range (0 to 4, but this includes values
between whole numbers), a different specification using the dimension scores as levels was tested.
This did not improve the results, with weak associations between predicted and observed SF-6D scores.
CORE-OM items provided better-fitting models. Items from all four dimensions (well-being, symptoms,
functioning and risk) were statistically significant in the item-level regressions. There was evidence of a
strong association between the observed and predicted scores using CORE items (see Figure 8). R2 values
were high (> 0.5), although adjusted R2 values were slightly lower (Table 21). There was some evidence of
misspecification for the CORE item models as well as collinearity. Although the CORE models had better
R2, they overpredicted SF-6D scores more than the PHQ-9 models at the severe end of the health scale as
well as underpredicting better health. Predicted SF-6D scores can discriminate between those with and
without depression. Tobit and response-level models were tested but these did not offer improvements
over OLS (see Appendix 3, Tables 46 and 47).





Model 9 Model 10
CORE items CORE significant items
Summary statistics
Mean 0.6193 0.6193 0.6193
SD 0.126 0.107 0.099
Minimum 0.301 0.3639 0.4113
Maximum 0.929 0.8898 0.8528
Regression performance statistics
R2 0.714 0.609
Adjusted R2 0.576 0.574
RMSE 0.054 0.062
BIC –235 –686
SF-6D range n Mean SF-6D Mean SF-6D RMSE Mean SF-6D RMSE
< 0.4 20 0.3610 0.4593 0.103 0.4855 0.125
0.4–0.499 51 0.4690 0.4971 0.046 0.5087 0.053
0.5–0.599 100 0.5587 0.5685 0.047 0.5729 0.050
0.6–0.699 125 0.6386 0.6442 0.047 0.6456 0.051
0.7–0.799 60 0.7444 0.7079 0.053 0.7005 0.057
0.8–1 38 0.8552 0.779 0.080 0.745 0.111
PHQ-9 cut-offs n Mean SF-6D Mean SF-6D RMSE Mean SF-6D RMSE
None/mild 90 0.7272 0.7156 0.061 0.7063 0.071
Moderate 84 0.6501 0.6508 0.053 0.6483 0.064
Severe 220 0.5634 0.5678 0.051 0.5726 0.057
Regression results are reported in Appendix 3, Table 55.
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General Health Questionnaire and SF-6D
The GHQ-12 item-level model performed better than the total score model. The coefficients were mainly
negative, as expected, but the plots of observed and predicted SF-6D scores show that there is weak
association in these values (Figure 9). R2 and adjusted R2 values were low as expected. Exclusion
of correlated items did not improve the GHQ-12 item-level models. There was no evidence of
misspecification, but the White’s test indicated the presence of heteroscedasticity. There was evidence of
over- and underpredicting of the SF-6D scores, with large differences between observed and predicted
SF-6D scores at the minimum and maximum values (Table 22). RMSE values ranged from 0.116 to 0.166 at
the top and bottom of the SF-6D scale; these values were not as large as those reported by some of the
models for other measures. Small RMSEs might be driven by small numbers at the top and bottom of the
SF-6D range. The predicted SF-6D scores did not vary significantly based on CIS-R severity levels. Tobit and
response-level models were not estimated as they were unlikely to improve on the poorly performing
OLS models.
Validation of best-performing models
Models 1 to 8 (HADS, PHQ-9, GAD-7) and model 11 (GHQ-12) were poor predictors of EQ-5D and SF-6D
scores and these were therefore not validated. The CORE-OM items models (models 9 and 10) performed
reasonably in estimating SF-6D scores within the sample. Validation of these models was therefore
undertaken using 75% of the sample to estimate and 25% of the sample to validate the models. Results
are reported in Table 23. Mean predicted SF-6D values were lower than observed values. As with
in-sample predictions, the RMSEs showed evidence of over- and underpredicting severe and better health
states. The RMSEs were larger across the EQ-5D range and severity measures, although focusing on
significant items improves the model’s predictive abilities. This is evident in Figure 10, which shows
observed and predicted scores with evidence of poor association, particularly at both ends of the SF-6D
scale. However, a larger sample may be required to validate this model, as although the sample matches
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FIGURE 9 Predicted and observed SF-6D – GHQ-12 (EMPIRIC).
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TABLE 22 Summary performance statistics: OLS regressions (EMPIRIC – SF-6D)














SF-6D range n Mean SF-6D GHQ items RMSE
< 0.5 38 0.4341 0.5469 0.116
0.5 to 0.599 82 0.5515 0.5862 0.050
0.6 to 0.699 65 0.6421 0.6039 0.051
0.7 to 0.878 28 0.7897 0.6237 0.166
CIS n Mean SF-6D GHQ items RMSE
12 to 17 43 0.6306 0.6061 0.087
18 to 23 58 0.6231 0.6057 0.082
24 to 29 51 0.5858 0.576 0.072
30 to 35 45 0.5374 0.5779 0.073
36+ 16 0.5159 0.562 0.062
CIS, Clinical Interview Schedule.
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Model 9 Model 10
CORE items CORE significant items
Mean 0.6208 0.6165 0.6159
SD 0.125 0.117 0.092
Minimum 0.301 0.3555 0.4387
Maximum 0.916 0.8858 0.7883
SF-6D range n Mean SF-6D Mean SF-6D RMSE Mean SF-6D RMSE
< 0.4 5 0.3526 0.5357 0.183 0.5033 0.151
0.4–0.499 13 0.4801 0.5085 0.055 0.5223 0.055
0.5–0.599 25 0.5602 0.5705 0.087 0.5727 0.060
0.6–0.699 31 0.6413 0.6667 0.072 0.6528 0.049
0.7–0.799 15 0.7368 0.6465 0.113 0.6777 0.068
0.8–1 10 0.8518 0.7122 0.144 0.6948 0.157
Total 0.6208 0.6165 0.092 0.6159 0.071
PHQ-9 cut-offs n Mean SF-6D Mean SF-6D RMSE Mean SF-6D RMSE
None/mild 19 0.7144 0.7002 0.091 0.6864 0.065
Moderate 19 0.6594 0.6501 0.097 0.6568 0.088
Severe 61 0.5796 0.58 0.091 0.5812 0.068
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FIGURE 10 Predicted and observed scores: SF-6D and CORE-OM (IAPT) out-of-sample validation. (a) CORE-OM items
(n = 99); and (b) CORE-OM significant items (n = 99).
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Discussion
This chapter tested different functions for mapping from commonly used condition-specific measures for
depression and anxiety to two generic preference-based measures, the EQ-5D and SF-6D. The results
indicate that commonly used mental health measures for depression and anxiety are not good predictors
of EQ-5D and SF-6D scores. This is not surprising as most of the mental health measures focus mainly on
mental health, and often on very narrow aspects of symptoms of mental health, whereas the generic
measures have a wider scope. For example, the HADS, PHQ-9 and GAD-7 focus on depression or anxiety
but there are no questions on how this may impact on normal activities in the items included in total
scores. The PHQ-9 and GAD-7 include an additional question on normal activities, which does not form
part of the total score but is used in the item-level regressions. This was an important predictor of SF-6D
scores. The GHQ-12 has a single question on the impact of symptoms on daily activities, but the other
11 questions concern symptoms. Both the EQ-5D and SF-6D have dimensions related to mental health but
they also cover other aspects of health, such as physical (mobility) and social functioning and normal
activities (role limitation, usual activities, self-care) as well as pain. There is, therefore, poor conceptual
overlap between these condition-specific measures and the generic preference-based measures, which can
be a problem when mapping from condition-specific measures to generic preference-based measures.178
The CORE-OM provides a better predictor of SF-6D scores than the other measures. This is mainly because
it is not just focused on mental health symptoms, but includes general and social functioning as well as
physical problems. Model validation of the CORE item-level models indicates that the model with
significant items may be a solution to providing utility values where utility values are not available.
However, further validation is required as the small sample size may be driving some of the results. There
may also be concerns regarding the transferability of this mapping function as the full range of SF-6D
scores was not available in the estimation sample.
Item-level models used to predict the EQ-5D/SF-6D scores fit better than the total or dimension score
models. However, the latter are more likely to be used as total and dimension scores are reported in
publications. Mortimer et al.191 compared the performance of item-based and dimension-based mapping
and concluded that the item-based approaches may be restrictive owing to data requirements. They found
that scale/dimension-based approaches offer similar results to item-based approaches where there is
conceptual overlap between measures.
Predicting generic preference-based measure dimensions instead of scores did not improve the results.
The relatively small sample sizes used in our analysis compared to other mapping studies do not provide
enough data to fit these types of regressions, particularly using condition-specific measure items. Generic
preference-based measure dimension levels and condition-specific measure item levels had to be collapsed
in order to fit the models, and this results in loss of information. Gray et al.,181 who developed the
response mapping approach, had large data sets (n > 10,000) which allowed them to carry out these
regressions without loss of data. Furthermore, the lack of conceptual overlap is magnified when fitting the
generic preference-based measure dimensions as condition-specific measures are poor at predicting the
majority of these.
Ordinary least squares provides the best model fit in this mapping analysis. The range covered in the
observed generic preference-based measures in the samples used did not include many individuals at full
health for the EQ-5D and none for the SF-6D. Tobit models which have been used in other mapping studies
to take into account the bounded nature of these generic measures did not improve the results. Two-part
models used to take into account the large number of individuals who report full health could not be
carried out. As with other mapping studies, models overpredicted severe health problems and
underpredicted better health. One potential solution to the overpredicting of severe health problems
(which tends to be greater than the underprediction of better health) is to use two separate regressions:
one for those with severe health problems and another for those in better health.192 A spline which takes
into account differences in the relationship between predictor variables and predicted values as the latter
changes may also provide a solution. The EQ-5D shows a bimodal distribution in both AHEAD and
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POPMACT samples at the lower end of the scale and so a two-part model may have improved
performance; however, given the poor predicting properties of the HADS, this was not tested. Development
of mapping functions for measures such as the CORE-OM to the EQ-5D should test such an approach.
A recent review of studies on mapping from condition-specific measures to the EQ-5D193 found only one
published study in mental health, by Serrano-Aguilar et al.194 This study developed a mapping function for
the GHQ-12 to the EQ-5D using data from a representative random sample in the Canary Islands
(n = 3567). Mean EQ-5D scores were high in this study (0.82) and only 19% of the sample showed
evidence of psychiatric problems based on the GHQ-12. Validation indicated that the mapping function
underpredicted the top end of the scale, with mean differences between observed and predicted scores of
0.25; however, predicted values were able to discriminate between psychiatric morbidity cases. RMSEs
were not reported. The lack of other published studies on mapping in mental health may be an indicator
of the poor performance of mental health condition-specific measures. However, it may also result from
the lack of available data to perform mapping, particularly for the EQ-5D.195 Future work should consider
identifying studies in which both generic preference-based measures and mental health measures for
depression and anxiety have been used, in order to perform further testing of mapping algorithms.
Overall, this chapter shows that mapping from mental health condition-specific measures, such as the
widely used PHQ-9, GAD and HADS, may not be an appropriate approach to generating EQ-5D and SF-6D
scores as these measures focus on specific symptoms and not on the wider impact of mental health
conditions. The CORE-OM was better at predicting the SF-6D, but there were still problems in terms of
under- and overpredicting. The poor performance of the mapping functions may also be a consequence of
the generic measures not being sufficiently sensitive to the range of mental health problems reflected in
the condition-specific measures. The way mental health impacts on quality of life is examined in more
depth through the use of qualitative techniques in the next two chapters.
MAPPING MENTAL HEALTH CONDITION-SPECIFIC MEASURES TO GENERIC PREFERENCE-BASED MEASURES
60
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Chapter 5 A synthesis of qualitative research
on the quality of life of people with mental
health problems
The review of the psychometric evidence presented in Chapter 2 and the analysis of the seven data setsin Chapter 3 found that the EQ-5D and SF-36 achieved an adequate level of performance in terms of
the quantitative psychometric tests of validity and responsiveness in depression, and to some extent in
anxiety and personality disorder. The mapping work in the previous chapter raises some additional
concerns as to whether or not the EQ-5D in particular is able to fully reflect the specific impact of common
mental health problems. Results from the psychometric analyses were mixed in schizophrenia and bipolar
disorder, with a suggestion that the EQ-5D and SF-36 may be reflecting depression rather than other
consequences of these conditions. It was not possible to determine the reason for the mixed results from
these analyses. This was the rationale for looking at qualitative research, as this provides evidence on the
content validity of these measures in people with mental health problems.
The overall purpose of the qualitative components of this project is to identify the domains that will be
used to assess the content validity of the generic measures presented in Chapter 7. The aim of this
systematic review of qualitative research was to begin to identify the quality of life domains that are
important from the perspective of an individual with mental health problems. It provides an important
input into the topic guide used in the interviews reported in Chapter 6, and a basis for starting to identify
the core themes of quality of life reported by people with mental health problems.
The focus of this review was primary qualitative research studies which, using methods such as interviews
and focus groups, explicitly asked adults with mental health problems what they considered to be
important to their quality of life or how their quality of life had been affected by their mental health
problems. A range of approaches is available for synthesising qualitative research.196 Paterson et al.197
recommend that the choice is made based on the nature of the research question and design, the
prevailing paradigm and the researcher’s personal preference. In this review, framework synthesis was
used. This is based on the ‘framework’ approach for the analysis of primary data198 and is a structured
approach to organising and analysing data which permits the expansion and refinement of an a priori
framework to incorporate new themes emerging from the data.196
This chapter reports a summary of the main findings of the review. A more detailed account is provided
in Connell et al. 2012.199
Methods
Search methods
Systematic reviews of evidence of clinical effectiveness require extensive searching based on a clearly
focused search question. Defining a focused question was not possible nor appropriate here, given the
exploratory and inductive nature of the review process. An iterative approach to searching was used, in
order to accommodate within the search process new themes emerging throughout the review. Extensive
searching was undertaken, using a number of search techniques. Database searches were undertaken
between October 2009 and April 2010 and included MEDLINE, Applied Social Sciences Index and
Abstracts (ASSIA), Cumulative Index to Nursing and Allied Health Literature (CINAHL), PsycINFO and Web
of Science. Search techniques included keyword searching, taking advice from experts, hand searching,
citation searching of relevant references and internet searching. Four iterations of searching were
undertaken (see Appendix 4, Table 56). The searches were not restricted by date, language or country.
Key search terms used were mental health, mental illness, mental disorder, quality of life, well-being, life
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satisfaction, life functioning, life change, recovery, subjective experience, lived experience, lifestyle, coping,
adaptation, qualitative and qualitative research. For a full list of search terms and details of the search
iterations see Appendix 4.
Inclusion and exclusion criteria
Quality of life
The review started from a premise of not imposing a preconceived definition of ‘quality of life’. Some
studies identified had an explicit aim to explore quality of life whereas others did not. Complexities arose
in deciding which studies were about the same substantive concept of quality of life and which were
tapping into a separate but overlapping concept. Sandelowski200 states that ‘often research purposes and
questions are so broadly stated it is only by looking at the kinds of findings produced that topical similarity
can be determined’. Taking this approach, it was evident that many studies had similar findings even
though quality of life was not the subject of investigation. The concepts examined in these studies were
recovery, lived experience, subjective experience, psychosocial issues, health needs, and strategies for
living. Inclusion of these studies had the potential to introduce themes that were not central to the
concept of quality of life but were rather allied to a separate but related concept. A pragmatic decision
was made to examine the research aims and interview questions of those studies that did not directly
investigate the concept of quality of life, and to include those that asked broad, open-ended questions
about how participants’ mental health affected their lives, or what was important to or would improve
their lives, as well as those studies that equated their findings with quality of life in some way. Studies
were excluded if they deliberately started with a premise assuming the importance of any particular
domain to quality of life, or if they were structured around a preconceived list of domains.
Qualitative research
We included primary qualitative research studies that used qualitative interview or focus group data to
collect the views of individuals with mental health problems. We excluded studies that used content
analysis and presented results as a frequency list with no supporting participant quotes. Some studies
sought the views of a range of people with mental health problems, carers and professionals; in such
cases, we only included those studies in which the views of people with mental health problems could be
separately identified.
Mental health
We included research on all mood disorders (e.g. depression, bipolar disorder and mania), neurosis and
stress-related disorders [e.g. anxiety, phobias and post-traumatic stress disorder (PTSD)], personality
disorders and schizophrenia, and schizotypal and delusional disorders. Included studies had to state that
participants had mental health problems, as identified through either diagnosis or attendance at an
establishment for people with mental health problems. Studies in which mental health problems were
secondary to a physical health problem were excluded.
Quality
The use of quality assessment in reviews of qualitative research is contested. Quality assessment is usually
used in framework synthesis but this may be associated with its use alongside systematic reviews of
effectiveness.196 In this review, articles were not quality assessed and systematically excluded on this basis.
However, it was of paramount importance that any included study elicited the perspective of individuals
with mental health problems, and where this appeared not to be the case the study was excluded.
Consequently, studies were excluded when it was strongly suspected that the views of the researcher, or
the method of analysis, had overly influenced the findings. These articles were examined and discussed at
length by the research team before being excluded.
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Language
Although the searches were restricted to English-language articles, non-English-language articles were
excluded because of the potential for misinterpretation. Five potentially relevant articles were excluded on
the grounds of language. Figure 11 shows a PRISMA flow diagram of the searches undertaken.
Data extraction and analysis
The following details of the studies were extracted: mental health problem studied, author affiliation, time
and location of study, number and demographic details of participants, research aims and questions,
recruitment and sampling methods, method of data collection and analysis, and themes within the
findings and discussion sections of the papers.
Framework analysis198 was used to allow the identification of common and variable patterns of themes
within and across different studies. The first stage of framework analysis – familiarisation – was
undertaken by reading all included papers. The second stage involved examining the findings from these
papers to identify initial themes for a thematic framework. These 10 initial descriptive themes were either
identified as main themes from more than one study or arose consistently across studies, and were as
follows: activity, relationships, the self, the future/aspirations, symptoms/well-being/emotions, spirituality,
control/coping, insight/education, health-care services/interventions, and resources/basic needs. The third
stage – data organisation – involved charting data from the findings and discussion sections of papers that
corresponded to each theme. Text was transferred verbatim to ensure contextual accuracy. It was common
for text to be identified as supporting more than one theme, for example a quote describing how work
was good for the individual's self-esteem would be placed in the thematic categories ‘activity’ and ‘self’. At
the next stage each initial theme was examined, and further subthemes identified and documented within
the framework chart. To assist with the final stage of framework analysis – mapping – the subthemes were















Included in qualitative synthesis
(meta-analysis)
16 articles relating to 13 studies
Articles excluded by abstract
(n = 1050)
(Plus nine articles
not received in time)
Excluded by abstract
(n = 35)
FIGURE 11 PRISMA flow diagram of searched articles.
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wider literature to find papers which would help us to understand the data and make connections
between subthemes, and would assist in the development of our final themes. For example, ‘belonging’
was an emerging theme, and we identified Hagerty et al.’s201 research which explored and defined this
concept. We then returned to our thematic framework to re-examine our data in the light of the wider
literature. Other influential literature at this stage was on the theory of ‘doing, being, becoming’,202
ill-being compared with well-being and intrinsic and extrinsic quality of life,203,204 and demoralisation.205
Validation and trustworthiness
Validation procedures were incorporated into the review at all stages. Two researchers (JC and MLJ)
independently identified articles from the first search iteration, and compared results to clarify the inclusion
and exclusion criteria. Potential full articles were identified from further searches by the primary researcher
and independently checked by the second researcher. The included articles were examined independently
by both researchers to identify the main themes for the initial framework. Disagreements at all stages were
resolved by discussion. Additionally, a multidisciplinary team of researchers met regularly in addition to
meetings with clinicians and a user representative to discuss and challenge the inclusion and exclusion
criteria, thematic framework, and conceptual interpretations and conclusions.
Findings
Description of included studies
Thirteen studies were identified from 16 articles,206–220 one of which was unpublished (E Chambers and
S Cook, Sheffield Hallam University, 2012; hereafter cited as Chambers 2012). Two of these journal
articles208,209 had fuller reports available.Chambers 2012,206 The fuller reports only have been referenced in the
findings. A further study indicated that not all emerging themes were presented in the paper and had a
supplementary paper dedicated to the impact of bipolar disorder on work functioning, which was included
in our analysis.207 The studies were published between 1994 and 2010 in a number of countries:
Canada209,210,212,215–218 UK,208,211,217 Sweden,214,219 USA220 Austrailia216 and New Zealand.213 The professional
affiliations of the first author were occupational therapy,208,209,212,215,217 nursing,210,213,214,219 psychology,211,216
psychiatry218 and social work.219
The mental health disorder most frequently represented was schizophrenia (or other psychotic disorder);
this was the only population researched in three studies211,212,215 and the majority population in a further
two studies.Chambers 2012,220 Three studies included individuals with bipolar disorder only216,218,219 and one
included those with panic disorder only.213 Other studies206,210 had a mixed population including the above
disorders plus persons with personality disorder, severe depression and anxiety disorders. Two studies did
not specify the disorder; they included persons described as having ‘enduring mental health problems’217
and ‘psychiatric disability’.214
Two studies had a primarily positive orientation in that they asked ‘what is required for a good quality of
life?’,218,219 and four showed a negative orientation through asking ‘how has your mental health affected
your quality of life?’.210,212,213,216 The remainder considered both ‘what had helped and hindered quality
of life’. Four studies had a conceptual orientation;210,212,213,219 the remainder presented their findings
descriptively. Further details of the studiesChambers 2012,206,207,210–220 can be found in Appendix 4 (see Table 57).
We identified six major themes from the initial descriptive themes: well-being and ill-being; control,
autonomy and choice; self-perception; belonging; activity; and hope and hopelessness. These themes are
now explored in detail.
Well-being and ill-being
Well-being has long been regarded as an important dimension of HRQL scales (see Chapter 1). The
emotional component of subjective well-being consists of high levels of positive affect (experiencing
pleasant emotions and moods), and a lack of low levels of negative affect (experiencing few unpleasant
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emotions and moods).204 Within our papers, symptoms of mental illness and aspects of emotional
well-being were intertwined, with an emphasis on the negative rather than the positive. This suggested
that ill-being, which is more akin to distress and the symptoms of mental illness, is an important aspect of
quality of life for those with severe mental health problems. The most evident ‘ill-being’ themes were
general feelings of distress, experience of psychosis/mania, depressed mood, fear and anxiety, and
problems with energy and motivation and fear and anxiety.
Distress from symptoms
Distress, or the subjective experience of the symptoms of mental illness, was evident in the majority of
studies147,206,211–213,216,217,220 and a major theme in four.206,211,216,220 The subjective experience of mental
illness was described as wretched,217 a burden, debilitating, painful,220 tormenting216 and having a
tyrannical power over life.206 Preoccupation with the symptoms of mental health problems interfered
greatly with the most basic tasks of everyday living,Chambers 2012,206,212,220 making it difficult to deal with
anything but the present moment.220 Instead, life was consumed with coping on a daily basis and living
‘one day at a time’ – sometimes on a moment-to-moment basis.206,212,215
Experience of psychosis/mania
Distressing symptoms reported included hallucinations and delusions (particularly hearing voices, thought
disturbances and paranoia),Chambers 2012,206,211 reality disorientation,206 mania and hypomania,207 feelings of
discomfort, weirdness or oddness,206 and irritability or agitation.211 These symptoms could interfere directly
with day-to-day living by having an effect on behaviour control,Chambers 2012,207,211,216 concentration, memory
or decision-makingChambers 2012,211,212 and sense of self-identity.206,212,218
When I hear voices erm, that stops me from doing a day to day existence, I’m preoccupied with
the voices[.]
. . . the voices, how they’ve affected my life, erm, er just day to day living basically . . . Erm just er,
getting out, getting out and doing things er . . . go to the shops, erm, erm, cooking, anything,
anything like that[.]




Depression was a diagnosis in a proportion of participants in two of the studies206,210 and bipolar disorder
was the primary diagnosis in three further studies.216,218,219 Negative affect, in the more severe form of
depression including feeling suicidal (as opposed to simply being sad and unhappy), was also identified in
studies in which the primary diagnosis was psychosis related.Chambers 2012,211,215,217,220 It was also the
symptoms of depression in bipolar patients that were reported as being particularly distressing,216 together
with the unpredictability and instability of mood.207,216,218
Energy and motivation
Depression was often expressed as associated with a lack of energy and/or motivation. Although energy
and motivation might be regarded as two distinct concepts (physical and psychological), they were closely
associated and for the most part reported together within the primary research. Energy, or lack of it, was
a major theme in one study219 and all but three of the primary research articles213,214,216 described the
debilitating effects of lack of energy. The three studies in which energy and motivation were not evident
focused on the nursing implications of panic disorder,213 the psychosocial issues related to bipolar
disorder216 and the positive determinants of health.214 Participants reported feeling generally
drained of energyChambers 2012,206,207,210,211,220 associated with a lack of motivation, enthusiasm, or
interest in things.Chambers 2012,206,210,211,215,217,220 The side effects of medicationChambers 2012 or problems with
sleepChambers 2012,211 were reported as having a causal effect. Whereas lack of energy was the dominant
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theme, hypomanic states in bipolar disorder were associated with increased energy and enthusiasm but
were often short-lived, with a return to a usual depressed state.207
Fear and anxiety
Two studies reported that ‘fear’ was a theme that was represented throughout its interview data.206,211
Fear, anxiety or worry was present in some form in all of the studies. The subjective experiences of the
symptoms were reported as being very frightening.Chambers 2012,206,212,213,216,220 This tended to be identified in
the studies on schizophrenia, bipolar disorder and panic disorder. As a consequence, individuals lived in
fear of relapse or a return to hospital.Chambers 2012,206,211 There were associated financial worries which had
implications for planning for the future and making commitments.211,215,218
Anxiety in social situations was especially evident and took various forms, including anxiety about
leaving the house, crowds and public places,Chambers 2012 concerns for their own safety206,217 and that of
others,Chambers 2012 worrying about what others thought of them and how they appeared,Chambers 2012,206 and
fears of rejection.220 Worries concerning relapse or aggravation of symptoms and social anxiety often
resulted in the avoidance of any activity or situation which might be perceived as stressful,Chambers
2012,206,211,214 thus limiting the possibilities of improving other aspects of quality of life. Individuals reported
avoiding situations they had previously enjoyed because of fear of how they would appear or that the
stress associated with those situations would mean deterioration in mental health:
I’ve cut down on the sort of positions I get myself in . . . because of bad experiences in the past . . .
you just try less things with the fear that you’re going to get very ill again and go to hospital[.]
Gee et al.211
Well-being
There tended to be an emphasis on the absence of ill-being rather than the existence of well-being.
However, positive themes were identified that included overall sense of well-being,212,214,219 feeling
healthy,212 peaceful, calm and relaxed,Chambers 2012,211,214,219 stable,211,216 safe214,219 and free from worry
and demands.214,219
Physical well-being
Physical health was not a strong theme within the reviewed studies (though, as reported in the next
chapter, it was a stronger theme in the interviews). The compounding effects of physical problems were
indicated in two studiesChambers 2012,217 and physical health was listed as the second most important aspect
of quality of life, alongside mental health, in another.218 A healthy lifestyle was considered beneficial; this
included exercise, avoiding drugs and generally taking care of oneself.Chambers 2012,206,214
Control, autonomy and choice
The importance of aspects of choice and control to quality of life was identified in eight
studiesChambers 2012,206,211,212,215,216,218,219 and was a main theme in three of these.211,215,216 It was often
discussed in the context of the availability of external resources which enabled choice and control,
including medication and treatment, support, information and finances.
Symptom control
One of the most evident aspects of control was the relief and management of the most distressing or
pervading aspects of mental illness.Chambers 2012,206,207,212–216,219 This was usually described as being achieved
through medication.Chambers 2012,206,207,214–216,218,219 Having this control meant that individuals could move
beyond ‘the all-encompassing world of their illness’206 and instead attend to other important areas of their
lives.206,212 However, medication could also have a detrimental effect on quality of life through side
effects,Chambers 2012,206,211,215 feelings of dependency215,216 and fear of the consequences of not taking it.211
It was therefore necessary to find the right medication to balance symptom management and side
effectsChambers 2012,206,213,214,216,219 as a means to a sense of well-being.206
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I think for me, apparently the most important one is just managing the illness . . . different
medications, side-effects, knowing what they are . . . for me there’s been limited discomfort.
Corring206
The concept of control was particularly important for those with bipolar disorder, and was related to an
inability to control or pre-empt the onset of mood episodes or their behaviour207,216,218 and to a need
for stability.216
Being informed and having an understanding of and insight into the illness was considered to be
important.Chambers 2012,206,213,215,219 To achieve this it was important to have an accurate diagnosis213,214 and
this also meant that people could receive effective medication,214 knew what to expect for the
future206,214,219 and could develop strategies to manage their illness and deal with it better.206,215 This was
regarded as a first step on the way to recovery213 and improving quality of life.219
Autonomy
There was a complex relationship between support, dependency and independence. Both
supportChambers 2012,206,212,214,215,219,220 and independence213,214,218 were regarded as being important for
quality of life. Support helped people manage their illness, access resources and increase their self-
confidence.214 However, it could also result in feelings of dependency,Chambers 2012,218 with a resulting loss of
a sense of control and self-esteem.218 Hence there was a dilemma between wanting help and support and
at the same time resenting it.210 On the other hand, choosing to be dependent could enhance power and
control.219 Personal autonomy, finding the optimum balance between support and independence, was
therefore important to quality of life.208,214 There was also an aspiration for financial independence and
autonomy from the health service, with a desire expressed by individuals to manage their own illness
without relying on medication.207,218
Personal strength, determination and self-sufficiency were also regarded as important.Chambers 2012,207,213,214
This meant people were able to make use of available resources and develop self-help and personal coping
strategies,Chambers 2012,206,213,218 which in turn promoted independence and a sense of control.206,213
Choice
The concept of choice was most associated with the availability of financial resourcesChambers 2012,206,211,214,215,218
and with limited employment opportunities.Chambers 2012,206,207,211,215,220 Having sufficient financial
resources meant people could more readily have a healthy lifestyle,214 engage in activities that
promoted well-being,Chambers 2012,206,211,214 attain an optimum balance between dependency and
independence,Chambers 2012,218 have a choice in their surroundingsChambers 2012,206,215 and be able to plan
for the future.211 Also of value was being able to choose whether or not to take part in things
(particularly social activities),206,215 flexible work conditions,207 when and with whom to disclose mental
illness,215 and choices associated with mental health services, workers and interventions.Chambers 2012
Self-perception
A number of aspects of self associated with quality of life were identified: ‘self-efficacy’, having a belief
and confidence in your own abilities; ‘self-identity’, having a perception of self and knowing who you are;
and ‘self-esteem’, having a sense of self-worth and self-respect. These were linked to a further theme of
self-acceptance. These ‘self’ concepts were closely associated and used interchangeably within the studies
reviewed. Aspects of the self and self-perception were a major theme in three studies206,213,216 and were
present in some form within all of the other studies except one,210 which had an abstract analytical style
and only had undertones suggesting low self-esteem/image.
Self-identity
Problems related to having a sense of self and ‘knowing who you are’ appeared particularly to be related
to bipolar disorder, schizophrenia and panic disorder. The studies described a loss of a sense of self,
identity and personality.212,216,218,219 This loss of a sense of self necessitated a renegotiation212 or
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reclaiming213 of self, based on self-acceptance, self-knowledge and understanding,212,213,218,219 and
relationships with reliable others.219 Spirituality also had a role in achieving a sense of self.206
Self-efficacy
This concept was expressed in the reviewed studies primarily as a lack of self-confidence, but also as
feelings of inadequacy, uselessness, failure, an inability to cope and helplessness.Chambers 2012,206,211–214,216,218
Mental health problems were associated with a lack of confidence.Chambers 2012,207,212,213,216 This
lack of confidence limited day-to-day functioning and activitiesChambers 2012 and access to helpful
resources,Chambers 2012 and affected choice and opportunities in employmentChambers 2012,206,207 and
relationships.Chambers 2012,206 However, bipolar disorder could be associated with an increase in
self-confidence.207
Self-esteem
The theme of self-esteem included the concepts of self-image, worth, value and shame, and a view
of the self as ‘defective’.Chambers 2012,206,211,216–218,220 It was closely associated with loss of self-identity207,218
and confidence.216 Occupational activity was considered particularly important for self-esteem and
status,206,207,217 as was the satisfaction gained from helping others.206 However, the difficulties encountered
in obtaining employment often resulted in a lowering of self-esteem.211,220
Self-acceptance
Self-esteem was usually reported as a sense of loss of self-worth and value. A related concept was that
of self-acceptance,206,213,218,220 acceptance of the self as a person with an illness213 or the belief that the
illness did not represent everything that they were.206,218
Self-stigma
The theme of ‘the self’ was closely related to the next theme of ‘belonging’, particularly through the
concepts of ‘stigma’ and ‘feeling normal’. For example, feeling normal had two inter-related dimensions:
not feeling normal within oneself,212,215,216 and not being treated as normal and not fitting in with the rest
of society.215 This inter-relationship is evident in the concept of self-stigmatisation, an internalisation of the
negative views of others, perhaps the most potent of stigmas as it has a profound effect on the inner
sense of self.206
I stigmatize myself. I just have a very low self-image. I’m kind of hard on myself for not conducting
myself the way I should be . . . not being as productive as I could be. It’s a reflection from general
community’s perceptions of what this illness is all about.
Corring206
Belonging
The concept of belonging has been defined as the experience of integration and personal involvement in a
system or environment at differing interpersonal levels. It can have two dimensions: ‘valued involvement’ –
the experience of feeling valued, needed and accepted; and ‘fit’ – the person’s perception that his or her
characteristics articulate with, or complement, the system or environment.201 Of the primary research
studies included in the review, one identified ‘connecting and belonging’ as being important to quality of
life.215 Others identified closely related main themes: being part of a social context,214 rejection and
isolation from the community,216 a need for acceptance by others,220 social support,218 relationships,206
barriers placed on relationships,211 labelling and attitudes from others,211 stigma,206,211,218,220 alienation220
and detachment and isolation.211
Relationships
Relationships were clearly central to the concept of ‘belonging’. These relationships included both close
connections with family and friends and more casual relations with the local community, in the workplace,
with service providers or with society at large. The complex nature of relationships and the positive and/or
negative effects on quality of life were evident in all the primary studies.
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The provision of support was a particularly strong theme, in three studies.214,218,219 Both
practicalChambers 2012,206,213,214,218,219 and emotionalChambers 2012,206,213–215,218,219 care and support from family and
friendsChambers 2012,206,212,214,215,218–220 and peers and work colleagues207,216,219 were identified as important to
quality of life, as was support received from professionals.Chambers 2012,206,213,214,216,219 When families and
professionals were unsupportive, quality of life was described as declining.Chambers 2012,206,219
If I didn’t have my parents and my family and friends . . . I wouldn’t be going nowhere . . . I’d
be stuck.
Gould et al.212
Good and reliable relationships also satisfied the need for love, care and affection,Chambers 2012,206,214,215,218,220
facilitated the experience of joy, fun and happiness,210,214 and offered company, shared interests and
camaraderie,206,210–212,214,215,217 as well as someone to talk to/share problems with.Chambers 2012,206,210,214,219
Such relationships also enabled individuals to feel needed/helpful to others,206,210,214,219 to be accepted and
understood,Chambers 2012,206,207,214–216,218–220 and to feel that there were people in whom they had trust and
confidenceChambers 2012,214,219 and who provided motivation and encouragement.214 Given their importance,
the well-being of others was also important to the quality of life of the study participants.214
Although relationships which satisfied the need to belong were important, difficulties forming and
maintaining these relationships were evident.Chambers 2012,206,210,211,215–217,220 These difficulties included
problems and tensions within supportive long-term relationships.Chambers 2012,206,210,216,218 Problems with
relationships represented a complex multidirectional interaction between the person and society at varying
interpersonal levels. This interaction involved the effect of the person’s illness when relating to others,
other people’s subsequent reactions and attitudes to them, and the effect of those reactions and attitudes
in further exacerbating symptoms of anxiety and depression and affecting the person’s perception of
themselves. Examples of the barriers experienced in connecting and relating to people included cognitive
and thought disorders resulting in problems with concentration and attention,206,211,220 problems
controlling behaviour211,216,218 including acting out,211,218 irritability, volatile or inappropriate behaviour,218 or
grandiosity or self-inflation,218 and feelings of anxiety when talking to or being around people, including
problems with trust and paranoia.Chambers 2012,206,207
Stigma
Stigma has been defined as ‘any condition, attribute, trait or behaviour that symbolically identifies the
bearer as culturally unacceptable or inferior’.221 Stigmatisation was a major theme in four of the
studies206,211,218,220 and evident in three others.Chambers 2012,215,216 The experience and perception of negative
reactions on the part of family, friends, service providers, employers and society at large was shown to
have a detrimental effect on quality of life. Individuals felt that they were perceived as lesser human beings
who were discriminated against and treated accordingly206 and that they were feared, avoided, or not
accepted, which in turn led to feelings of rejection, marginalisation or being written off.206,211,216,218,220 As a
result, disclosure of mental illness was problematic and often avoided, and this had consequences for
employment and close relationships.206,215,218 Stigma had a detrimental effect on most aspects of life,
including relationships,Chambers 2012,206,211 employment and career,Chambers 2012,206,211,218 going out and pursuing
leisure activities,Chambers 2012,211 obtaining services206 and planning for the future.206 Stigma was considered to
be more predominant in bipolar than unipolar depression.218
Feeling normal
A major barrier to achieving a sense of belonging was that informants were not perceived by others – and
often did not perceive themselves – as ‘normal’.215 Whereas feeling normal was something they held in
high regard, instead they were aware of being perceived differently and, consequently, treated
differently.220 Feelings that they were different, and attempts to appear normal, do normal things, or be
accepted as normal, formed a theme that permeated many of the studies reviewed,206,211,212,215,216,220 being
a major theme of three.206,212,215 This is consistent with the dimension of ‘fit’ within the concept of
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‘belonging’ – the person’s perception that his or her characteristics articulate with, or complement, the
system or environment.201
Loneliness/isolation/alienation
Feelings of isolation, loneliness, and particularly the concept of alienation can be regarded as the antithesis
of a sense of belonging. Although highlighted as a main theme in one study only,220 these feelings were
evident within the themes of relationships and stigmatisation in all studies except one.212 The symptoms
of mental illness, the barriers these caused in the formation of relationships, and the stigma and
consequential effects on the self, together with feelings of being different and not accepted, resulted in a
pervasive sense of loneliness and isolation. People chose isolation, or avoided relationships, as a way of
protecting themselves against rejection and dealing with the fears of how they appeared and what others
thought of them.206,211,220 The effects of being consistently treated as undesirable or different became
internalised and further influenced their sense of self.206 Isolation was further compounded by the feeling
that they were the only person suffering in this way.206 Hence, isolation was not just feeling as though
they did not have any friends but became a painful feeling of despair that affected all aspects of life.
I think one of the things about schizophrenia, I don’t know whether it’s schizophrenia or whether it’s,
it happens in other mental illnesses too, is this terrible, terrible kind of inner isolation feeling, like
you’re the only person . . . who is going through what you are going through and you, and you’re
completely alone . . . it’s just a terrible, painful sense of utter loneliness and isolation[.]
Reproduced with permission from Corring DJ. ‘Being Normal’: Quality of Life Domains for Persons
with a Mental Illness. Dissertation Abstracts International Section B: Sciences and Engineering
2006;67.206
For quality of life, people wanted a reciprocal relationship with others214,218 which involved understanding
and acceptance.Chambers 2012,206,214–216,218,220 This could be achieved through ‘supportive own’, those
who share their illness and experiences,206,207,214,215,218,219 or through belonging to a religious
community.Chambers 2012 However, it was also possible to have a sense of belonging to a social network that
was ultimately not beneficial to quality of life,218 and difficulties disentangling ‘real’ spiritual experience
from hyper-religiosity when hypomanic could make belonging to a religious community problematic.218
Activity
By ‘doing’, a person achieves a sense of self and mastery, and successfully participates in the external
world.202,222 The importance of activity in some form to quality of life was expressed in all of the studies
except the one which examined panic disorder from a nursing perspective.213 There was a difference in
emphasis between studies: some focused specifically on the benefit of employment207,211,216,220 and
others on activity or occupation in its broader sense, including both employment and leisure
activity.Chambers 2012,206,212,214,215,217,219 Whatever the type of activity, it was stressed that it should be meaningful
or fulfilling,Chambers 2012,206,212,214,215,217,219 enjoyable,212,217,219 and suited to need and capabilities.212,214
The benefit of activity is that it can provide the means for many of the factors important to quality of life
discussed above. It is through activity that the opportunity arises to interact with others and hence
develop a sense of belonging.215 Activity can also improve mood,Chambers 2012,206,212,214,215 increase energy
and/or motivation,206,215,219 relieve stressChambers 2012 and boredom215,217 and provide a distraction from
problems.Chambers 2012,214,215 It also helps self-esteem and self-confidence, engenders a positive
self-identityChambers 2012,206,207,211,215,217,220 and enables people to take control of their lives.215
One further factor not already discussed is how activity provides order, routine, and structure.211,214,215,218,219
Routine and structure can be achieved through employment,211,218 childcare211,218 or activity in general,
be it work or leisure.214,215,218,219 However, one study highlighted how too much structure could
be problematic and that what was important was flexibility and choice.218 Having a physiological
routine – particularly regular sleep, meals and exercise – was considered important for general
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well-being.218,219 Using activity to structure time increased motivation, provided a diversion from problems
and avoidance of negative moods:215
The actual work, whatever it is, is good for the mind and soul . . . you forget yourself. You forget your
own problems when you are working[.]
In the morning I have to do something. Some job or something I should do. Otherwise, I become
bored and then become depressed because I don’t have anything to do . . .
Laliberte-Rudman et al.215
Although activity was almost universally considered to be beneficial, taking part could be difficult if the
activity was too demanding and not suited to needs.207,214,219 The symptoms of mental illness could make
difficult even the most rudimentary of activities, such as self-care, cooking and shopping,Chambers 2012,217 and
taking up employment was especially problematic.212 Even potentially enjoyable leisure activities were
avoided because of concern regarding other people’s reactions,Chambers 2012,211,217 problems relating to
people,217 and the associated fear and stress resulting in a deterioration in health.Chambers 2012,211 Lack of
money also put a restriction on enjoyable pastimes.211 For those in employment, interpersonal relationships
at work were particularly affected due to social withdrawal and irritability, or interfering, inappropriate or
volatile behaviour during hypomania, although work productivity could increase during hypomania.207
Hope and hopelessness
The importance to quality of life of personal achievement or having dreams and goals was evident in six of
the studies;206,210,212,214,215,218 the importance of activity and/or life in general being fulfilling and having
some meaning and purpose was also evident.206,214,215,218,220 Both were necessary to instigate change, make
plans, and to move forward. Again, the difficulty of achieving this was stressed.206,212,215
Losses experienced in the past affected the view of the future with a perception of reduced opportunities
and choices216 and diminished hopes and dreams,210,212 particularly in the fields of employment207,211,220
and relationships.210,220 Loss and the effect of past experiences was a theme in eight of the
studies,Chambers 2012,206,207,210–212,216,220 and a major theme in three of these.210,212,216 These losses included the
loss of life roles generally and, more specifically, the loss of work and career opportunities, relationships
and the parental role, skills and ability, time, financial losses, and, ultimately, the loss of a sense of self and
identity. Losses which had occurred in the past were perceived as a burden,206 with a pervasive sense of
‘something missing’220 which had long-lasting effects and made life a constant struggle.210,216,220
Participants compared their own lives negatively with those of others,210,216,220 or with their own lives
before illness struck,210,212 and all of this brought about feelings of failure and of being cheated, and a
sense of unfairness.207,216,220
Past losses, including the loss of meaning and purpose in life, and a sense of helplessness and inability to
cope, all brought about a feeling of hopelessness, necessitating a renegotiation and a lowering of
aspirations and priorities.206,210,212 The concepts of ‘hope’ and ‘hopelessness’ permeated the review
studies206,210,211,216,219,220 and formed a major theme for two210,216 Hopelessness was an expression of the
view that life would never change for the better, and brought about a pervasive feeling of distress.220
Conversely, hope provided a catalyst for change and a better life.219
Well, my whole life feels problematic, I feel as if I’m not going anywhere . . . I know it sounds
negative and I’m not really negative like this all the time, but you know, I find it hard, projecting
myself into the future, and leading a happy life . . .
I don’t have hope that I’ll ever have a nice boyfriend, I don’t have any hope that I’ll get married, I
don’t have any hope that I’ll work a full week – week after week after week. I don’t really have hope
for stability . . .
Lim et al.216
DOI: 10.3310/hta18340 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 34
71
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Brazier et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
Discussion
We identified six major themes associated with quality of life for those with mental health problems from
this review of the literature: well-being and ill-being; control, autonomy and choice; self-perception;
belonging; activity; and hope and hopelessness.
Measuring quality of life for people with mental health problems has been of growing interest because of
concerns about the emphasis placed by mental health services on reducing symptoms. This has also been
true of physical health services. Yet our review identified the importance of distress and symptom control
from the perspective of people with mental health problems. The distress caused by the symptoms is
integral to the quality of life of people with mental health problems, and in some instances seeing beyond
this distress is difficult.
One of the strongest themes revealed by the review was a sense of belonging, achieved principally by
good quality relationships and lack of stigma. It has been stated that people are fundamentally motivated
by a need to belong,223 and that belonging is the missing conceptual link in understanding mental health
and mental illness.224 Our review also indicates that negative social relationships are detrimental to quality
of life. This is supported by research that shows that whereas a large social network and satisfaction with
social relations are associated with a better quality of life,225 negative social interactions and stigma are
related to a worse quality of life.226 Social exchange theory emphasises that social interaction entails both
rewards and costs, and that negative social outcomes can have a greater impact on well-being than
positive outcomes.227 There is also evidence that loneliness is caused more by a lack of intimate
connections than by a lack of social contact.228 Hence, the important factor is the sense of belonging,
rather than social contact. So, although there is a strong argument that those people who experience
supportive, caring, loving relationships and have a sense of belonging have a better quality of life, it is
less clear which is the more detrimental – to experience and risk the negative impact of uncaring and
disrespectful relationships, rejection and stigma, or to protect oneself through self-isolation.
As good and poor relationships can have a positive or negative impact, so activity can both help and
hinder quality of life. For some, the severity of symptoms can mean that basic self-care and day-to-day
functioning are difficult. Activity beyond perceived capabilities can also result in feelings of anxiety, which
in turn can lead to deterioration in other mental health symptoms such as hearing voices and paranoia.
This results in avoidance of any potentially stressful situations. This finding is supported by the findings of
research into the occupational activity of those with severe mental illness, which indicated that, though
employment was valued, people made choices constrained by fear of relapse, and entered, avoided and
shaped their social and occupational activity to remain well.229 It was found that doing too much could
exacerbate symptoms, yet doing too little could also cause illness and, therefore, people with severe
mental illness sought out daily occupations with structure, flexibility and easily-met demands over which
they had control.229 Therefore, to achieve well-being and quality of life, people need to find a balance and
be enabled towards that to which they are best fitted.202
Although avoidance of social and occupational activity may reduce anxiety and the occurrence of other
related symptoms, at the same time it can compromise other aspects of quality of life. The consequent
reduction in choice and opportunity has a detrimental effect on self-esteem and confidence. However,
self-worth is gained through positive social feedback and successfully engaging in activity. Lack of
self-esteem has also been shown to increase the risk of psychiatric disorders, the development of delusions
and the maintenance of psychotic symptoms.230 The perception of self is therefore both a cause and a
consequence of mental health, and can be regarded as being pivotal to quality of life.
In relation to the finding of the importance of hope and hopelessness to quality of life, parallels can be
seen between the results of this review and the concept of demoralisation,205,231 whereby a persistent
inability to cope with internally or externally induced stresses results in feelings of helplessness,
incompetence, and loss of mastery and control, leading to diminished self-esteem, hopelessness and
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demoralisation. This in turn adds to the distress of symptoms and further reduces a person’s capacity to
cope. The demoralised person clings to a small number of habitual activities, avoids novelty and challenge,
and fears making long-term plans.205,231 This feeling of demoralisation further impacts upon ill-being and,
if untreated, leads to chronic distress and possible suicide.205,232
Strengths and limitations
Complexities arose when setting boundaries around the concept of quality of life. It was evident that there
was a considerable overlap in findings, with studies examining ‘recovery’, ‘lived/subjective experience’,
‘psychosocial issues’, ‘health needs’ and ‘strategies for living’. After much discussion and deliberation,
these studies were excluded from the review. Since completion of our analysis, a systematic review of the
concept of ‘personal recovery’ has been undertaken,233 a concept previously defined as ‘a way of living a
satisfying, hopeful, and contributing life even with limitations caused by illness’.234 Interestingly, the
authors identified five recovery processes comprising ‘connectedness’, ‘hope and optimism about the
future’, ‘identity’, ‘meaning in life’ and ‘empowerment’, which are very similar to our own final themes.
They do not include ‘well-being’ and this may be due to the rejection of an emphasis on symptoms within
the recovery movement and hence a separation of ‘clinical’ recovery and ‘personal’ recovery. This suggests
that the concepts of ‘personal recovery’ and ‘quality of life’ are very closely related. This is important to
understand as the concept of ‘recovery’ is gaining prominence as a guiding principle for mental
health services.235
There were also difficulties setting boundaries around themes because of the strong inter-relationship
between the different domains which make up quality of life. To avoid repetition, subthemes have been
placed within the main theme with which they were considered to be most strongly associated, but
aspects of these themes could be placed in other themes. For example, ‘feeling normal’ has been included
under the main theme of ‘belonging’ but could also be regarded as an element of ‘ill-being/well-being’
and ‘the self’.
Reliance on secondary data can limit the ability to make connections between subthemes, as can a reliance
on that which researchers choose to report within a paper from their primary data. This is another reason
for conducting our own primary research reported in the next chapter.
The primary studies included those with severe mental health problems only, with a majority covering
schizophrenia or psychotic disorders. Where there was a mixed population, studies rarely indicated any
differences between people with different diagnoses. The findings may therefore have biases towards
those with psychotic rather than affective disorders. The interviews reported in the next chapter recruited
more people with affective disorders to counteract this bias.
Implications for the wider project
This review has identified six potential domains of quality of life. These formed the basis of a topic guide
for the interviews of people with mental health problems reported in the next chapter. They also provided
an initial set of themes for the framework used to analyse the data collected from the interviews.
Measuring quality of life for people with mental health problems has been of growing interest because of
concerns about the emphasis placed by mental health services on reducing symptoms. Yet this review has
highlighted that the distress caused by symptoms is integral to the quality of life of people with mental
health problems, and in some instances seeing beyond this distress is difficult. However, the review offers
a partial picture because of the focus of studies on people with psychotic rather than affective disorders.
The qualitative interview study reported in the next chapter addresses this limitation by including people
with affective disorders. There is also concern that the review may be partial due to reliance on secondary
data. The qualitative interview study in the next chapter addresses this possible limitation by gathering
primary data on quality of life from the same samples as those included in the review.
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Chapter 6 A qualitative analysis of interviews
with mental health service users
This chapter builds on the systematic review of qualitative research into the meaning of quality of life forpeople with mental health problems reported in Chapter 5. The review identified six major themes:
well-being and ill-being; control, autonomy and choice; self-perception; belonging; activity; and hope and
hopelessness. One limitation of the review was that available studies focused on the quality of life of people
with severe and enduring mental health problems, particularly schizophrenia. To complement the review we
undertook primary research with participants from mental health services serving those with severe and
enduring mental health problems and mild to moderate common mental health problems. This allowed us
to explore the extent to which the review addressed important aspects of quality of life for those with
severe mental health problems, given that most concerns have been expressed about the utility of
preference-based measures in this group, and also to explore the views of people with less severe problems,
which represent a gap in the current evidence base. This chapter presents the additional insights from the
interviews and presents an assessment of the content validity of the EQ-5D and SF-36 against the themes
identified. This assessment of content validity is extended to a new generic measure, the ICECAP-A, as this
was developed from interviews with members of the general public.
Method
We undertook a qualitative study of face-to-face semistructured interviews with current users of mental
health services.
Recruitment
Participants were recruited from three mental health service providers in a city in the north of England.
One service (IAPT) provided psychological therapies for those suffering from mild to moderate depression
and anxiety. The other two were community mental health teams (CMHTs) providing services for those
with more severe problems, one working with individuals with severe and complex non-psychotic disorders
(e.g. severe depression, PTSD, personality disorder) and the other with those with psychotic disorders
(e.g. schizophrenia, bipolar disorder). Recruitment was undertaken by service providers who applied wide
inclusion criteria in order to capture as broad a range of mental health problems as possible. Exclusions
included those individuals facing acute episodes of their mental health condition, those not well enough
to take part, and those who could not speak English or give consent, as well as cases where there was a
known recent forensic history or any doubt relating to the safety of the researcher undertaking the
interview in the person’s own home. After a brief explanation of the research by the mental health
provider, those persons who expressed an interest in taking part were given a recruitment pack consisting
of a letter from the university-based researcher and a flyer giving concise information about the research,
plus an ‘expression of interest’ form to be returned to the researcher in an included SAE. The researcher
subsequently contacted the person to give further details, answer any questions and arrange the interview
if the person was still happy to go ahead (none refused at this stage). A confirmation letter was sent,
together with detailed information about the research (including confidentiality, anonymity and right to
withdraw) and a consent form for completion prior to the interview. A choice of venue was offered, which
could be the person's own home, a room at a university in the north of England or a centre frequently
used by mental health services in an easily accessible part of the city. A £10 shopping voucher was offered
for participation in the research. Approval for the above procedures was given by the local Research
Ethics Committee.
The services recruited 21 people to take part in the research and 17 were subsequently interviewed, nine
from the IAPT service and eight from the CMHTs. Four potential participants were recruited by the service
providers but did not attend interview, two could not be contacted and did not respond to messages left
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on their telephones (one IAPT, one CMHT), one arranged an interview but cancelled because they felt too
ill to attend (CMHT) and another did not attend an arranged interview (CMHT). A further two participants
with psychotic disorders were recruited by one of the participants subsequent to her own interview.
Interviews
All 19 participants were interviewed by a member of the project team (JC), a mental health researcher
with a background in behavioural sciences and outcome measure development. The interviews were
semistructured with the use of a topic guide (see Appendix 5) to ensure that a common set of questions
was asked. The topic guide was based on the synthesis of a qualitative review presented in Chapter 2 and,
as the ultimate aim of the research was to establish the suitability or otherwise of the most commonly
used generic quality of life measures, it included the item content of the EQ-5D and the SF-36. Three pilot
interviews had taken place with people with different diagnoses (schizophrenia, bipolar disorder and
depression) to test the topic guide. The guide was not changed substantially apart from a decision being
made to include questions relating to the items of the EQ-5D and SF-36 as part of the interview rather
than administering the actual measures. The first part of the interview aimed to elicit what was important
to quality of life from the perspective of the individual, without any prompts. The interview started by
asking for background information, and information on current activities and the participant's health,
using responsive questions to probe these aspects of his or her life and to determine their relative
importance. Participants were asked general open-ended questions about what affected their quality of life
both from a positive and negative perspective, what they enjoyed and why, what they would most like to
change, what helped, and what was stopping them doing what they wanted to do. Once their own
perceptions had been exhausted, the interviewer introduced concepts that the research review had raised
or that were included in the EQ-5D or SF-36. The interviews took place when the researchers were part
way through analysing the data from the review, when the themes were descriptive in nature rather than
conceptual. These were raised only if they had not already been discussed in the interview, and included
questions about the relative importance or effect on their quality of life of relationships, support, stigma,
work, leisure activities, mental health symptoms and their relative effects, medication and side effects,
physical health/pain, energy/motivation, self-esteem/confidence, mental health services/workers,
and finances.
All the interviews were tape recorded apart from one, where notes were taken at the request of the
interviewee. One further interview was recorded but accidently deleted; notes for this interview were made
3 days after the interview took place. The interviews lasted between 25 minutes and 1 hour 50 minutes,
averaging 1 hour 16 minutes. Seven of the interviews took place in the participant’s own home. These
tended to be people with more severe problems, five of whom were recruited by the CMHTs. The
remaining two, from the IAPT service, had difficulties leaving their homes because of anxiety. The
remainder of the interviews were conducted in a room at the university.
Participants
Interviewees included 11 men and eight women. These comprised one participant in his 20s, six in their
30s, eight in their 40s, three in their 50s and one in his 60s. One participant was of African Asian descent
and another African Caribbean; the remainder were white European. A broad range of mental health
problems were represented including schizophrenia, schizoaffective disorder, personality disorder, PTSD,
mild to severe depression, anxiety, agoraphobia, eating disorder and anger. All, with the exception of one,
were not in paid employment at the time of the interview although most had worked at some time in
the past or were currently employed in a voluntary capacity. Five were married or with a partner; the
remainder were not currently in a relationship. Further contextual information about the participants can
be found in Table 24.
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1 F 40–50 Married House person CMHT1 Depression/eating
disorder
Long-term problems – abused as a child
2 M 20–30 Married Returning to
employment
IAPT Anxiety Traumatic event
3 M 40–50 Separated Benefits
Work history
IAPT Depression/anger Relationship break-up – long-term anger-related
problems
4 M 40–50 Single Benefits
Work history
CMHT1 Depression/anxiety Long-term problems – abused as a child
5a F 50–60 Married Unemployed
Work history
CMHT1 Depression/anxiety Financial debt – previous history of depression
6 M 60–70 Single Benefits
Voluntary work
Work history
Otherb Schizophrenia/depression Psychosis-related problems controlled by medication
and own coping strategies – some symptoms remain
in milder form. Previously depressed – ‘solved’ by
long-term medication
7 M 40–50 Married Benefits
Work history
CMHT1 Depression Multiple stressors – previous history of depression




Severe traumatic event, bereavement, abused as a
child
9 F 50–60 Divorced Benefits
Work history
IAPT Depression Physical health problems and relationship break-up
10 M 40–50 Divorced Benefits
Work history
IAPT Anxiety/agoraphobia Stress-related panic attack
11 F 30–40 Separated Benefits
Work history
IAPT Depression/anxiety Work-related stress and trauma, redundancy
12 F 30–40 Single Benefits
Work history





































































































































































































































































































































































































































































































Long-term problems – no attributable cause disclosed
14 M 30–40 Single Benefits
No work history
CMHT2 Schizoaffective disorder Depression with periodic psychotic episodes –
recovering from a recent severe episode. Previous
diagnosis of bipolar disorder and schizophrenia
15 M 50–60 Single Benefits
Voluntary work
IAPT Depression Long-term difficulties exacerbated by bereavement
and housing problems
16 M 30–40 Single Benefits
No work history
CMHT2 Schizophrenia/depression Psychosis-related problems not controlled by
medication. Depression due to schizophrenia illness
and current situation




Episodic when stressed or does not take medication –
no current psychosis-related symptoms
18 M 60–70 Married Retired
Work history
IAPT Depression Long-term grief due to bereavement – consequential
financial and relationship problems
19a M 40–50 Separated Returned to
work
IAPT Depression Relationship break-up
F, female; M, male.
a Interview notes used in analysis.















































































The interview recordings were transcribed verbatim. Notes were used for two interviews. The interview data
were analysed thematically using framework analysis.198 Framework analysis was used to allow the
identification of common and variable patterns of themes within and across different groups, in particular
relating to problem severity and type. This analytical method also allowed for comparisons to be made with
thematic findings from the review of qualitative research previously undertaken. The themes identified in the
review made up the initial themes of the framework. Next, each transcript was read for refamiliarisation.
Interview text was then charted onto the framework for the most part using the predefined themes of the
review. This was either charted verbatim or paraphrased depending upon the relevance and focus of the
response to the research question. Nothing was considered irrelevant and all data were coded in some form.
All charted text was indexed with the interview timings that had been noted in the transcript so that actual
dialogue could be returned to ensure contextual accuracy. It was not unusual for text to be coded under more
than one theme, often one descriptive and another conceptual. Cross-references between themes were noted.
Findings
Subjective well-being and ill-being
Within the review (see Chapters 5 and Connell et al.199) the focus of subjective well-being was on the
negative rather than the positive aspects of well-being; that is, what takes quality away from life rather
than what adds quality to life. Thus the focus was on overall feelings of distress related to the symptoms
of mental illness. These included the feelings of depression, a lack of energy, motivation and enthusiasm,
fear and anxiety (particularly in social situations, and fear of relapse) and the distressing symptoms of
psychosis including hearing voices, hallucinations and paranoia. These aspects of ill-being were also
described in our interviews, particularly by those with severe and enduring mental health problems. Thus,
when asked what would improve their lives, participants tended to cite the absence of these negative
issues rather than the presence of the positive aspects of subjective well-being such as feeling happy.
When asked what made them happy the response was often ‘nothing’. The expectation of ever feeling
happy for this population was low.
I’m wanting to change – the biggest issue with my life, but there is a waiting list. There’s a new
therapy coming out called EMDR [eye movement desensitisation and reprocessing]. I got put down
for it once but I was having suicidal thoughts, erm I’ve not attempted this year so I have been
accepted . . . I will still get flash backs but I won’t get the trauma afterwards and that’s what I want
to get rid of, I don’t want to be traumatised every day, my coping strategies don’t work for me . . .
I would just want limited life back, instead of the full quality of life[.]
Participant 8 (CMHT, PTSD)
Interviewer: Can you think of anything that might make you happy, or happier?
Interviewee: No! Perhaps if I was a different person that would make me happy, I don’t know what else
to say . . .
Participant 4 (CMHT, anxiety/depression)
In contrast, interviewees with less severe mental health problems did speak of the experience of happiness
and enjoyment, although it was often tempered. They spoke of enjoying current hobbies and pastimes, or
happiness as a feeling they wished to regain.
Interviewer: What makes you happy?
Interviewee: Making sure that my wife is comfortable and happy, my son, my garden is just – simple
things really, there is no major thing that I can think of . . . my grand-daughter makes me happy[.]
Participant 18 (IAPT, depression)
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There were aspects of well-being that were identified in the review, but were much more prominent in
the interviews. The first was the desire to feel calm, relaxed and peaceful, which was described across all
mental health problem types and levels of severity. For one interviewee the need to feel calm and relaxed
was in contrast to feelings of anger, which was an emotion affecting quality of life that was not included
in the review.
I can remember when I used to be relaxed and chilled and not feeling like I do now, but I’ve felt like
this for such a long time and anxious for such a long time, but I can remember what it was like not to
feel like this, it’s a marvellous feeling[.]
Participant 10 (IAPT, anxiety/panic attacks)
. . . it’s hard but I have just got to lose this anger, if not I am just not going to get any better, I’m just
going to carry on and I am going to end up, like I said before, I will end up either crippled, dead or
locked up and I don’t want that, I just want to be able do what I want to do in the daytime and get
home at night and just relax[.]
Participant 3 (IAPT, depression/anger)
Related to a desire to feel calm and relaxed was a need to feel safe. However, the strategies used to
ensure these feelings of safety could inhibit other aspects of quality of life.
Where you are familiar with, where you feel alright like in [name of student area] full of students,
they’re harmless, as long as you don’t bother them, that’s it, they think you are one of them because
you’re young as well . . . everything matters, whether the people are safe whether the area is nice
area, whether you know it properly, everything matters, yeah, every little bit contributes[.]
Participant 16 (CMHT, schizophrenia)
It is the safety issue that is most important, I have to keep myself safe . . . I can’t like go out now in
case I bump into somebody in [name of district] they go home and they say ‘oh I met a young lady
called so and so, in a different area‘ and they know me and my life might not be worth living . . . I am
now trying to get out more, even just walk round the shops or summat, but it is hard[.]
Participant 8 (CMHT, PTSD)
Lack of concentration was a negative aspect of subjective well-being that was more prominent in the
interviews. Those with severe problems, or experiencing feelings of depression at their worst, reported that
they were no longer able to enjoy even the simplest of activities such as reading or watching TV because
of difficulties concentrating. This also meant that they were unable to find a distraction from their
problems. Those with less severe problems reported a perception that their concentration was getting
worse, but not to the extent that it took away from enjoyment of hobbies or pastimes.
I used to play golf quite a lot, but I’ve not played for quite a while . . . I just don’t get the same
enjoyment out of it like I used to do. It used to be a nice walk and concentrating on – I think that’s
the other thing, I can’t concentrate on it anymore. It takes a lot of concentration, does golf . . . I can’t
hit t’ball like I used to, just because I’ve got depression, it sounds weird, that, but I can’t play like I
used to do[.]
Participant 7 (CMHT, depression)
Missing from the review was any indication of the aspects of subjective well-being affecting quality of life
the most. Those who gave an indication at interview of having comorbid problems were asked this
question and the overwhelming response was ‘the depression’. When asked why, they stated that it was
due to its all-consuming nature over which they felt they had no control. They could obtain some relief
from anxiety or the voices, but depression was an ever-present darkness that they found much more
difficult to cope with.
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The depression is worse than the voices, because the voices sometimes, when you are with people,
like now with you, I’m not hearing them, if you’re doing serious matters, but I don’t know how long
that be, with me not hearing voices, but the depression is always there . . . it’s like the English
tradition, you heat milk – in the oven, in a pan, or in the microwave, and when you heat it properly
you get something covering the upper layer of the milk, that’s the depression, covering all the good
moods and everything, and interests . . . and it covers all your body, it affects your motivation, your
energy, and you don’t want to do nothing and you end up sad . . . so like it covers up all your
happiness and everything, to me, in my opinion[.]
Participant 16 (CMHT, schizophrenia)
. . . well both things stop me doing things but the depression is a lot harder to cope with, the anxiety
you can take medication so that helps erm it might get severe like if I have panic attacks but panic
attacks only last for a few minutes whereas depression just seems to go on and on and feels a lot
harder to cope with[.]
Participant 13 (CMHT, depression)
Physical health
Physical health was not evident as a theme within many of the studies in the review. In contrast, the
majority of our interviewees reported a physical health problem and this was mentioned by interviewees
with all diagnoses and severities of problems covered in the sample. Physical and mental health interacted
in various and complex ways.
Some reported that their mental health problems, or medication, caused or exacerbated their physical
health difficulties.
It feels physical as well as mental . . . my body aches and like I think I just become really tense and
that is what makes my body ache and I feel like erm I feel like my chest is being crushed and erm I
can’t breathe and things like that and erm I just want to be asleep all the time to escape but I
can’t sleep[.]
Participant 13 (CMHT, depression/affective personality disorder)
For others it was their physical health problems that contributed to deterioration in their mental health.
I’ve got diabetes, I’ve got high blood pressure, I’ve got arthritis, I’ve got angina, I’m on too many
medications. I don’t know what they are all for and it’s just this last 6 months it has just been getting
me down[.]
Participant 3 (IAPT, depression)
Participants were asked whether their physical or mental health problems affected their quality of life the
most. Some found this difficult to answer, or described how the two interacted with each other. The
presence of both seemed to make life particularly difficult to cope with.
. . . the two now are sort of like together on a par, I can’t cope with both of them at all . . . it is bad
enough trying to cope with what’s going off in my head, but with my body in pain every day I can’t
even cope, I can’t cope with that as well[.]
Participant 12 (IAPT, depression)
Self-perception
The concepts of self-efficacy, self-identity, self-stigma and self-esteem identified within the review were all
revealed as having an effect on many aspects of our interviewees’ lives. This was often communicated
after prompting rather than being something immediately obvious to them and explicitly stated. Consistent
with the review was an acknowledgement that a lack of self-worth and confidence was preventing them
from doing things that might potentially improve their quality of life, yet it was difficult to overcome.
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. . . it is the area of, um, you know, not willing to take, to step out and get out of my comfort zone is
what I’m the most challenged on. So I do generally feel, er, inadequate in a way because I don’t, I
won’t, should I say, I ought to, sort of, you know, take control, risk, if you like, and actually get on
with it rather than, you know . . . like I say, well in terms of finding a partner, it’s a confidence thing,
you know, I see too much danger and, sort of, think perhaps that if you find, it would be difficult to
find somebody who genuinely loved me for who I am [laughs], so, um, and I know it’s not just
in – it’s in other life choices as well and er – but I’m not saying be reckless and gamble, recklessly do
things but, on the other hand, um, sometimes chance favours those who will be prepared to
take a chance . . .
Participant 17 (other, schizophrenia)
A negative perception of the self that affected quality of life was expressed by interviewees with all
diagnoses and severities of illness. However, those who appeared most distressed at the time of the
interview reported how a lack of self-esteem and confidence currently affected their lives in a detrimental
way. Those with less severe problems talked about how their confidence was improving or that they were
trying to address this and consequently improve their lives.
Yes it has improved a lot, if you had asked me to come here 7 week ago there was no way I would
be able to come but now I have come on the bus. I feel a lot better in myself, if you had asked me
7 weeks ago I would have had to say come to my house, there was no way I could have come out.
It was the thought of going out in the open I know it is horrible saying it but it knocked me for six
kind of thing.
Participant 2 (IAPT, anxiety)
A further difference identified within our interviews was that for some a lack of confidence and
self-esteem was something they felt had affected them all their lives and had contributed to their mental
health problems, whereas for others this was a consequence of their illness.
I have got no confidence to do the things I used to do and self-esteem, no, just lack it. You see before
I was a right confident person, until what happened to me happened, so I don’t know whether my
self-confidence will come back, ’cos before I was very confident, I had to do hand overs at work and
like talk to GPs and things like that, and it didn’t bother me, and now I don’t even like talking to
people some days [laughs], I don’t know what it is, I just put it down to my illness[.]
Participant 8 (CMHT, PTSD)
The review identified how those with bipolar disorder, schizophrenia and panic disorder in particular
described difficulties with having a coherent sense of self. This was also evident in our interviews;
however, one interviewee diagnosed with schizoaffective disorder described how this could have a positive
as well as a negative effect.
. . . it’s almost like this different personality of voices bouncing round your head, kind of, you know
what you’d call your train of thought, your own, kind of, inner dialogue, that kind of, it’s like you’ve
got that, but yet there’s other ones trying to, kind of, take over and become that train of thought
and they’ve got their own voices and their own personalities and their own characteristics and you’re
like struggling to, kind of, stop them hijacking your brain, in a way, and so you kind of, you’re having
conversations in your head with them and, kind of, talk, and sometimes it’s really funny and good, it’s
like having two mates round and you’re just arguing and talking and at other times, you kind of, you
lose track of who you are, if you know what I mean[.]
Participant 14 (CMHT, schizoaffective disorder)
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Autonomy, control and choice
Consistent with the review, our interviews revealed the importance to quality of life of the related
concepts of autonomy, control and choice. The review highlighted the complex juxtaposition between
support and independence: the dilemma between needing support and valuing independence while not
wishing to be too dependent. This same quandary was communicated by our interviewees. They spoke of
an aspiration for independence but with an acknowledgement by some that support, and sometimes
dependence, were necessary during periods of illness when they were not in a position to help themselves.
The need and desire for support and independence therefore changed over time.
. . . when you’re depressed, you’ve got, kind of, you’re very reluctant or unable to help yourself, and
even if there’s loads on offer, you won’t find it, you kind of, you need to keep in touch with people,
like, so me seeing my family or as many friends as I can and like the social worker, is vital, otherwise
you could, you know, get really really down[.]
Participant 14 (CMHT, schizoaffective disorder)
In our interviews, the value of support for quality of life was expressed primarily by those with severe
mental health problems, whereas those with less severe problems were more likely to be actively working
towards greater independence. Of our interviewees, the person for whom independence appeared to be
of the greatest importance and dependency the most troublesome had physical as well as mental health
problems which affected their mobility. Being independent was important for dignity, pride and privacy,
whereas being dependent resulted in feelings of guilt and being a burden which could put a strain on a
good relationship.
Interviewee: Just to sort of do something on my own without like oh well I’ve got to get out or
whatever, will you come to bus stop with me, or got to ring a taxi, just to be able to say ‘right I’m off’
not disappear but just say ‘right, I’ll see yer’ and just go without having ‘where you going, what time
you coming back’ . . . I am dependent on people.
Interviewer: How does that make you feel?
Interviewee: Fed up sometimes, I mean don’t get me wrong, I would go out with my daughter or my
friend but that would be by choice. You know like ‘oh I am meeting’ her rather than [daughter saying]
‘oh well I’ve got to meet her cos I’ve got to go shopping’. That sounds awful, but that’s the – do you
know what I mean. You know without her thinking ‘oh I can’t do this cos I’ve got to make sure me
mam’s all right’[.]
Participant 9 (IAPT, depression)
Also consistent with the review was a need for control, particularly symptom control, for those with
psychosis and anxiety-related problems. For these interviewees a fear of losing control was evident.
However, this prevented them from doing some of the things they would like and increased dependency
upon others. This showed that although control was desired, and increased feelings of well-being, too
much control could have a detrimental effect on quality of life. Our interviewees were very much aware of
this but found it difficult to change and find the balance between the two. A consequence of this was
that they felt bad about themselves because they were not living up to their own and others’ expectations.
I seem a bit of a control freak, I want everything to be worked out before I decide to do a certain
thing, you know, I want everything to be fairly straightforward and I mean, you can’t, in a way, you
can’t live life like that, and yet I still want to live life like that, do you know what I mean? . . . it’s
about the stress, erm having faith or taking this, stepping out of your comfort zone, whatever you
want to call it, yeah[.]
Participant 17 (other, schizophrenia)
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Having choices and opportunities was also important to quality of life. As with the review, choice was
particularly associated with having sufficient finances, which in turn was often linked with the availability
of suitable employment. However, the opportunity of employment, or at least employment that was not
demeaning to their values and expectations, was something they felt was denied, often due to perceived
and experienced discrimination. Not having money meant they did not have the opportunity to pursue
those things that could improve their lives in ways that were related to leisure activities, their environment
or their physical and mental health care. Our interviews also showed how having choices and
opportunities was cumulative, with one leading to another.
I ended up going to the halfway house [gives name] at halfway homes they had lots of opportunities
. . . they were brilliant because they there was a pot of money every month that they could spend I
mean I learnt to drive through that . . . it would encourage you and enable you to do these life things
so I did driving, somebody else did fishing . . . I don’t think they have a training budget now which is
a bit of shame because it opened my life to lots of things. I went on courses . . . I got the money for
the driving, knowing that I could drive triggered off other things for me and I did get benefits at that
point which allowed me a little bit more to do these things . . . So that’s how my life got built by
having guidance and opportunities really . . . and I think that’s a big thing isn’t it, there’s not all the
opportunities there and stuff[.]
Participant 1 (CMHT, depression/eating disorder)
Because it was difficult to find suitable work, and because of the stresses that employment entailed, some
participants chose the safety of remaining on benefits. Some preferred to do voluntary work instead,
which provided them with the benefits linked to employment, apart from financial, but with more
flexibility and control to protect themselves from becoming ill.
Relationships and belonging
Within the review, ‘belonging’ was defined as having two dimensions: ‘valued involvement’, the
experience of feeling valued, needed and accepted, and ‘fit’, the person’s perception that his or her
characteristics complemented the environment they lived in.201 The focus was on how well people
perceived they fitted with society. The importance of a sense of belonging was also present in our
interviews. In contrast to the review, our interviewees also felt that society did not fit with them. This was
expressed as a dilemma about whether or not they wished to be part of a society that they felt had
different values to their own. This sense of being ‘alien’ to society was something expressed by those with
severe depression and schizotypal disorders. Those with mild to moderate anxiety/depression expressed
feelings of being isolated from society but not that they did not belong to it.
I have feelings of err not belonging to the human race, like I feel very – it’s not an outcast, I just don’t
feel a connection. I don’t know how else to describe that, it’s like being an alien, that is the only way
I can describe it, and I know that that sounds weird but that is the only way that I can describe the
feeling of it . . . I don’t cope with most people [sighs] I – [pause] my values and norms are very
important to me and I know that everybody has not got the same ones[.]
Participant 4 (CMHT, depression/anxiety)
Similar to the review, there was an expression of a desire to do ‘normal’ things or to return to a normal
self, particularly for those who had experienced a traumatic event. However, in contrast to the review, our
interviewees communicated a sense of being different, rather than abnormal.
A QUALITATIVE ANALYSIS OF INTERVIEWS WITH MENTAL HEALTH SERVICE USERS
84
NIHR Journals Library www.journalslibrary.nihr.ac.uk
You know, you will not make any sense to ’em with voices or whatever you want to call them,
bouncing around your head, because then that fires my, you know, it fires my imagination, but I’m
talking to people that aren’t, kind of, a bit oddball or a bit, kind of, you know, a lot of people are
really, kind of, straight and they’re not strange enough, you know, they don’t – I look at things and,
kind of, from a certain angle, a lot of people don’t, and likewise for them, they’ll just think I’m
f*****g mad or, you know, dark or depressing, which I can be, but, it’s like gallows humour,
you know[.]
Participant 14 (CMHT, schizoaffective disorder)
Stigma was a strong theme in the review and though present in our interviews, was disclosed primarily by
those with problems related to gender identity and schizophrenia, particularly related to employment
opportunities. Stigmatisation was less of a problem for those with anxiety and depression.
Rather, a need for a better understanding of the impact of mental health problems was expressed by
interviewees with all diagnoses and severities of illness. This lack of understanding resulted in them not
receiving the support they needed and a feeling of not being able to talk to people about their problems.
Interviewer: Thinking of quality of life – what would have improved things for you at the time.
Interviewee: Well, more understanding from people in authority, like the council, by helping people that
have got problems that need the help . . . I find a lot of people don’t understand depression and they
don’t understand the way it affects people and, you know, I’ve had many people say to me, ‘oh you’re
stupid, you just pull yourself together’, but they don’t understand the way it affects people, you know.
Participant 15 (IAPT, depression)
The review identified the importance of good quality relationships. These satisfied a need for support, love,
care and affection, and a need to have someone they could trust and confide in, who accepts and
understands them, and with whom they could experience fun and happiness. These themes were also
identified in our interviews. Similarly, our interviews revealed that, particularly for those with severe and
enduring mental health problems, there were difficulties forming and maintaining close, family and social
relationships. The relationships that could fulfil these desired needs felt out of reach, which had a
reciprocal effect on subjective well-being and self-perception. These interviewees tended to live alone with
care and support provided by their mental health worker only.
I alienate myself because I don’t share. I have to take responsibility for that, but I can’t – without
sharing they don’t understand why I don’t share, it’s a bit of a vicious circle. But to have that trust to
share, is quite difficult for me, but, of course it is, it is not going to be easy, it takes a long time for
me to be friends or something with anybody really . . . [name] from [name] she helps me a lot she is
from an organisation to support people with mental health issues to do everyday things to encourage
you to go out and things like that, and without [name] I think I would go insane. I only see her once a
week or once a fortnight but she does understand me[.]
Participant 4 (CMHT, depression/anxiety)
In contrast, interviewees who tended to have less severe or relatively short-term problems had difficulties
associated with current relationships that affected their quality of life, but these difficulties were less
profound. They did not express any difficulties in their abilities to form new relationships and spoke of the
support received from other family and friends.
Not evident in the review was the way in which people made negative and positive comparisons with
others in order to evaluate their own quality of life. In our interviews, envious comparisons were made
with people in the interviewee's immediate family or social circle. On the other hand, positive comparisons
tended to be made with remote referents, people who were less fortunate than themselves with whom
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they might rarely come into contact. For some interviewees there was an internal struggle between
the two.
I think ‘oh everybody’s at me and they’re all paired off and I haven’t got my mother and dad and
everybody’s, all the world’s got a mother and dad’ even though they haven’t and then I say ‘well my
sister hasn’t got a mother and dad’ she’s only same as me but she’s got a good husband, and he is a
good husband. And then I say I’ve got a sister, I’ve got a brother-in-law as well . . . and I thought you
know ‘pull your bloody self together, at least you’ve got legs that work to moan at, there’s some
people sat in a wheelchair’ . . . and so I know I’m lucky it’s just, [sighs] oh I don’t know[.]
Participant 9 (IAPT, depression)
Activity and functioning
The findings related to activity from both the review and our interviews were very similar – that leisure and
work activity had a positive effect on subjective and psychological well-being, was enjoyable, engendered
a sense of belonging through social interaction, and generated feelings of self-worth, pride and a sense of
achievement. Importantly, it also provided the income often needed to take part in activities that are
pleasurable and aid recovery.
I went on a year’s course at engineering and I was absolutely scared about going on that, but I did it
and I did it, you know, quite well . . . and at that time, I was really happy in my life and I thought well
I’ve done something, I’ve achieved something here doing this . . . I think [I was happy] because I had
the drive and a purpose of getting up and going out every morning and doing what, you know,
normal people do, sort of thing, you know, I got into a routine which was very good, so I was happy
and more stable . . . I just felt a little bit more worthwhile, you know. I don’t like to feel useless . . .
I’ve missed the banter I think as well, as part of being a team, or even on your own or whatever, I
miss the camaraderie[.]
Participant 10 (IAPT, anxiety/panic attacks)
Again, similar to the review, our interviews also revealed that when no enjoyment could be found from
activity, it still had the benefit of providing a structure and routine to the day, relieved boredom, kept the
mind active and – as expressed by many as being of particular importance – provided a distraction
from problems.
[After feeling suicidal] my interest in things started coming back it has made a lot of difference
because it meant that I was able to distract myself to a certain extent . . . so I was grateful that that
came back a bit, rather than just being completely immersed in this world of depression, at least I got
a few minutes out of, you know, it was just a few minutes at a time, but it gradually built up to the
longer periods where I could go back on the computer again or I could say watch EastEnders,
whereas I just completely lost interest, so that was one thing that improved[.]
Participant 13 (CMHT, depression)
Also consistent with the review was the finding that in certain circumstances activity could be detrimental
to quality of life. This occurred when the activity, usually employment, felt beyond their capabilities.
Reasons given for this were stress and anxiety related to pressure of work, problems concentrating,
difficulties with social interaction and the exacerbation of other mental health symptoms.
. . . they systematically bullied me, unbeknown to me, I didn’t even realise because I was that stressed
and sort of, out of it, my work life balance doesn’t work very well, I don’t tend to put myself first,
and therefore I get iller and iller whilst enabling other people at the end of it I went off sick because I
wasn’t sleeping at all, I developed symptoms of erm – it’s what I called jelly brain, and it’s when you
turn your head it feels like your brain is slowly turning, even though your head has already turned, it
is a very strange sensation, and it’s a sleep deprivation sign. Erm, but obviously I was still awake
because of all the anxiety, it was the anxiety that usually kept me going.
Participant 4 (CMHT, depression)
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Our interviews highlighted an additional issue around the dilemma people faced when choosing between
short- and long-term quality of life: they could foresee the potential long-term benefits of taking part or
resuming activities they previously enjoyed, but often found the prospect of doing so too daunting in the
short term. The fear that their mental health and well-being might deteriorate further seemed to take
priority over the potential for more long-term life benefits – ‘I’d like to but I can’t’.
. . . what the psychiatrists advocate is a relatively low stress environment, that’s how I keep my mental
health on an even – you know, my mental health healthy as it were . . . part of me thinks that
perhaps if I could do a job where even if it was just cleaning, and if I could, in a way, confront stress
to a certain extent, be more, you know . . . I think to a certain extent, it would probably be a bit more
healthy to have a bit more in my life, if you know what I mean[.]
Participant 1 (other, schizophrenia)
Our interviews also revealed some differences associated with the severity of mental health problems.
Those with severe problems and who appeared most distressed at the time of interview reported finding
little enjoyment in any activity, often due to an inability to concentrate. Difficulties with basic functioning
and lack of self-care were reported as demonstrating a lack of interest in life itself, as was taking part in
particularly risky activity, which was communicated by one participant as an illustration that she did not
care whether she lived or died.
I don’t look after myself, I’m not interested in myself . . . I’m not! I’m just not interested in myself I
don’t care if I am not here today gone tomorrow, I am not bothered[.]
Participant 8 (CMHT, PTSD)
In contrast, those with less severe problems spoke of leisure activities and hobbies they enjoyed when
asked what improved their quality of life. These were often lone activities as, although social activities were
described as potentially the most enjoyable, those activities that involved social contact appeared to be the
first to diminish as problems worsened.
Hope and hopelessness
The review showed how important a positive view of the future was to quality of life. This involved having
goals and aspirations, and being involved in activities that were fulfilling and had meaning and purpose.
These were necessary in order to instigate change and have hope for a better future. This was also evident
in our interviews, with some further insight into how difficult this was for some, particularly those with
severe and enduring mental health problems.
I think whereas I was feeling completely hopeless that things would never change and I would be
stuck like this for ever, and just the desperation for things to end or things to change, she just gave
me that little bit of hope that things would change . . . eventually I came round to their way of
thinking and it gave me hope that at least I could hang on for just a bit longer to see what happens
and to see if things would change[.]
Participant 13 (CMHT, depression/affective personality disorder)
There were noticeable differences between our interviewees in how they viewed the future. This could be
related to their expected level of achievement before they became ill and whether or not they felt that was
something they could return to, given time.
The most negative outlook and evidently poorest quality of life was reported by those for whom previous
attempts at positive action to change their situation had failed, and coping mechanisms they previously
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drew upon no longer had an effect. As a result, they could not conceive of their situation changing in
the future.
. . . why carry on, what with my head f****d, and the pain, oh do you know, I just, I really have to
ask myself, really why do I carry on . . . It is really difficult to justify yourself at night, at 3 o’clock in
the morning, why are you putting up with all this, and why you just don’t commit suicide to be
honest because, I don’t know, it’s just really quite exhausting, I am going to the gym to help with my
back and stuff like that, but it hasn’t, but my blood pressure has come down. Hurrah! [cynically] after
3 bloody years[.]
Participant 4 (CMHT, depression/anxiety)
In the review, the emphasis was on the negative concept of hopelessness as related above. A more
positive outlook tended to be expressed by our interviewees referred via the primary care services who had
less severe and/or relatively short-lived mental health problems. In contrast to a perception that things
were unlikely to change, they were more likely to talk about having goals and plans in place which they
were actively working towards, however difficult. They were also more likely to compare themselves
positively with others. Religion also provided solace for some. However, this optimism may in some respect
have been due to these participants being recruited through a service specialising in cognitive behavioural
therapy interventions which focus on goal setting and positive thinking techniques.
I think that I have turned the corner I’ve settled down even though I probably might be on my own
now, but I’ll have to wait and see about that . . . alright I have got problems, but there are people
worse off than I am, they have got more problems than me and if some people can do it I think I
should be able to do it myself[.]
Participant 3 (IAPT, depression/anger)
Content validity of EQ-5D, SF-36 and ICECAP-A
Content validity is the extent to which the items of the EQ-5D and SF-36 (and the SF-6D) reflect
the content of the domains of interest identified by the qualitative research. This research has provided a
depth of understanding that is rarely possible with conventional psychometric techniques. It has identified
seven themes that were important to people with mental health problems. In this section we return to the
main aim of this project, which is to examine the validity of the EQ-5D and SF-36. This is achieved by using
the seven themes identified in the qualitative research to assess the extent to which these two measures
comprehensively cover them.
A key criticism of the EQ-5D and SF-36 is that they have been designed by researchers with little or no
input from people with the relevant health problems. As a result, it has been suggested that these
measures are too focused on physical health-related problems and so exclude potentially important mental
health-related quality of life.11,12 Patient-reported measures are being increasingly developed from
interviews with the relevant populations and this is in line with guidance in the academic literature56 and
some policy-makers.58 A recent example of this is a new generic instrument called ICECAP-A40 which, the
authors claim, can measure capabilities. A key feature of this instrument is that the content is based on
the results of a qualitative analysis of semistructured interviews with members of the general public. The
resultant classification system is less focused on physical health and functioning, and instead takes a
higher-level and broader view of the constituents of quality of life. It covers five dimensions: feeling settled
and secure; love, friendship and support; being independent; achievement and progress; and enjoyment
and pleasure. The ICECAP-A was not available at the development stage of this project and there are no
relevant data for undertaking quantitative psychometric analysis for this group of people. However, it
became apparent during the research that the ICECAP-A has similarities to the emergent themes and
provides a broader descriptive system that is potentially more relevant to mental health populations.
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It was therefore decided to include it in this assessment of content validity. The review of the content of
these three instruments against the seven themes is summarised in Tables 25–31.
EQ-5D
The content of the EQ-5D was presented in Table 1. As shown in Tables 25–31 there is only a modest
amount of overlap between the EQ-5D and the seven themes.
TABLE 25 Summary of subjective well-being/ill-being and a content validation of the EQ-5D, SF-36 and ICECAP-A
Subtheme Summary description EQ-5D SF-36 ICECAP-A
Distress –
overall theme
A key dimension in QoL literature covering
positive and negative aspects of well-being.
People with severe mental health problems
tend to focus on negative feelings and the
symptoms of their condition. Symptoms are
really a part of subjective well-being,
particularly for depression and anxiety
For those with the severest mental health
problems, feelings of distress associated
with depression, experience of psychosis
and mania, and anxiety had a major impact
on quality of life. The day-to-day experience
of symptoms and coping with them was
dominant. Described by one as ‘wretched’,
‘debilitating’, ‘painful’, ‘tormenting’ and
having a ‘tyrannical power of their life’
(Connell et al.199). Often interactions
between different types of stress – with one
making the others worse
Depressive
mood
For those with comorbidities, this was often
the most important symptom and was
described in interviews as being
all-consuming, constant (and least
amenable to medication), outside of their
control, and associated with poor
concentration (on things they used to
enjoy), low energy and poor motivation
Positive well-being: happiness and










Fear or panic can be the primary condition
and can be caused by social situations.
Respondents sought to reduce anxiety by
avoiding stressful situations. Those with
mild to moderate depression tended to talk
about worry










Distress caused by critical voices, like living a








QoL, quality of life.
Note: some symptoms related to specific conditions, whereas depression and anxiety occur across conditions.
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TABLE 26 Summary of activity and functioning and a content validation of the EQ-5D, SF-36 and ICECAP-A
Subtheme Summary description EQ-5D SF-36 ICECAP-A
Positive Activities like work, hobbies or social
interaction can be associated with providing
structure, energy, motivation and meaning.
A person achieves a sense of self and
control, develops a sense of belonging and
overall improves well-being. A means of









Negative Can be stressful if too demanding and
beyond their capabilities. Fear of stress can
result in avoiding activities that might be
enjoyable and beneficial in the longer term
People with severe mental health problems
(like severe depression) may lack energy





QoL, quality of life.
TABLE 27 Summary of social well-being – relationships/belonging and a content validation of the EQ-5D, SF-36
and ICECAP-A




These relationships include those with close
ones, family, friends and care worker
Positive consequence: provided practical
and emotional support, satisfied need for
love and affection, promoted confidence
and facilitated enjoyment. Those with more
serious problems did not feel close and
supportive relationships were not possible
for them
Negative consequence: can be source of
rejection and tension, and low self-esteem.
Can be part of a multidirectional
interaction, with the reactions and attitudes
of others exacerbating the problem. So they
may seek to avoid people to whom they
were previously close
Usual activities –












Participants talked about social life and
sociability being important to improving
their QoL and may be an alternative to
close relationships. For some, withdrawal
made life easier in short term. Work
colleagues, volunteering or groups with
similar problems can provide this
Negative: not seen as normal by themselves
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TABLE 27 Summary of social well-being – relationships/belonging and a content validation of the EQ-5D, SF-36
and ICECAP-A (continued )






Being treated in a non-judgemental way.
Understanding is an important theme in the
interviews
Negative reactions and lack of
understanding, including rejection and
stigmatisation, take QoL away. Stigma was
reported mainly by people with
schizophrenia (i.e. identifies a person as
culturally unacceptable or inferior), and is
associated with being avoided or not
accepted (e.g. by family), resulting in feeling
of rejection, being marginalised or written




This is feeling a part of society as a whole.
Came out as important from the review and
was an overall experience of integration,
involvement and fitting in. It was found to
be less important in the interviews
Some did not feel a part of society and
felt rejected
QoL, quality of life.
TABLE 28 Summary of self-perception and a content validation of the EQ-5D, SF-36 and ICECAP-A
Subtheme Summary description EQ-5D SF-36 ICECAP-A
Self-identity The review identified this as a problem of
‘knowing who you are’. It appeared to be
mainly related to bipolar disorder,
schizophrenia and panic disorder. Required





Terms used interchangeably to describe a
lack of self-worth and confidence. The
review also found feelings of uselessness
and inability to cope
Participants in the interviews recognised it
as having a detrimental impact on QoL.
Common across conditions and impacts on
social- and work-related activities. Those
with milder problems saw it as an area they











Self-stigma Poor self-image resulting from negative
connotations associated with the illness.
Impacts negatively on life due to the
individual’s own and other people’s
perceptions
QoL: quality of life.
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TABLE 29 Summary of control, autonomy and choice and a content validation of the EQ-5D, SF-36 and ICECAP-A




Support was valued and seen as important for
QoL. Indeed, those in more severe conditions
aspired to more support and accepted they
could not be independent
However, support can make people feel
dependent and this can be associated with
loss of control and esteem. Concerns about
loss of independence expressed by those with
less severe conditions and/or
physical comorbidity
In review, discussed importance of personal
autonomy to find the right balance between
support and independence. Autonomy does
not imply independence
Being independent
(‘I am able to be
independent . . .’) –
but does not deal
with need for
support
Control Self-control: mainly related to relief and
management of symptoms, usually through
medication. Anxiety and panic associated with
fear of loss of control, and depression with
lack of control
Environment control: there was a desire to
control the environment in order to feel safer.
Can involve withdrawing into a smaller
world – into a comfort zone
Feeling settled
and secure
Choice Having choice and opportunity is important for
QoL. Participants usually associate this with
money and access to resources which enable
someone to do the things they want to do
(capabilities theory). To get money, need
opportunities to do paid work; these are
limited by perceived discrimination and stress
from work (so some did voluntary work)
QoL, quality of life.
TABLE 30 Summary of hope and hopelessness and a content validation of the EQ-5D, SF-36 and ICECAP-A
Summary description EQ-5D SF-36 ICECAP-A
Having dreams and goals, and being
involved in activities that gave meaning and
purpose in life, was necessary to have hope
for the future
Sense of hopelessness that life would never
change for the better resulting in a lowering
of aspirations
Those with more positive outlook had goals






(‘I can achieve and progress
in all aspects of my life’)
TABLE 31 Summary of physical health and a content validation of the EQ-5D, SF-36 and ICECAP-A
Summary description EQ-5D SF-36 ICECAP-A
This can be a physical comorbidity or






limitation due to physical
problems, vitality, bodily pain
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Well-being and ill-being
The anxiety and depression dimensions of the EQ-5D may reflect the important aspects of ill-being of
depressive mood and fear and anxiety, and this is reflected in the psychometric evidence (see Chapter 2).
However, the qualitative evidence would suggest that these two elements are different in terms of the
impact they have on the lives of sufferers: namely, that depression was identified as being an order of
magnitude worse due to its all-consuming and long-lasting nature. In contrast, experiences of fear and
anxiety tended to be shorter term. It is therefore important to separate these into two dimensions.
Depressive mood is associated with low energy, poor concentration and poor motivation, which are not
really directly covered by this dimension. Symptoms of psychosis that have important and distinctive
implications for quality of life are not measured. Finally, the EQ-5D is concerned with negative aspects of
these themes and so excludes the positive counterparts such as happiness and enjoyment or feeling calm
and peaceful.
Activity and functioning
Usual activities is a rather crude and generic dimension that covers aspects of activity in a limited way.
People limited in their activities by their mental health condition may report a problem on this dimension.
However, this does not allow for the negative side of activity highlighted as an issue in the qualitative
work. People with mental health problems often find that activity can have a negative as well as a
positive impact.
Social well-being – relationships and belonging
Usual activities may again be seen as a catch-all dimension that covers some aspects of this theme.
However, it provides no information on the consequences. Relationships can be those with close friends
and family through to social relationships with colleagues, volunteers and neighbours. They can be
supportive and enjoyable, or they can be stressful or a source of rejection and stigmatisation. The concept
of usual activities also fails to capture a sense of belonging to society.
Physical health
The EQ-5D has content to cover key aspects of physical functioning related to mobility, self-care, usual
activities and pain. These four dimensions have been shown to be valid in many common physical health
problems, but research has found that some consequences of physical ill health are not reflected in the
EQ-5D, such as those resulting from poor vision.236
This leaves the themes of control, autonomy and choice, self-perception and hope/hopelessness, which
are only addressed through mobility and self-care that indirectly contribute to a person’s ability to be
independent. However, this does not include the more psychological components of this theme.
SF-36
The SF-36 covers more emotional aspects of health than the EQ-5D by including mental health, role
limitations due to emotional problems, vitality and aspects of general health (see Table 2). This is reflected
in the results in Tables 25–31.
Subjective well-being/ill-being
The mental health dimension of the SF-36 has five items covering depression (e.g. feeling downhearted
and low), anxiety (e.g. being a nervous person) and positive affect (‘have you been a happy person’ and
‘feeling calm and peaceful’). The vitality dimension covers positive (e.g. ‘feeling full of life’) and negative
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energy (e.g. ‘did you feel worn out’). On the face of it, the content of this instrument would seem to cover
most aspects of well-being and ill-being. One omission is concentration, though this is partly covered in
role limitation due to emotional problems (i.e. ‘did not do work or other activities as carefully as usual’).
Another is psychosis-related symptoms (e.g. hearing critical voices), though the extent to which this should
be in a measure of quality of life is debatable.
Activity and functioning
Role limitation due to emotional problems in the SF-36 would appear to cover this theme (i.e. ‘cut down
on the amount of time you spent on work or other activities’, ‘accomplished less than you would like’,
‘didn’t do work or other activities as carefully as usual’). However, this dimension does not consider the
levels of stress from activities found to be important to people with mental health problems.
Social well-being – relationships/belonging
There are two social functioning items in the SF-36: ‘has your health limited your social activities (like
visiting friends or close relatives)’ and ‘to what extent has your physical health or emotional problems
interfered with your normal social activities with families, friends, neighbours or groups’. The focus on the
way in which health impacts on social activities, through the general terms of ’limited’ and ’interfered’,
should cover some aspects of this theme, but does not capture all issues discussed by participants, such as
deep feelings of alienation or stigma, nor the responses of others. It also fails to incorporate the sense of
belonging. In other words, this SF-36 dimension is less able to reflect the psychological consequences
of social activities.
Hope and hopelessness
This theme overlaps with the depressive mood subtheme under the well-being/ill-being theme, and to that
extent feelings of hopelessness may be partly covered by items like ‘feeling down in the dumps all the
time’. The notion of hopelessness is also partly reflected in the general health perception item of ‘I expect
my health to get worse’. However, the overall feeling of hope and having goals to aspire to is not
captured by the SF-36.
The themes of self-perception and control, autonomy and choice are not covered by the content of the
SF-36. As for the EQ-5D, the items in physical functioning will be related to independence.
SF-6D
The preference-based SF-6D is derived from the SF-36 and so shares much of the same content. However,
there are some important differences owing to the fact that it contains only a subset of 11 of the 36 items
(see Table 3). The SF-6D does not cover general health perception and this means that it does not have
any item for tapping the hope and hopelessness theme. It combines role limitation due to emotional
problems with that due to physical problems. In addition, the SF-6D does not cover positive affect or
negative energy (i.e. tiredness).
ICECAP-A
ICECAP-A is a classification like the EQ-5D with a single item per dimension. The five dimensions are
feeling settled and secure; love, friendship and support; being independent; achievement and progress;
and enjoyment and pleasure. The content of this instrument would seem from the summary in
Tables 25–31 to be more closely aligned with the themes identified from qualitative work, and to some
extent this is reassuring as they are based on a similar qualitative approach. The main difference is that the
ICECAP-A was based on interviews with members of the general public rather than those with mental
health problems.
Subjective well-being/ill-being
The main observation for this theme and the others is that the ICECAP-A only considers the positive
aspects of the themes. Two dimensions are related to this theme, one for depressive mood (i.e. ‘I can have
XX of enjoyment and pleasure’) and the other for fear and anxiety (‘I am able to feel settled and secure in
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all areas of my life’). Although it is important to cover positive aspects, the findings from qualitative
research in people with mental health problems is that those with more severe problems do not talk about
enjoyment and pleasure, but rather focus on the negative aspects of well-being. The best they hoped for
was the absence of depression. Only in those with mild to moderate problems were these positive aspects
raised in the interviews. Well-being is part of a spectrum and so to exclude ill-being is likely to result in
floor effects (i.e. respondents clustering at the lowest level). ICECAP-A also does not assess the positive or
negative components of energy.
Activity and functioning
None of the dimensions of ICECAP-A seem to cover this theme.
Social well-being – relationships/belonging
The dimension of love, friendship and support captures this theme better than either of the generic
measures, the EQ-5D and SF-6D. However, again ICECAP-A fails to cover the negative aspects of
relationships including rejection and stigmatisation and feelings of loneliness and alienation. For people
with mental health problems, these consequences are an important part of their experience. It also does
not capture the sense of belonging and being part of society.
Self-perception
ICECAP-A does not cover most of the issues raised under this theme, such as self-identity, self-acceptance
and self-stigma. It may capture aspects of the positive side to self-efficacy and self-esteem in the
achievement and progress dimension (i.e. ‘I can achieve and progress in all aspects of my life’), though this
dimension fits better with hope and hopelessness.
Control, autonomy and choice
This is another theme where ICECAP-A provides a better match than the generic measures of health
through the dimension of ‘being independent’ (‘I am able to be XXX independent’). The wording is based
around the ability to be independent and so allows for respondents to say they could be independent but
choose not to be. However, it does not include aspects of control nor choice more generally.
Hope and hopelessness
The notion of hope is captured by the dimension ‘achievement and progress’ (‘I can achieve and progress
in all aspects of my life’). Interviewees reported that having dreams and goals gave meaning and
purpose in life. The worst level in this dimension is ‘I cannot achieve and progress in any aspect of my life’,
but this may not capture the very low levels of hopelessness reported in the interviews, with some
respondents indicating that life would never change for the better. To confirm this would require
psychometric evidence to establish the extent of any floor effects and whether or not it is able to
discriminate those with the most severe mental health problems.
Physical health
By way of contrast with the generic measures of health, ICECAP-A does not contain items that directly
assess aspects of physical health. This was raised in the interviews by participants who reported mental
health problems to be associated with physical manifestations, and there were interactions with physical
comorbidities. It could be claimed that the impact of these physical health problems is captured by the
higher-level domains of the ICECAP-A instrument. However, this requires further psychometric evidence.
Discussion
The primary research reported in this chapter builds upon a review of qualitative studies reported in
Chapter 5. The aim of the research was to further examine the views of people with mental health
problems on what is important to quality of life. We undertook a qualitative study of face-to-face
semistructured interviews with current users of mental health services. Participants were primarily recruited
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from three mental health services in the north of England. One (IAPT) provided psychological therapies for
people suffering from mild to moderate depression and anxiety. The other two were CMHTs providing
services for those with more severe problems, one working with individuals with severe and complex
non-psychotic disorders (e.g. severe depression, PTSD, personality disorder) and the other with those with
psychotic disorders (e.g. schizophrenia, bipolar disorder). This expanded the scope of diagnosis and severity
of illness covered in the review to include people with affective and anxiety disorders as well as people
with psychosis-related disorders. The seven themes to emerge from this qualitative work have been used
to assess the content validity of the EQ-5D and SF-36. Below we summarise the findings from the
interviews and compare and contrast them with those from the review. We address the limitations of this
part of the study and summarise the implications for the generic measures examined in this report.
Summary of findings
Our review and synthesis of qualitative research studies undertaken with people with mental health
problems, reported in the previous chapter, identified six domains of quality of life: well-being and
ill-being; control, autonomy and choice; self-perception; belonging; activity; and hope and hopelessness.
Despite widening the types and severities of mental health problems studied, we found our interview data
fitted well with the themes from the review; any differences tended to be within the themes and related
to the degree of impact of the themes on different levels of severity, chronicity and diagnosis. With some
exceptions, those with severe chronic difficulties were more likely to talk about losses and what took
quality away from life, whereas those with moderate or relatively short-lived problems spoke of the things
that added quality to life. The EQ-5D and SF-36 were found to have only a modest overlap with the seven
themes identified from the research, and though the ICECAP-A had better overlap, it only considers the
positive end of the spectrum.
Importance of physical health
The interviews identified more of the impact of physical health conditions which interacted with mental
health problems and made people’s life situations much worse and difficult to cope with. This may have
been less of an issue in the review as it excluded studies in which participants had major physical health
comorbidities. As a result, physical health makes an important additional major theme, as opposed to a
minor subtheme in the review. It also means that any measure of HRQoL for use in people with mental
health problems should include domains on physical health.
The spectrum from ill-being to well-being
Consistent with the review, we found that the distress related to symptoms is integral to quality of life for
those suffering from mental health problems. This indicates that symptomology and quality of life are not
separate entities, and consideration should be given to the inclusion of symptoms in quality of life
assessment. Our interviews revealed differences in the emphasis placed on distress between those with
severe and enduring, and those with mild to moderate, problems. The former tended to be at the negative
end of the well-being/ill-being spectrum, where quality of life was perceived as an absence of distressing
feelings and emotions. This priority of a reduction in the symptoms of mental health is consistent with
other studies237 where the desired outcome of people with functional mental illness was to feel less
anxious or depressed. In contrast, those with moderate and relatively short-lived problems did speak of
happiness and enjoyment with a greater expectation of achieving this. This is consistent with evidence
indicating that positive and negative affects play an independent role in health outcomes, and that
quality-of-life assessment should be bipolar, consisting of the independent dimensions of negative and
positive well-being.238,239 The shift in focus of mental health services away from mental illness and towards
mental health over recent years is commendable. However, people still enter these services with suicidal
feelings, and a change from feeling suicidal to non-suicidal is an important change in quality of life that
needs to be considered in outcome measurement.
Additionally, our interviewees said that depression had a greater impact on quality of life than other
mental health problems. This suggests that anxiety and depression should be treated as separate items
rather than combined as they are currently in the EQ-5D and SF-36. In their research, Headey et al.240
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concluded that four dimensions of well-being should be distinguished: life satisfaction, positive affect,
anxiety and depression. They found that life satisfaction was negatively correlated with the distress
dimension of depression, but there was no association between life satisfaction and anxiety; people could
be both satisfied with life and anxious.
Subjective versus psychological well-being
There are strong arguments that hedonic well-being in terms of pleasure, enjoyment and satisfaction is
insufficient for a good quality of life.29 Also crucial is human potential, or eudaemonic well-being,241 and
self-actualisation,242 which considers how satisfied people are with their lives. This differentiation also has
parallels in the study of subjective and psychological well-being.243 The concept of psychological well-being
extends subjective well-being beyond happiness and positive affect,243,244 suggesting a multidimensional
model of psychological well-being consisting of six dimensions: self-acceptance, environmental mastery,
autonomy, positive relations with others, purpose in life and personal growth. The initial three concepts
are not dissimilar to our themes of self-perception, autonomy, control and choice, relationships and
belonging. Furthermore, meaning and purpose is one of the main components of our theme of activity.
One difference is that this literature is primarily concerned with what makes a good life and what adds
quality to life, whereas for many of our interviewees, quality of life was expressed in terms of what took
quality away from life.
An easier, restricted life or a stressful, fuller life?
For those with more severe and enduring problems such as long-term depression, PTSD and schizophrenia,
there was an acknowledgement that a lack of self-worth and confidence was preventing them from doing
things that might improve their quality of life, and that this was difficult to overcome. For some, life was
easier if they were able, or allowed, to stay within their own comfort zone. This might mean choosing to
remain on state benefits rather than risk the stresses of employment, despite an acknowledgement of the
benefits employment could bring to quality of life, such as self-esteem, social engagement and improved
finances. This was one of the common threads throughout our research on the views of people with
mental health problems, which we alluded to in the review and which became more explicit in the
interviews. There was a conflict and dilemma between short-term well-being and other aspects of quality
of life. Our interviewees expressed how they engaged in negative coping strategies, such as avoiding
things that made them feel anxious, but at the same time these strategies stopped them doing those
things that might ultimately enhance their quality of life. This is consistent with research indicating that
certain aspects of positive functioning, such as the realisation of one’s goals and purposes, require effort
and discipline that may well be at odds with short-term happiness.245 This seemed to be all the more so for
those with serious mental health problems, for whom added stress could exacerbate or induce other
mental health symptoms (e.g. hearing voices). It was difficult for some of our interviewees to decide which
was more important to quality of life – a restricted life, free from anxiety and stress, or a fuller life which
involved negotiating barriers, anxiety and stress and the risk of exacerbating other aspects of their
mental illness.
Capabilities approach
Both the review and interviews revealed how a lack of choice and opportunity prevented people with
mental health problems from reaching their potential, particularly in the field of employment. The concept
of choice is an important aspect of the capabilities approach to quality of life. A person has a set of
‘functionings’ which refer to what a person can ‘do’ or can ‘be’, the relative importance of which are
assessed by the person him or herself. Whether or not a person is capable and can benefit from these
‘functionings’ is determined by the choices and opportunities available to him or her. Many of our
interviewees were well educated and once had aspirations of successful careers. However, opportunities
were often denied, either due to the limitations imposed upon them as a result of their mental health
difficulties or due to both actual and perceived discrimination, particularly in the workplace. So where
some were once considering careers as bankers, lawyers or writers (as stated by our interviewees), they
were now deliberating whether or not they would be capable of a full-time job stacking shelves or
cleaning. Not being able to live up to their own and others’ expectations could have a cumulative effect
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on subjective and psychological well-being, which in turn made it harder to cope and change their
situation. Added to this is a lack of understanding of their problems, both by the people close to them and
society at large, and a consequential lack of support and other resources. This was a problem for some of
our interviewees more than others, and particularly for those with psychosis-related disorders and severe
depression. Those with less severe problems had current difficulties fulfilling their potential but tended to
feel it would be something they could potentially regain once they recovered.
The importance of relationships
Understanding and support is an important component of good-quality relationships. The importance of
good relationships, and also the effects of poor relationships, was a theme that ran throughout our
interviews and was expressed by people with different types and severities of illness. Those with severe
and enduring problems were more likely to speak of the damage that had been a result of poor
relationships in the past and which, in turn, affected their potential for fulfilling relationships in the future.
Avoidance of damaging relationships, usually within the family, improved quality of life. Those with less
severe problems had difficulties with specific relationships but those problems were less profound, and
they were more likely to speak of the benefits of the positive relationships in their lives. This was reflected
in a sense of being alienated from society for those with severe difficulties, which was not expressed by
those invited to our research via the primary care service, perhaps because it was something that was
taken for granted. The importance of relationships is reflected in the inclusion of this theme in the majority
of quality-of-life models, including needs based, psychological, social health and cohesion, environmental
and objective social indicators.239
Is quality of life different from recovery?
As already described (see Chapter 5, Discussion), our domains closely match those of a recent review of
the ‘personal recovery’ literature which was released after we had completed the analysis of the review
studies.233 Personal recovery could therefore be regarded as a further model of quality of life in addition to
those outlined in Chapter 1. Importantly, both our research and that into personal recovery are based on
the voices of people with mental health problems.
How does this help us to understand the quantitative findings?
The psychometric evidence presented a mixed picture, with the EQ-5D and SF-36 apparently achieving a
satisfactory level of performance in depression, and to a lesser extent in anxiety and personality disorder.
However, the evidence was clear for schizophrenia and bipolar disorder, and there was a suggestion that,
even in these conditions, these crude quantitative tests were actually picking up differences in depression.
The range of themes identified in the synthesis reported in the last chapter and the interviews reported
here provides some insight into the problem. Essentially, both generic measures, and particularly the
EQ-5D, are focused on physical health and functioning and seem to miss large areas of mental
health-related quality of life mentioned by the interviewees. What the participants spoke about was closer
to the quality-of-life models described in Chapter 1 than the narrow dimensions that form the content of
these generic measures. The extent of this mismatch of content has been detailed above. This would seem
to account for the mixed results, as large elements of the lives of these people that are affected by their
mental health problems are not assessed.
Strengths and limitations
One of the primary aims of the interview research was to ascertain what was important to quality of life for
people with a wider range of mental health disorders and levels of severity than was available within the
review. To a large extent we achieved this, with interviews being undertaken with people recruited from
primary and secondary services catering to the needs of people with severe and enduring problems and
mild to moderate anxiety and depression. However, despite attempts, we did not receive any referrals from
these services of women with psychosis-related disorders, or people with obsessive compulsive disorder.
Our findings may not, therefore, be inclusive of their views. There was also an over-representation of
referrals from one member of the CMHT who was a nurse. Although we are unaware of any biases that
may have been introduced as a result of this, it is possible that the perspective of those being seen by a
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nurse in the team could be different from those whose key worker was a psychologist, occupational
therapist, etc. Finally, we had hoped that practitioners would introduce the possibility of taking part in the
research to all their current clients and would let them decide whether they felt able, or wished, to be
interviewed. However, the number of referrals received strongly suggests that service providers acted as
gatekeepers and the voices of all types of service users were not necessarily included. The implication is that
further interview work could be undertaken to address these gaps.
Conclusions
The review and synthesis of qualitative research undertaken with people with mental health problems,
and the interviews reported in this chapter, have together identified seven domains of quality of life:
well-being and ill-being; control, autonomy and choice; self-perception; relationships and belonging;
activity; hope and hopelessness; and physical health. It is important that these domains are addressed in
some way in quality-of-life measures. People enter mental health services with varying degrees of distress
and chronicity, and as our research shows, recovery can be a long and difficult process. However, people
may perceive large improvements in their quality of life without registering on the positive end of any
quality-of-life scale, although undoubtedly this should be the aim. It is therefore necessary that the full
spectrum of negative through to positive aspects of each domain is included within quality-of-life
measures. The EQ-5D and the SF-36 and its derivatives were found not to cover large elements of the
seven themes identified by the research, and this calls into question the content validity of these measures
for large parts of the population with mental health problems.
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Chapter 7 Discussion and conclusion
We have presented the results of a detailed examination of the appropriateness of the EQ-5D and theSF-36 (and its derivatives) in people with mental health problems. We have used mixed methods to
evaluate the key properties of validity and responsiveness. Studies employing quantitative methods,
including systematic reviews of the literature and psychometric analyses of existing data sets, have been
used to examine the construct validity (testing for known-group validity and convergent validity) and the
responsiveness to change in mental health status of these measures. Qualitative evidence on content
validity has been obtained from a systematic review of the literature and analyses of interviews with people
with a range of mental health problems. This chapter begins by presenting a brief overview of the results
of each study. It then discusses the main findings of this research and presents the implications for policy
and recommendations for further research.
Summary of main studies
Psychometric evidence
Systematic reviews were undertaken of the psychometric literature in five mental health conditions:
depression, anxiety, bipolar disorder, personality disorder and schizophrenia. Overall, the results from
91 studies identified by an exhaustive search of the literature were used to assess the construct validity
and responsiveness of the EQ-5D and SF-36.
Generic measures were found to adequately reflect differences between groups or changes over time in
populations diagnosed with depression. In populations with anxiety, the evidence was less clear as the
differences between known groups may have been driven by comorbid depression rather than anxiety
disorders themselves. For personality disorder, most studies supported the construct validity of the EQ-5D,
but there was insufficient evidence on the SF-36. Within schizophrenia the evidence demonstrated
known-group differences, but this was mostly limited to differences between individuals diagnosed with
schizophrenia and the general population. Contradictory evidence was found in studies using clinical
measures of symptom severity, where the generic measures failed to reflect differences or correlate with
the clinical indicators. In bipolar disorder, generic measures reflected known differences in clinical
measures of depression but not mania.
The amount of evidence found in the literature was limited in terms of size and coverage, so it was
decided to expand the evidence base by undertaking further psychometric analysis of a number of existing
data sets. This provided more evidence in depression, anxiety, personality disorder and schizophrenia and
used more patient-based assessments in the validation. These analyses broadly supported the findings of
the reviews, with the EQ-5D and the SF-6D being found to be valid in samples with mild and moderate
depression and anxiety. For schizophrenia, the findings were less clear, with the EQ-5D and SF-6D not
being responsive to change in comparison with the condition-specific measures.
The tests of construct validity and responsiveness tend to be rather crude, as they depend on the validity
of the construct used to assess the criteria. Tests of known-group validity, for example, usually either rely
on comparison with the general population or use clinical assessments of severity that may not reflect
meaningful differences in quality of life from the perspective of the population with mental health
problems. Such evidence cannot prove or disprove the validity of a measure; at best it can provide support
for appropriateness of the measure. The findings from our review and the further analyses seem to
highlight potential concerns in anxiety, bipolar disorder and schizophrenia (particularly with regard
to responsiveness to treatments). It is important to judge these findings alongside qualitative evidence on
the content validity of the measure.
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The psychometric evidence presented an interesting and mixed picture in terms of the performance of the
EQ-5D and SF-36 in populations with mental health problems. However, this quantitative evidence is not
able to offer an explanation for these mixed results. For this reason, qualitative research was undertaken
on the impact of mental health problems on quality of life.
Qualitative evidence
The review of previous research found 13 studies that had interviewed people with mental health
problems about the way their condition impacts on their lives. It was difficult to be sure that all informative
studies had been identified given differences in terminology. The findings from those studies located were
synthesised using the ‘framework’ approach.198 We identified six domains from this review: well-being and
ill-being; control, autonomy and choice; self-perception; belonging; activity; and hope and hopelessness.
The complementary primary research involved semistructured interviews of people with mental health
problems. These interviews expanded the scope of diagnosis and severity of illness covered by the studies
in the review to include people with affective and anxiety disorders referred via NHS services, and those
with severe and enduring mental health problems and mild to moderate depression/anxiety. We found
that our interview data corresponded well with the themes from the review, and any differences tended to
be within the themes and related to the degree of impact of the different levels of severity, chronicity and
diagnosis. The only change to the themes was that physical health was found to be more important
among the interviewees than suggested from the review, so this was added as a seventh theme. The
review and interview data found that each theme had a spectrum of positive and negative components.
Mapping between mental health and generic scales
When generic measures are not being used, one solution is to estimate mapping functions where
condition-specific measures are regressed onto generic measures to produce health-state values. We
estimated mapping functions between widely used condition-specific measures (HADS, CORE-OM, PHQ-9,
GAD-7, and GHQ-12) for depression and anxiety and the EQ-5D and SF-6D, using four data sets available
to the investigators. Mapping functions were not estimated for other conditions as the psychometric
evidence suggested that the generic measures were not appropriate.
The statistical models mapping the HADS onto the EQ-5D had poor predictive performance. The mapping
functions for the SF-6D fitted the data sets better, particularly the CORE-OM onto the SF-6D, but they
still suffered from some degree of over- and underprediction towards the ends of the ranges. Given the
psychometric evidence that the generic measures performed satisfactorily in this group, this result is
perhaps surprising. These analyses were limited by the small size of some of the data sets and the
condition-specific measures available, with the EQ-5D only being mapped onto the HADS. Furthermore,
most of the mental health measures only focus on mental health, and often on very narrow aspects of
symptoms of mental health, which may not translate into a general health score. We conclude that these
mapping functions should not be used, but that the original generic measures should be used in trials and
other clinical applications in order to obtain accurate estimates.
Implications of findings
The content of the EQ-5D and the SF-36 was compared with the seven themes identified in the qualitative
research in order to provide an assessment of content validity. In summary, the EQ-5D would seem to
cover little of the content of these seven themes owing to its focus on physical health. Only physical health
seems to be covered, along with activities and functioning, which is included in a rather crude way
through usual activities, and ill-being in terms of depression and anxiety. The SF-36 covers more by having
a multi-item dimension on mental health and a vitality dimension that covers more aspects of well-being
and ill-being, and some aspects of social functioning. However, like the EQ-5D it fails to include the
response of participants and others to activities and social well-being; self-perception and control;
autonomy and choice; and hope and hopelessness. It was decided to extend this analysis to a new
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measure, the ICECAP-A, as this was derived from interview data, although it was obtained from the
general public and not people with mental health problems. The ICECAP-A has greater overlap with the
themes, but it is limited to the positive manifestations of these themes, and this may be because people
with mental health problems were not targeted in the interview sample used to develop the measure. It
should also be emphasised that there is no psychometric evidence on the performance of ICECAP-A in
a mental health population, and it may miss important changes, particularly in populations with more
severe problems.
Care must be taken in drawing any firm conclusions about the generic preference-based measures of
health reviewed in this report due to the following limitations:
l The quantitative psychometric evidence is limited to a comparatively small number of studies that in
many cases have small sample sizes. Furthermore, the tests were reliant on measures of symptoms and
clinical diagnosis which, although widely accepted in mental health research and validated in the
populations concerned, are not measures of the construct of HRQoL.
l The population of people with mental health problems in the qualitative research was not
comprehensive despite an extensive review of the literature and an attempt to recruit across the
spectrum of conditions. An important problem is the risk of selection bias by professionals in assessing
the suitability of service users for interview.
l There has not been time to undertake a full theoretical analysis of the qualitative data. Further work is
required to fully understand the themes and consider them in relation to existing models of quality of
life and related concepts.
A more general problem arises from the lack of an agreed definition for quality of life or mental
health-related quality of life, and hence there is no gold standard for examining the validity of these or any
other measures. This is a major handicap for the field. However, improving the mental health-related
quality of life of people with mental health problems is a key objective, so it is incumbent on researchers
to develop measures and assess their performance as best they can, and to use accepted tests such as
known-group validity, convergent validity and content validity to provide support or otherwise for the
measures they use. Policy-makers also need guidance on which measures to use for assessing the
cost-effectiveness of interventions and monitoring the outcomes of services.
Despite these concerns, there are conclusions to be drawn about the implications of the findings.
l The combined evidence from the psychometric research and the qualitative research suggests that the
generic measures of health do not capture many of the concerns of importance to people with mental
health problems. While the ICECAP-A is better in covering many of the themes, it does not consider
the negative end of the spectrum of these themes, more relevant to people with mental
health problems.
l For depression and personality disorders, the generic measures of health would seem to be adequate
in picking up differences between known groups, but there is less support for their responsiveness to
changes over time. These also exclude key themes.
l For anxiety, bipolar disorder and schizophrenia, the generic measures fail to capture many of the
problems that arose in the interviews and this is reflected in the psychometric evidence on validity
and responsiveness.
Further research
This has been an extensive and rigorous testing of generic measures of health in mental health population
through the application of quantitative and qualitative techniques. However, there are important gaps
remaining in the literature and limitations in the research reported here that need to be addressed.
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Further research is required to improve the robustness of the findings as follows:
l The quantitative analysis needs to be extended to include further data sets that can allow the further
testing of the construct validity and responsiveness of the generic measures. The relevance of the tests
would be improved by administering other measures of self-perceived HRQoL rather than relying on
clinical indicators to examine construct validity and responsiveness.
l This report has examined tests drawn mainly from classical psychometric theory, but further insight
could be gained from the application of modern methods using latent trait models, such as Rasch and
item response theory, to examine how well the items used in the generic measures reflect the
dimension in general. This would require the collection of generic measures alongside more specific
measures of the dimension of interest, such as depression or anxiety, before pooling the items and
running these models to examine item performance in terms of characteristics such as model fit,
differential item functioning across groups, item severity and ordering of responses.246
l Further interviews need to be carried out in those conditions not well represented, such as obsessive
compulsive disorder and alcohol and drug misuse. It is also important to recruit some respondents
through different channels in order to avoid the risk of a selection bias caused by relying on
professionals. This is difficult to achieve from an ethical viewpoint, but there may be scope through
patient groups.
Research implications of the findings reported here include the following:
l The analysis of content validity should be extended to mental health-specific outcome measures. This is
important for guiding the choice of mental health measures for use in research to measure mental
health-related quality of life.
l Consideration should be given to the development of a preference-based measure for calculating
QALYs that is more appropriate to mental health. This could be an enhanced version of an existing
generic measure. A recent development has been the addition of extra dimensions or ‘bolt-ons’ in
order to make the EQ-5D more relevant.247 The problem for the EQ-5D and SF-6D is that adding more
dimensions makes them difficult to value using one of the preference elicitation techniques (such as
TTO). A more fruitful avenue might be to develop preference-based measures more specific to mental
health either from existing measures51,248–252 or by the development of new measures. Developing from
an existing measure has the advantage of building on past work and can be applied to existing data
sets containing the measure. A recent example of this has been the development of the CORE-6D
preference-based measure from the mental health-specific CORE-OM.52,253 A limitation in this case is
that it is concerned with common mental health problems such as depression and anxiety rather than
more complex conditions such as schizophrenia and personality disorder. The other option would be to
develop a new preference-based measure for use in mental health populations. This could build on the
findings from the review of qualitative evidence and the interviews presented in this report and
elsewhere, but it would be a major research endeavour.
Conclusion
The results of this mixed-method study are that the generic EQ-5D and SF-36 seem to achieve an
adequate level of performance against some psychometric tests and may be acceptable for use in
depression, and to some extent in anxiety and personality disorder. However, there are concerns regarding
the way depression and anxiety are combined into a single dimension in the EQ-5D and SF-36. Results
from the psychometric analyses in schizophrenia and bipolar disorder have been more mixed. These
measures provide only a limited coverage of the themes found in the qualitative research carried out with
people with mental health problems, and so may present a misleading impression of the impact of these
problems on the lives of those affected. This has implications for the validity of economic evaluation in
mental health. Recommendations for further work include the development of a new preference-based
measure in mental health based on the themes identified in thus research and existing measures.
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Appendix 1 Study proposal
1. Title: Validating generic preference-based measures of
health in mental health populations and estimating mapping
functions for widely used specific measures
2. Importance
The last decade has seen the increased use of economic evaluation and particularly the use of cost
effectiveness, where interventions are assessed in terms of their cost per Quality Adjusted Life Year (QALY).
The QALY provides a way of measuring the benefits of health care interventions, including improvements in
health related quality of life (HRQL). The most commonly used method for putting the ‘q’ into the QALY is
to use a generic preference-based instrument such as the EQ-5D (Brook, 1996), as preferred by NICE.
It is claimed that the EQ-5D and other ‘generic’ preference-based measures such as SF-6D (Brazier et al.,
2002) are applicable to all interventions and patient groups. This claim has support in many physical
conditions where these instruments have managed to pass psychometric tests of reliability and validity
(e.g. Marra et al., 2006). For other conditions the claim has not be substantiated, such as in relation to
visual impairment in Macular Degeneration (Espallargues et al, 2006) and hearing loss (Barton et al., 2004).
For mental health the evidence is rather limited, but suggests a potentially mixed picture. There is evidence
that generic instruments are able to reflect the impact of common conditions, such as mild to moderate
depression and anxiety (Lamer et al., 2006), while in a study of chronic schizophrenia using measures of
psychopathology and functioning to establish change, the EQ-5D did not have a significant correlation
with negative symptoms, disorganisation, depression, excitement and general symptoms (Willige et al.,
2005). The impact of a range of mental disorders on the generic preference-based SF-6D has been
modelled by researchers in Sheffield using data from the 8,580 respondents to the ONS Psychiatric
Morbidity Survey (Towers et al., 2006). After adjusting for covariates, major anxiety disorders and
depressive episodes were found to have a significant impact on SF-6D. However, obsessive compulsive
disorder, personality disorder and probable psychosis were not significant.
Generic HRQL measures are rarely used in mental health research and this has been seen as a major
limitation to conducting economic evaluations in mental health (Gilbody et al., 2003). This is either
because: 1) these measures are not regarded as valid in the patient group or 2) investigators are keen to
keep patient burden down and prefer to use a more specific measure. There are many outcome measures
specific to mental health and these make an important contribution to clinical research. The Department of
Health’s Expert Group on mental health outcomes identified the more widely used measures, including
HoNOS, CORE-OM, GHQ, BDI, Lancashire Quality of Life Scale, CAN, FACE, MHI-5 (from the SF-36) and
MANSA (DH, 2002). More recently the Improving Access to Psychological Therapies initiative has made
a Minimum Data Set mandatory that includes the PHQ-9 and GAD-7 (for depression and anxiety
respectively). However, these condition specific measures are not suitable for use in economic evaluation
since they are not preference-based, that is they have not been scored with the values of the general
public obtained using a recognised elicitation technique (as required by NICE and similar agencies around
the world).
This proposal aims to address two issues: 1) to examine whether or not the low take-up of generic
measures in mental health research is justified; and 2) to examine methods for overcoming the low use of
generics by mapping relationships between widely used condition-specific measure and generic measures
in order to permit evidence synthesis and cost-effectiveness analysis. This is important methodological
ground work for conducting economic evaluation in mental health in a way that is consistent with other
areas of health care and with the methods preferred by NICE. This will also provide important evidence on
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the appropriateness of existing generic preference-based measures in mental health and whether it is
necessary to adapt them in some way or develop a new preference-based measure in mental health.
3. Scientific potential
3.1 People and track record
Applicants: The team has the expertise required to undertake the study. John Brazier is a recognised
international expert on the development of preference-based measures for use in economic evaluation. His
work includes the development of the SF-6D and a number of condition specific measures. He currently
has an MRC grant to develop a new method for mapping between measures of HRQL. Alicia O’Cathain, is
a mixed methodologist with special expertise in qualitative methods and has worked in the area of quality
of life research for many years. Michael Barkham is also a clinical psychologist with an international
reputation in outcome measurement in mental health including the development of the CORE-OM
(Barkham et al., 2001). Myfanwy Lloyd Jones has extensive experience in conducting systematic reviews,
including in the area of qualitative evidence. Donna Rowen has expertise in estimating mapping functions.
Simon Gilbody is an expert in all aspects of evidence synthesis and mental health outcome measurement,
and is Editor of the Cochrane Depression and Anxiety Group. He is also an Honorary Consultant
psychiatrist and psychotherapist within the local NHS trust. David Richards has a background in nursing
and behaviour therapy, and has been a leading figure in the expansion of provision of psychosocial care
for common mental health problems in response to the Layard agenda. He has developed and
implemented low intensity-high volume care in the National Improving Access to Psychological Therapies
(IAPT) demonstration site in Doncaster. Sarah Byford and Martin Knapp are senior mental health
economists with considerable experience with using the EQ-5D and SF-36 across a range of MH services.
Collaborators: Glens Parry has considerable research and policy experience and is leading on the
SDO-funded evaluation of the DH demonstration sites for increasing access to psychological therapies.
Eleni Chambers is a user researcher with expertise in advising on issues related to public and patient
involvement at all stages of the research process, from pre-protocol planning to publications/dissemination.
She is a member of various national and local networks and user groups. Tony O’Hagan is an Emeritus
Professor of Bayesian Statistics who has worked with JB for many years on mapping these types of data
and will provide advice on key statistical aspects of the mapping.
3.2 Environment
The project will be led from the School of Health and Related Research (ScHARR) at the University of
Sheffield, but is very much collaboration with the University of York and Kings College London, Institute of
Psychiatry. ScHARR is a large multi-disciplinary School within the Faculty of Medicine at the University of
Sheffield with over 200 staff of social scientists, epidemiologists, statisticians, public health specialists and
health economists. It provides a stimulating and supportive environment in which to conduct applied and
methodological health services research. The health economics groups has developed a special expertise in
the development and testing of outcome measures, including preference-based measures. The Mental
Health Section provides the local clinical and academic support needed to conduct the study. ScHARR is




A previous proposal to develop a new preference-based measure in mental health was rejected by the
MRC Board on the grounds that they did not believe there was sufficient evidence of the need for such a
measure and they recommended pilot and feasibility work to establish this. Our proposal is partly aimed at
addressing these suggestions, but more specifically it aims to address two issues: 1) to examine whether or
not the low take-up of generic measures is justified and 2) to examine methods for overcoming the low
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use of generics by mapping relationships between widely used condition specific measure and generic
measures. Specific objectives are as follows:
l To establish the domains of quality of life that are important to people with mental health disorders
from the literature and interviews with users
l To examine the extent to which EQ-5D and SF-36 (12) cover these domains
l To examine the psychometric properties of the EQ-5D and SF-36 across a range of mental
health problems
l To estimate mapping functions between the measures commonly used in mental health trials and the
EQ-5D and SF-6D (a derivative of the SF-36) and make these publicly available on the internet.
3.3.2 Plan of investigation
To address the two main aims of the study there will be two parts to the plan of investigation. The first
part is concerned with testing the psychometric properties of the EQ-5D and SF-6D in mental health
populations. The second part will be the estimation of mapping functions between commonly used
measures in mental health and the generic measures (in those disorders where they seem to have
acceptable properties). Part 1 uses a combination of qualitative and quantitative methods including:
1) a review of the qualitative evidence on the domains of quality of life raised by mental health service
users; 2) qualitative interviews with a small number of users in order to examine the coverage and
relevance of the generic measures and those raised in the literature; 3) review of the literature on the
psychometric properties of these generic measures; and 4) a quantitative examination of the psychometric
properties of the measures using existing data sets.
Study design
Part 1: Testing the properties of two generic measures in mental health
This will adopt the standard criteria for assessing measures recommended by Fitzpatrick et al. (1999) and
adapted for preference-based measures by Brazier et al. (1999) that include feasibility, reliability, validity
(content validity, face validity and construct validity) and responsiveness.
Feasibility is a problem general to all instruments, but some are more prone to non-response and missing
data than others due to length, complexity and relevance to patients (McColl et al., 2000). This has
important implications for the power and validity of studies. Reliability over time is a desirable characteristic
in any measure but it is strictly encapsulated in responsiveness. An unreliable instrument will not be very
responsive. Internal reliability is an even less direct way at measuring the key property of responsiveness,
though it can provide useful evidence of item functioning across different populations in different settings.
Validity is the extent to which an instrument measures what it is intended to measure. In the absence of a
gold standard measure for quality of life, various indirect ways of establishing validity will be used in this
study including content and face validity, construct validity and concurrent or convergent validity (Streiner
and Norman, 1989; Bowling, 2002). Content and face validation are best tested using qualitative methods
based on interviews with the relevant population. Construct and current validation require data sets with
indicators or measures of severity that can be used to assess group differences and degree of association.
Responsiveness is the ability of an instrument to measure clinically significant changes in health. Responsiveness
is usually assessed statistically using measures such as the ‘effect size’, where the mean change in score is
divided by either the standard deviation at baseline or the standard deviation of the change. A common
assumption in the assessment of responsiveness is that for a given health change, the measure with the
largest effect size is the better measure (Katz et al., 1994). Where the objective is to minimise sample size
this makes sense and maximises the ability to detect differences in the context of performance assessment.
For economic evaluation this is less important, and instead it is simply a case of establishing that the
descriptive content is able to detect change of significance to users. Related to this is precision which is
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concerned with the ability of a measure to detect changes over the range experienced by patients being
assessed. This requires the items and levels of the domains to be well spread over the range of the measure.
These criteria are going to be assessed using evidence from a range of different sources: the literature,
interviews with users and a number of existing data sets. They will be applied to three broad groups of
people with mental health problems: 1) common mental health problems (e.g. mild to moderate
depression, anxiety, obsessive compulsive disorder and panic disorders); 2) severe and complex
non-psychotic disorders (e.g. personality disorder); 3) schizophrenia and other psychotic disorders. These
groups are not mutually exclusive, but are designed to help achieve a sample that covers the main groups
of users. It is anticipated that much of the existing evidence will be by specific mental health disorder.
1) Review of qualitative evidence on dimensions of quality of life important
to people with mental health disorders
Comprehensive systematic searches of the major relevant electronic bibliographic databases will be
undertaken: these will include MEDLINE, PreMEDLINE, CINAHL and EMBASE. The reference lists of relevant
identified articles and reviews will be searched for additional studies and authors and, where appropriate,
citation searching will be conducted using CINAHL and the Web of Science. The search strategies will
employ a combination of free-text and, where available, keyword searching. The terms to be used will
include terms related to quality of life and mental health disorders, and terms or filters designed to identify
qualitative research studies. The search strategies will be modified for different databases to take account
of the thesaurus and limitations of each. The searches will not be restricted by date or language.
References identified by the literature searches will be screened for relevance in three stages, first by title,
then by abstract, and finally by full text, excluding at each stage those which clearly do not satisfy the
inclusion and exclusion criteria (Meade & Richardson 1997). Those studies which meet the inclusion criteria
will then be appraised, and the data extracted, using a customised appraisal and data extraction form which
draws on the primary research appraisal tool proposed by Paterson et al (Paterson et al. 2001) and on
Sandelowski and Barroso’s guide for reading qualitative studies (Sandelowski & Barroso 2002). The purpose
of this appraisal is not to critique the quality of individual reports but to achieve an understanding of each
study on its own terms (Sandelowski, Docherty, & Emden 1997), thus enabling consideration of the ways in
which the methodology used has shaped understanding (Paterson et al. 2001). Studies will be excluded for
reasons of quality only if the researcher’s ‘political’ agenda is evident throughout, or if the depth and
breadth of the reported data is insufficient to suggest that the findings are trustworthy (Paterson et al.
2001). Data will be analysed and synthesised using meta-study techniques developed by Paterson et al.
(2001) facilitated by use of the Ritchie and Spencer’s Framework approach (Ritchie and Spencer,1994).
2) Qualitative interviews with mental health service users
The aims of the interviews are: 1) to explore the dimensions found from the qualitative literature and 2) to
explicitly examine whether users feel the generic measures cover the aspects of their quality of life affected
by their condition. There will be around 24 semi-structured interviews conducted across the three broad
categories of mental health disorders identified above. Sampling within each group will aim to achieve
maximum variation until saturation of themes in the qualitative analysis is achieved. To this end, people
will be recruited in a purposive manner from different settings, disorders and backgrounds. Sampling will
be purposive to ensure all the main types of disorders in each group are covered. The numbers are small,
but the aim is mainly to examine the extent to which the content of existing measures cover their
concerns, rather than provide a definitive study of quality life in these groups of users.
Participants will be recruited in Sheffield from a number of different settings, specifically primary care for
the common mental health problems, and the other two groups will be recruited from a combination of
community mental health teams and inpatient services. Professionals responsible for the care of the users
will be asked to approach them regarding their willingness to participate in the study and obtain their
consent to be seen by an interviewer. These details will be sent to the interviewer at the University of
Sheffield who will contact them to arrange the interview. Users in primary care will be identified by
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considering those referred to brief psychological interventions within GP practices or to the primary care
counselling services and by considering their medication. Secondary care users will be identified using the
Sheffield patient database (known as ‘Insight’) which records service utilisation, demographic details and,
in a number of services diagnoses and routinely collected assessment information.
Participants will be asked whether they are comfortable with the interview being recorded and transcribed
verbatim, if not notes will be taken. A topic guide will be used to ensure that a common set of questions
are asked about the person, including important background information, current activities, positive and
negative influences on quality of life. The topic guide will be agreed by a project team (including user
representation) based on the results of the qualitative review and the content of the EQ-5D and the SF-36.
Interviews will be conducted sensitively, starting with general questions about their day to day lives. By the
use of responsive questions the interviewer will probe those aspects of their quality of life identified and
why these aspects are important. The interviews will be analysed using the ‘framework’ approach that
helps to classify and progressively organise the data according to emergent themes (Ritchie and Lewis,
2003). The aim will be to identify a common set of dimensions across the groups and disorders. It will
examine aspects of QL identified by the review and the two generic measures.
The use of in depth interviews to obtain people’s views on what matters to their quality of life has become
a key component in the development of quality of life measures in this field (Bowling, 2002; FDA, 2006).
There is a growing body of literature on successful application of quantitative methods in various mental
health populations, including schizophrenia (Gee et al., 2003; Rose et al., 2008; Michalak et al., 2005).
3) Reviews of empirical studies using EQ-5D and SF-36 in mental health
Systematic searches of the main literature databases will be undertaken including MEDLINE, EMBASE, NHS
Economic Evaluation Database (EED) and HTA, OHE Health Economic Evaluations Database (HEED), Quality
of Life Database (QOLID), Cochrane Central Register of Controlled Trials, Science Citation Index (SCI),
Social Sciences Citation Index (SSCI), Cochrane Database of Systematic Reviews (CDSR). The search terms
will be based on those described for the qualitative review and various terms for SF-36, SF-12, SF-6D and
EQ-5D. All papers searched will be sifted by title and then by abstract. All empirical studies using one or
both of these measures in mental health populations will be included. Papers meeting the inclusion criteria
will be reviewed in detail in order to extract data on the following for each health state value reported:
disorder, severity of disorder, demographics of patients, measures, descriptive statistics for the values
reported (mean, SD, median, IQ etc.) and evidence on validity and responsiveness.
4) Psychometric testing of the two instruments on existing data sets
To undertake new surveys of patients across the 3 groups would be difficult, complex and expensive. It
would be hard to justify a new primary study, when there are a large and varied range of existing data
sets available to the applicants from past trials and other studies that have not been exploited to address
these methodological questions. The data sets currently available to the investigators have been listed in
the Table below in terms of the study, sample (including size), and different instruments used. The review
is expected to identify more data sets and access to these will be sought from the investigators.
The practicality of the instrument will be assessed in terms of the proportion of returned questionnaires
and the proportion of questionnaires completed. Reliability will be examined in those data sets where
there have been re-tests and evidence of no change in health status. Agreement will be examined in terms
of their intra class correlation coefficient and Bland-Altman plots. Construct validation will be tested
between groups with known differences defined using indicators of severity and mental health specific
instruments. Testing will be undertaken on the preference-based index scores of the EQ-5D and SF-6D and
also at the dimension levels. Statistical tests will include standard t-tests for the indices and K-W tests for
the dimension levels. Responsiveness of the instrument will be examined in data sets that have some
indicator of change. Changes in scores will be tested for statistical significance at the 5% level and the
clinical importance of any difference will be assessed using the standard response mean (mean change
over time divided by the standard deviation of the change).
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Part II: Estimation of mapping functions between mental health specific
measures and the generics
For those situations where the EQ-5D and/or SF-6D prove to be acceptable in terms of their psychometric
properties, then the next stage in the project will be to estimate mapping functions between those mental
health specific measures widely used in clinical studies onto the two generic measures. The PI recently
completed a review of mapping functions (Brazier et al., 2007) and will be drawing on the best practice
identified in that review.
Regression analysis will be used to estimate the relationship between the preference-based scores of these
two measures and the various mental health measures across different mental health disorders and
conditions. One set of models will use the dependent variables of the EQ-5D and SF-6D indices. The
explanatory variables will be the various mental health instruments entered into the models a variety of
ways including dimension scores with main effects, squared terms and interaction terms. Models will also
explore using item and item response variables. The inclusion of other covariates, including age and
gender, will also be examined.
More complex specifications will include random effects generalised least squares (to allow for clustering in
the data – usually around the individual), random effects (RE) tobit and censored least absolute deviations
(CLAD) models. The RE tobit model is an appropriate alternative for estimating models using censored data
(Sullivan and Ghushchyan, 2006) and as EQ-5D utility scores exhibit a ceiling effect, where a large
proportion of subjects rate themselves in full health with a utility score of 1. CLAD will also used since its
estimator does not depend upon assumptions of homoscedasticity and normality and hence produces
consistent estimates in the presence of heteroscedasticity and non-normality (see Powell, 1984, and
Sullivan and Ghushchyan, 2006). Another approach will be explored using EQ-5D and SF-6D dimensions as
the dependent variables. A multinomial logit model will be used to estimate the probability that a
respondent will choose a particular level for each dimension of each instrument (Gray et al. (2006)).
Subsequently predicted EQ-5D level responses for each dimension are generated using Monte Carlo
simulation methods and the corresponding preference-based index utility score for that health state is
calculated using the relevant value sets. Bayesian approaches to modelling the data will also be developed
drawing on work with modelling SF-6D using Gaussian approaches (Kharoubi et al., 2007) that proved
more flexible and better at predicting health state values.
Model performance will be mainly assessed in terms of their ability to predict EQ-5D/SF-6D index values in
independent data sets, including the difference between predicted and observed values at either the
aggregate health state level by calculating Mean Error (ME); or the individual level by calculating the Mean
Absolute Error (MAE) or the Root Mean Squared Error (RMSE). Mean error will be examined by severity of
health problem. The main purpose is to predict differences in values across sub-groups of patients, such as
between arms of a trial or over time. So models will be examined in terms of the size and direction of error
in their prediction of differences between sub-groups in independent data.
TABLE 1 Timetable of project (months)
Phase 1: Validation of measures
Preparatory work – liaising with SCT and GP, research governance and ethics 1–3
I. Literature reviews 1–6
II. Qualitative interviews 6–15
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4. Ethical and other implications
For the qualitative interviews it will be necessary to obtain informed consent. Researchers will only have
access to potential participants’ names after the clinical person responsible for their care has agreed and
given consent. The research team will not have access to NHS databases of patients and their diagnoses
(under Data Protection Act legislation). The interviewer will have experience with the client group, able to
minimise any possible anxiety or distress during the interview process. During the interviews there will be
an emphasis on gaining trust and building rapport. Interviews held in place of participant’s choosing with
someone present if they wish, positive feedback given at end of interview. User representatives (‘Experts
with experience’) will help with preparing written materials and verbal explanations. At each interview
researchers will check that the participant continues to give consent and understands that he or she can
withdraw at any time. Data will be kept in line with the Data Protection Act. Names and addresses will be
anonymised in the data base. Qualitative and quantative data will be reported in an anonymised form.
Some mental health service users are at risk of relapse, self-harm or suicide and occasionally risk of harm
to others. If such risks are revealed to researchers, the user’s clinician will be informed. This potential need
to break confidentiality will be clearly explained in the patient information sheet and consent form.
5. Public engagement
The proposed research has implications for the public in terms of its impact on policy decision-making
processes in the Department of Health, NICE and the NHS. Service users have been involved in the
development of this bid and will continue to be involved throughout the study. Users will also be on the
Advisory Group. A summary of the findings will be advertised through user organisations. The results will
be presented at a number of local workshops involving users up and down the country.
6. Exploitation and dissemination
We will offer to make presentations to NICE, Department of health and other interested public agencies
on the results of this work. The qualitative work will be of interest in its own right to mental health
services researchers and mental health professionals, so the results will be submitted to key national and
international conferences. The results will also be written up for publication in academic journals. A key
output of this part of the project will be a set of mapping functions programmed in standard software,
including spss and excel, for researchers around the world to use and downloadable from the web.
Dissemination will also be via user-focussed publications and through user networks.
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TABLE 2 Data sets for examining the psychometric properties of the EQ-5D and SF-6D and estimating
mapping functions
1) Common mental health problems Patient population (n) Instruments
Improving Access for Psychological Therapy in





McCabe et al. (1996) General population n = 1896 SF-36 (SF-6D)
GHQ-12
PONDER trial. Morrell et al. (2008) Mothers at 6 and 12 months
post-partum n = 2600 and 1700
SF-12, EPDS, CORE-OM
Mindfulness-based cognitive therapy to prevent
relapse in recurrent depression (Kuyken et al.,
submitted)
Depression (n = 123) EQ-5D, HRSD, BDI,
WHO-brief QoL
SSRIs and routine care with and without CBT in
adolescents with major depression (Goodyer et al.,
2007)
Depression (n = 208) HoNOS,CA, EQ-5D, MFQ,
CDRS-R, CGAS, CGI-I
RCT of counselling, CBT and usual GP care for
patients with depression.
Ward et al. (2000)
Depression (n = 197) EQ-5D, BDI, Brief symptom
inventory, modified social
adjustment scale
2) Severe and complex non-psychotic
RCT of brief CBT versus treatment as usual in
recurrent deliberate self-harm: the POPMACT





Patient attending a centre in the Netherlands
Soeteman et al. (2008)
Patients with personality disorder
n = 1708
EQ-5D
TMSECT: treatment of people with severe
depression with ECT or transcranial magnetic
simulation. Eranti et al. (2007); Knapp et al. (2008)
Patients referred for RCT with
severe depressive episodes




3) Schizophrenia and other psychotic problems
SCAP (Lilly). Mangalore et al. (2006) Schizophrenia n = 600 EQ-5D, SF-12
PANSS, MADRS, GAF, QLS,
AIMS
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Appendix 2 Chapter 2 appendices
Quantitative review search strategy
1. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or
shortform thirty six or short form thirtysix or short form thirty six).tw. (9816)
2. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw. (976)
3. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short
form twelve).tw. (1373)
4. (euroqol or euro qol or eq5d or eq 5d).tw. (1748)
5. exp Mental Disorders/ (748,722)
6. exp mood disorders/ or exp affective disorders, psychotic/ or exp bipolar disorder/ or exp depressive
disorder/ (88,818)
7. exp Schizophrenia/ (70,221)
8. exp self-injurious behavior/ or exp suicide/ (43,194)
9. exp personality disorders/ (26990)
10. exp Eating Disorders/ (17,636)
11. Stress Disorders, Post-Traumatic/ (14,172)
12. Gambling/ (2042)
13. exp Anxiety Disorders/ (50,236)
14. exp “sexual and gender disorders”/ or exp sexual dysfunctions, psychological/ or exp paraphilias/
(23,682)
15. exp Sleep Disorders/ (46,193)
16. ((mental or psychiatric) adj2 (disorder$ or condition$ or disease$)).tw. (39,628)
17. or/6–16 (350,409)
18. or/1–4 (13,357)
19. 17 and 18 (1155)
20. limit 19 to english language (1082)
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Schizophrenia review studies
TABLE 32 Schizophrenia review studies
Study details Population characteristics Properties measured




Inpatients and outpatients (numbers not reported)
n = 207 (141 males and 66 females)




Schizophrenia (classification not reported)
N = approx. 2949 (n = 2128 on olanzapine; n = 821 on
risperidone or haloperidol; small numbers on other
antipsychotics)




Non-affective psychosis diagnosis (criteria not specified).
Includes schizophrenia, schizoaffective disorder, bipolar
disorder and psychotic depression
Participants had to screen positive for psychotic symptoms
and in relative remission (≤ 4 on PANSS)
n = 77 (55 males, 22 females)
Mean age = 28.9 years (range 18–52 years)
50/77 had a diagnosis of non-affective psychosis






ICD-10: schizophrenia, schizotypal or delusional disorders
49.4% outpatient, 41.6% inpatient and 9.0% day clinic
n = 166 (97 males, 69 females)




ICD-10: schizophrenia, schizotypal or delusional disorders
51.7% outpatient, 38.5% inpatient and 9.8% day clinic
n = 166 (97 males, 69 females)





SCAN interview diagnosed schizophrenia (classification
scheme not specified)
‘Chronic high disability sample’ based on number of years
on medication, number of psychiatric inpatient days last
year and GAF score
n = 409 (245 males and 164 females)
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TABLE 32 Schizophrenia review studies (continued )




n = 2657 (1691 males, 966 females)
Not stated if inpatient or outpatient
n = 2128 on olanzapine; n = 417 on risperidone; n = 112
on haloperidol




N = 637 (n = 551 with schizophrenia; n = 86 with
schizophreniform disorder)
414 males, 223 females
Aged 18 to 40 years (no mean age reported)
Inpatient/outpatient status not reported
Convergent validity
van de Willige (2005)48
Netherlands
DSM-IV schizophrenia (described as chronic sample)
Auditory hallucinations for > 2 years after adequate
treatment
Use of at least two antipsychotic drugs
Inpatients and outpatients – numbers not reported
n = 76 (42 males, 34 females)





DSM-IV schizophrenia inpatients and outpatients
(numbers not reported)
n = 207 (141 males, 68 females)
Mean age = 37.3 (SD = 10.9) years (range 18–70 years)
Convergent validity
Bebbington (2009)67
UK, France and Germany
DSM-IV schizophrenia
n = 1208 (743 males, 465 females)
Aged 18 to 64 years (no mean age reported)







All outpatients measured by PANSS as out of acute
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TABLE 32 Schizophrenia review studies (continued )
Study details Population characteristics Properties measured





DSM-IV schizophrenia or schizoaffective disorder
n = 486 outpatients (317 males, 169 females)
n = 164 (42.3%) on typical antipsychotics; n = 198
(51.1%) on atypical antipsychotics Mean age = 54.7





n = 307 outpatients (253 males, 54 females)




n = 271/321 available for follow-up analysis (4 years)
Outpatients
220 males, 51 females
208 defined as being long-standing cases (duration of
illness between 3 and 30 years) and 63 defined as having
recent-onset illness (onset within the last 2 years)





ICD-10 schizophrenia. Untreated psychosis – participants
experiencing first episode
Inpatients and outpatients (mostly outpatients, numbers
not reported)
n = 117 (63 males, 54 females)





DSM-IV schizophrenia or schizoaffective disorder
N = 725 completed the trial (n = 615 schizophrenia;
n = 110 schizoaffective disorder)






Aged 18–65 years. No mean age or sex data reported
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TABLE 32 Schizophrenia review studies (continued )
Study details Population characteristics Properties measured
Milliken (2007)83
Canada
Schizophrenia spectrum disorder (classification not
specified)
Treatment: 6 months’ exposure to antipsychotic medication
Inpatients/outpatients status not reported
n = 15 (first patients with complete SF-36 data)






Treatment: long-acting injection and oral risperidone vs.
oral risperidone
n = 369 (275 males, 94 females)
Inpatients or outpatients (numbers not reported)
Mean age across four treatment groups ranged between





n = 56 (23 males, 33 females)
Inpatients – during hospitalisation. Usual treatment
including antipsychotic medication, psychosocial support
and a rehabilitation programme
Mean age = 39 (SD = 10.9) years (range 21–65 years)
Compared with an age-matched sample of Danish




DSM-IV schizophrenia treatment; olanzapine vs. ziprasidone
N = 548 (n = 277 assigned to olanzapine and n = 271
assigned to ziprasidone)
Mean age in olanzapine groups = 40.1 years and mean
age in ziprasidone group = 38.2 years
No data on sex reported





n = 91 (47 males, 44 females)
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TABLE 32 Schizophrenia review studies (continued )
Study details Population characteristics Properties measured
Pyne (2003)95
USA
DSM-IV schizophrenia or schizoaffective disorder
N = 134 (n = 85 schizophrenia; n = 49 schizoaffective
disorder)
Inpatients and outpatients (numbers not reported)
126 males, 8 females





36% outpatients and 64% inpatients
Phase: first episode (7%); readmission period for an acute
phase (31%); stabilised (62%)
N = 205 (139 males, 66 females)





Germany, Italy, Poland, Spain,
USA, Canada and UK
DSM-III-R schizophrenia, schizophreniform disorder and
schizoaffective disorder
Inpatients or outpatients (numbers not reported). BPRS
score ≤ 18
Treatment: olanzapine vs. haloperidol (RCT)
n = 1159 (787 olanzapine patients and 372 haloperidol
patients)





DSM-III-R schizophrenia or schizoaffective disorder
Outpatients n = 36 (25 males, 11 females)





N = 637 (n = 551 with schizophrenia; n = 86 with
schizophreniform disorder)
414 males, 223 females
Aged 18 to 40 years (no mean age reported)




DSM-IV schizophrenia or schizoaffective disorder.
‘Medically, psychologically and pharmacologically stable’
Mostly outpatients (numbers not reported)
n = 137 (91 males, 46 females); mean age = 57.9
(SD = 8.9) years
n = 77 ‘normal’ participants (30 males, 47 females);
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TABLE 32 Schizophrenia review studies (continued )
Study details Population characteristics Properties measured
Strakowski (2005)70
USA and Western Europe
DSM-IV schizophrenia, schizoaffective disorder and
schizophreniform disorder
First episode of psychosis-active psychotic symptoms (at
least two PANSS psychosis items ≥ 4 or one psychosis
item ≥ 5, and a CGI score ≥ 4)
Inpatient/outpatient status not reported
RCT olanzapine vs. haloperidol
n = 195 (156 males, 39 females)
Mean age = 24 (SD = 5) years (no range reported)
Normative data were taken from published tables
(Ware JE, Jr, Kosinski M, Keller SD. SF-36 Physical and
Mental Health Summary Scales: A User’s Manual. Boston,
MA: Health Assessment Lab; 1994) and were weighted to
the age and sex of the study sample
Known-group validity
Tunis (1999)71
USA, UK and Canada
DSM-III-R schizophrenia, schizophreniform disorder or
schizoaffective disorder. Experiencing ‘clinically
significant psychosis’
Inpatients and outpatients (numbers not reported)
n = 1155 (802 males, 353 females)
Mean age = 39.29 (SD = 11.32) years (range not reported)







Clinic and home-based settings
n = 78 (male/female not reported)
Mean age = 40 (SD = 11.9) years (range 18–64 years)
Inpatient/outpatient status not reported
Convergent validity
CGI, Clinical Global Impression; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders – Third Edition-Revised;
SCAN, Schedules for Clinical Assessment in Neuropsychiatry; SE, standard error.
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Bipolar disorder review studies
TABLE 33 Bipolar disorder review studies






Bipolar disorder – type I and II
N = 225
Type I: n = 150
Type II: n = 31
Missing data: n = 31
Mean age = 41.42 (SD = 11.49) years





Bipolar disorder – type not specified
n = 221/253 completed the study
Mean age = 41.5 (SD = 11.0) years







Bipolar disorder – type I, II, NOS, cyclothymia and
substance-induced
N = 40
Bipolar disorder type I: n = 14
Bipolar disorder type II: n = 14
Bipolar disorder NOS: n = 7
Cyclothymia: n = 3
Bipolar disorder, substance-induced: n = 2
Mean age = 43.84 (SD = 10.88) years





Bipolar disorder – type not specified
n = 86 (70 males and 14 females)
All completed








Bipolar disorder – type I and II
N = 105
n = 44 with bipolar I; n = 61 with bipolar II
Mean age = 47.33 (SD = 12.25) years
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TABLE 33 Bipolar disorder review studies (continued )
Study details Population characteristics
Properties
measured
Comorbid anxiety disorders: current; lifetime
At least one disorder: n = 34; n = 43
Panic disorder (with or without agoraphobia): n = 5; n = 11
Social phobia: n = 3; n = 7
OCD: n = 13; n = 14
GAD: n = 16; n = 17
Arbuckle (2009)98
USA
Bipolar disorder – type I and II
N = 225
Type I: n = 150
Type II: n = 31
Missing data: n = 31
Mean age = 41.42 (SD = 11.49) years







Bipolar disorder – type I, II and NOS
N = 44
Type I: n = 38
Type II: n = 5
NOS: n = 1
Mean age = 41.8 (SD = 9.8) years





Bipolar disorder – type I and II
n = 328
Mean age = 46.6 (SD = 10.1) years
Female/male not reported
Anxiety disorders: current; lifetime
Any: n = 126; n = 142
PTSD: n = 85; n = 93
Panic disorder: n = 56; n = 65
Panic disorder with agoraphobia: n = 37; n = 44
Panic disorder without agoraphobia: n = 19; n = 21
OCD: n = 28; n = 36
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TABLE 33 Bipolar disorder review studies (continued )





Bipolar disorder – type not specified
n = 43





Bipolar disorder – type not specified
n = 54 bipolar individuals (30/54 had SF-36 data as this
measure was introduced later in the study); mean age = 57.6
(SD = 9.2) years; 34 males and 20 females
n = 38 healthy comparison subjects; mean age = 64.7







Bipolar disorder – type I and II
n = 30 bipolar individuals; mean age = 60.2 (SD = 11.2) years;
16 males and 14 females
n = 31 healthy comparison subjects; mean age = 59.7







Bipolar disorder – type I, II and cyclothymic
N = 108
Type I: n = 80
Type II: n = 22
Cyclothymic: n = 6
Mean age = 48 (SD = 14) years







Bipolar disorder (not type II disorder)
n = 264 [69 recent-onset (within the last 2 years) cases and
195 long-standing cases (> 2 years)]
Mean age = 29.3 (SD = 0.5) years






Bipolar disorder – type not specified
n = 293
Mean age and age range not reported





Type I bipolar disorder
Euthymic patients: mean age = 42.5 (SD = 12.8) years; 14
males and 20 females
Depressed patients: mean age = 38.5 (SD = 9.9) years; 14
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TABLE 33 Bipolar disorder review studies (continued )





Bipolar disorder – type I and II
N = 142
n = 90 bipolar I: mean age = 41.04 (SD = 11.80) years; 43
males and 47 females
n = 52 bipolar II: mean age = 47.92 (SD = 10.76) years; 21





Bipolar disorder – type not specified
N = 139
Olanzapine group, n = 70; placebo group, n = 69
Mean age: olanzapine group = 40.2 (SD = 11.6) years;
placebo group = 38.7 (SD = 10.3) years
72 males and 67 females
Responsiveness
Shi (2004)112
Australia, Colombia, Greece, Mexico,
Portugal, Spain and USA
Type I bipolar disorder
N = 573/833 completed the trial
Baseline data for N = 573 who completed are provided:
Olanzapine group (n = 250): mean age = 42.0 (SD = 12.4)
years; 85 males and 165 females
Olanzapine–fluoxetine group (n = 58):
mean age = 38.4 (SD = 12.4) years;
18 males and 40 females
Placebo group (n = 265): mean age = 40.6 (SD = 12.5) years;





Type I bipolar disorder
n = 453 enrolled
Demographics provided for 298 patients included in analyses:
Olanzapine: mean age = 40.3 (SD = 12.8) years; 62 males and
99 females





Bipolar disorder: type I and II
N = 50
Type I: n = 45
Type II: n = 5
Mean age = 45.14 (SD = 12.9) years
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TABLE 33 Bipolar disorder review studies (continued )





Bipolar disorder: type I and II
N = 441
Type I: n = 336
Type II: n = 105
Mean age = 44 years





International – 15 countries
Type I bipolar disorder
n = 520/598 completed the SF-36
Reasons for non-completion were not reported
Mean age = 42 years (SD not reported)







Bipolar disorder – type not specified
n = 1999
Mean age = 40.6 (SD = 12.8) years






Bipolar disorder – type not specified
n = 86
All completed
Mean age = 47.3 (SD = 6.9) years (no range reported)





GAD, generalised anxiety disorder; NOS, not otherwise specified; OCD, obsessive compulsive disorder.
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Personality disorders review studies
TABLE 34 Personality disorders review studies






Patients ‘at risk’ of PDs: determined by completion of the SCID for
DSM-III-R for personality disorders
N = 93
n = 65 patients at high risk of one or more PDs;
mean age = 44.7 (SD = 15.3) years; 17 males and 48 females
n = 28 patients at low risk of PDs; mean age = 39.7 (SD = 15.1) years;






n = 91 (43 males and 48 females)











4705 males and 5936 females
Age data not reported





Sample taken from Australian National Survey of Mental Health and
Well-being (n = 10,641) – a nationally representative household survey
of mental disorders in adults
5214 males and 5427 females
Participants in survey mean age = 45 years
No mental disorder: n = 9902






DSM–IV-TR axis II cluster A personality disorders
n = 57
17 males and 40 females
Mean age = 29.4 (SD 8.2) years
PD diagnosis
‘Pure’ cluster A, n = 9; cluster A and B, n = 7; cluster A and C, n = 18;
cluster A, B and C, n = 23
Paranoid PD, n = 49; schizoid PD, n = 5; schizotypal PD, n = 4
Responsiveness
continued
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TABLE 34 Personality disorders review studies (continued )
Study details Population characteristics
Properties
measured
All received psychotherapeutic treatment in one of three settings:
Outpatient, n = 20
Day hospital, n = 19
Inpatient, n = 18
Bartak (2011b)125
Netherlands
DSM–IV-TR axis II cluster B personality disorders
n = 207
70 males and 147 females
Mean age = 31.3 (SD = 8.5) years
PD diagnosis
Pure cluster B, n = 84; cluster B and C, n = 93; cluster B and A, n = 7;
cluster A, B and C, n = 23
Borderline PD, n = 160; narcissistic PD, n = 47; histrionic PD, n = 26;
antisocial PD, n = 18
All received psychotherapeutic intervention in one of three settings:
Outpatient, n = 46
Day hospital, n = 81




DSM–IV-TR axis II cluster C personality disorders
n = 371
110 males and 261 females
Mean age = 33.5 (SD = 9.5) years
PD diagnosis
Pure cluster C, n = 247; cluster C and B, n = 88; cluster C and A,
n = 15; cluster C, B and A, n = 21
Avoidant PD, n = 235; obsessive-compulsive PD, n = 183; dependent
PD, n = 84
All received one of five modalities of psychotherapeutic interventions:
Long outpatient, n = 68
Short day hospital, n = 77
Long day hospital, n = 74
Short inpatient, n = 59;




Complex personality problems or personality disorders
n = 1651
541 males and 1110 females
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TABLE 34 Personality disorders review studies (continued )






605 males and 1103 females







5 males and 43 females
Mean age of completers was 31 (SD = 8.55) years
Responsiveness
DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition-Text Revision; PD, personality disorder;
SCID, Structured Clinical Interview for DSM Disorders.
DOI: 10.3310/hta18340 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 34
147
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Brazier et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
Anxiety and depression review studies
TABLE 35 Anxiety and depression review studies
Study details Population characteristics
Properties
measured
Validity and responsiveness – EQ-5D and SF-6D
Aydemir (2009)129
Turkey
74 patients, aged 18–65 years, diagnosed major depressive episode
according to DSM-IV criteria
Exclusions: other psychiatric disorder, comorbid condition








Patients with minor or mild-major depression in primary care
Exclusions: currently receiving antidepressants or psychological therapy
n = 44 usual care no antidepressants; mean age = 48 years; 73% female




n = 513 patients in primary care, with clinically diagnosed episode of
depression requiring pharmacological treatment
Mean age = 49.2 years, 72.9% female









293 outpatients (aged 18–85 years) fulfilling DSM-IV criteria for severe MDD,
without suicidal tendencies
Exclusions: history mania, bipolar, schizophrenia or psychotic disorder,
evidence of obsessive compulsive disorder, eating disorder, mental
retardation, pervasive development disorder
n = 126 assigned to escitalopram; mean age = 48.4 years; 75.4% female









389 patients with anxiety disorder from 46 GP practices
23 practices allocated to intervention (training) group (n = 201), and 23 to
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TABLE 35 Anxiety and depression review studies (continued )





Patients aged 18–65 years with a diagnosis of a major depressive disorder,







114 patients with depression participating in RCT on collaborative care
(MDD according to SCID)








374 non-depressed patients with GAD treated with pregabalin,
venlafaxine-XR or placebo






623 women in a RCT of postnatal support. 1046 declined. 312 allocated to
control group receiving usual care. 311 offered 10 visits by a community
postnatal support worker. 493 had complete data





Of 388 patients with a new episode of depression referred to the study,
67.3% female, mean age 42.5 years




395 primary care patients screened positive for depression using PHQ-9
360 completed 6-month follow-up, 335 completed 12 months





Patients (aged ≥ 18 years) with clinical depression enrolled prior to
commencing antidepressant treatment
Of 3468 at baseline, 343 had no follow-up data; 271 had data at 3 months
only; 2854 had data at 3 and 6 months





297 patients with GAD; 72% female, mean age 47.6 years
HAM-A score: ≤ 9 = asymptomatic; 10–15 =mild; 16–24 =moderate;







Population survey, aged ≥ 30 years






Outpatient population consulting at GP for new episode of MDD according
to DSM-IV
Aged ≥ 18 years, not treated with any antidepressants prior to inclusion
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TABLE 35 Anxiety and depression review studies (continued )





Subjects attending GP at 56 centres in Sweden
N = 447; baseline data on n = 394
Mean age = 47 years, 67% female
Aged ≥ 18 years with a diagnosis of depression (according to centres‘










Alberta Mental Health Survey, stratified random sample
Sample size n = 5410 (77% return), n = 5383 successful data





N = 87,797 veterans, n = 58,442 with depression
Identified from VA depression registry and VA outpatients
Mean age = 60 years, 10% female
Known-group
validity
GAD, generalised anxiety disorder; GP, general practitioner; HAM-A, Hamilton Anxiety Rating Scale; MDD, major depressive
disorder; SCID, Structured Clinical Interview for DSM Disorders; VA, Veterans Administration.
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Appendix 3 Chapter 4 appendices
Preliminary analysis




HADS-T 0.8184* 0.7533* 1
EQ-5D –0.3606* –0.2839* –0.4089*
Mobility 0.0814 0.0224 0.0673
Self-care 0.1856* 0.1245 0.1988*
Usual activities 0.2815* 0.1727* 0.3011*
Pain/discomfort 0.0354 0.0897 0.0640
Anxiety/depression 0.4033* 0.3943* 0.5031*
SF-6D –0.5346* –0.3368* –0.5618*
* Significant at 1% level or less.
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HADS-T 0.8927* 0.8387* 1
EQ-5D –0.4533* –0.3947* –0.4858*
Mobility 0.1148 0.0073 0.0785
Self-care 0.1623* 0.1098 0.1609*
Usual activities 0.4052* 0.2601* 0.3861*
Pain/discomfort 0.2079* 0.1571* 0.2115*
Anxiety/depression 0.4524* 0.4363* 0.5045*
* Significant at 1% level or less.
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TABLE 38 Correlation analysis: SF-6D, PHQ-9, GAD-7 and CORE-OM totals/dimensions (IAPT)
PHQ-9 GAD-7 CORE T CORE W CORE F CORE S CORE R
SF-6D –0.6174* –0.5272* –0.6209* –0.5618* –0.5273* –0.6480* –0.3457*
Physical functioning 0.3877* 0.2806* 0.3449* 0.3069* 0.2902* 0.3895* 0.1449*
Role limitation 0.4632* 0.4049* 0.4755* 0.4359* 0.4340* 0.4718* 0.2464*
Social functioning 0.5032* 0.4316* 0.5392* 0.4806* 0.4802* 0.5466* 0.2920*
Pain 0.2572* 0.2224* 0.2810* 0.1958* 0.1856* 0.3505* 0.1650*
Mental health 0.6846* 0.6453* 0.6888* 0.6638* 0.6121* 0.6681* 0.4305*
Vitality 0.5233* 0.3600* 0.4721* 0.4942* 0.4352* 0.4715* 0.2370*
F, function; R, risk; S, symptoms; T, total; W, well-being.
* Significant at 1% level or less.
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TABLE 39 Correlation analysis: SF-6D and PHQ-9 items (IAPT)
PHQ1 PHQ2 PHQ3 PHQ4 PHQ5 PHQ6 PHQ7 PHQ8 PHQ9 PHQ10
PHQ1 1
PHQ2 0.7727* 1
PHQ3 0.6195* 0.5720* 1
PHQ4 0.6216* 0.5350* 0.6095* 1
PHQ5 0.5273* 0.5154* 0.5107* 0.4963* 1
PHQ6 0.5744* 0.6569* 0.4709* 0.4387* 0.4913* 1
PHQ7 0.6263* 0.5921* 0.5752* 0.5471* 0.5592* 0.5843* 1
PHQ8 0.5198* 0.4736* 0.4393* 0.3757* 0.4238* 0.4747* 0.5777* 1
PHQ9 0.4654* 0.5022* 0.3294* 0.3445* 0.3805* 0.5151* 0.4080* 0.3743* 1
PHQ10 0.6120* 0.5780* 0.4561* 0.5428* 0.4621* 0.5147* 0.5449* 0.5053* 0.4250* 1
SF-6D –0.5827* –0.4971* –0.4486* –0.5657* –0.4019* –0.4022* –0.5287* –0.4145* –0.3434* –0.5949*
Physical functioning 0.4132* 0.2870* 0.3086* 0.4360* 0.2253* 0.1665* 0.3571* 0.2455* 0.1927* 0.3900*
Role limitation 0.4217* 0.3779* 0.3611* 0.3925* 0.3180* 0.3514* 0.4330* 0.3289* 0.2231* 0.5140*
Social functioning 0.5057* 0.3740* 0.2998* 0.4286* 0.3143* 0.3380* 0.4442* 0.3950* 0.2848* 0.5814*
Pain 0.2217* 0.1898* 0.2041* 0.2850* 0.1763* 0.1055 0.2170* 0.1849* 0.1309* 0.2414*
Mental health 0.6128* 0.6311* 0.4635* 0.4903* 0.4706* 0.5574* 0.5503* 0.4414* 0.4321* 0.6183*
Vitality 0.5195* 0.3893* 0.4154* 0.6311* 0.3495* 0.3477* 0.4288* 0.2765* 0.2366* 0.5247*





































TABLE 40 Correlation analysis: SF-6D and GAD-7 items (IAPT)
GAD1 GAD2 GAD3 GAD4 GAD5 GAD6 GAD7 GAD8
GAD1 1
GAD2 0.7353* 1
GAD3 0.7170* 0.8924* 1
GAD4 0.6338* 0.6554* 0.6784* 1
GAD5 0.5638* 0.5204* 0.5443* 0.6517* 1
GAD6 0.5176* 0.4775* 0.4980* 0.5327* 0.4873* 1
GAD7 0.5729* 0.5951* 0.5786* 0.4976* 0.4534* 0.4431* 1
GAD8 0.5833* 0.5461* 0.5293* 0.5274* 0.4308* 0.4455* 0.5061* 1
SF-6D –0.4896* –0.4593* –0.4362* –0.4403* –0.3659* –0.3630* –0.3787* –0.5143*
Physical functioning 0.2864* 0.2453* 0.2170* 0.2391* 0.2227* 0.1513* 0.1703* 0.2678*
Role limitation 0.4116* 0.3680* 0.3468* 0.3590* 0.2399* 0.2916* 0.2712* 0.4600*
Social functioning 0.4343* 0.3993* 0.3583* 0.3729* 0.2961* 0.2705* 0.3114* 0.4964*
Pain 0.1862* 0.1532* 0.1531* 0.1860* 0.1768* 0.1513* 0.1751* 0.2070*
Mental health 0.6001* 0.6056* 0.5763* 0.5186* 0.4263* 0.4802* 0.4759* 0.5831*
Vitality 0.3216* 0.3567* 0.2956* 0.3231* 0.2168* 0.2579* 0.2415* 0.4037*



















































































































































































































































































































































































































































































TABLE 41 Correlation analysis: CORE-OM items (IAPT)
CORE1 CORE2 CORE3 CORE4 CORE5 CORE6 CORE7 CORE8
CORE1 1
CORE2 0.6054* 1
CORE3 0.3192* 0.1954* 1
CORE4 0.5982* 0.5103* 0.3145* 1
CORE5 0.5303* 0.5319* 0.0666 0.4527* 1
CORE6 0.1920* 0.0852 0.1403* 0.1174 0.1345* 1
CORE7 0.4937* 0.4551* 0.2019* 0.5607* 0.4099* 0.0998 1
CORE8 0.1621* 0.2598* 0.0161 0.1760* 0.2996* 0.1097 0.1276 1
CORE9 0.4893* 0.3362* 0.1803* 0.4222* 0.2707* 0.2263* 0.3508* 0.1305*
CORE10 0.5537* 0.5119* 0.1897* 0.4353** 0.4222* 0.0992 0.4418* 0.1568*
CORE11 0.5948* 0.6685* 0.1763* 0.4839* 0.5250* 0.1087 0.4470* 0.3079*
CORE12 0.5249* 0.4398* 0.2860* 0.6151* 0.4029* 0.1490* 0.5021* 0.1118
CORE13 0.5332* 0.4939* 0.1809* 0.4346* 0.3533* 0.1646* 0.3869* 0.2290*
CORE14 0.5604* 0.4991* 0.1677* 0.4640* 0.4691* 0.1429* 0.4156* 0.1543*
CORE15 0.5332* 0.6971* 0.1321* 0.4285* 0.4502* 0.1307* 0.3849* 0.2461*
CORE16 0.4916* 0.3521* 0.1592* 0.3419* 0.2782* 0.2315* 0.3052* 0.1226
CORE17 0.7112* 0.6587* 0.2336* 0.5686* 0.5387* 0.1797* 0.4985* 0.2089*
CORE18 0.4190* 0.4509* 0.1025 0.3281* 0.3775* 0.1509* 0.2716* 0.2870*
CORE19 0.3661* 0.2019* 0.2774* 0.3364* 0.2021* 0.1666* 0.2921* 0.0737
CORE20 0.6075* 0.6192* 0.1524* 0.5420* 0.5185* 0.1227 0.4398* 0.2774*
CORE21 0.5095* 0.4400* 0.2097* 0.5070* 0.4480* 0.1446* 0.4958* 0.1915*
CORE22 0.2474* 0.1798* 0.1070 0.1338* 0.1070 0.4875* 0.2205* 0.1466*
CORE23 0.7157* 0.5894* 0.2667* 0.6455* 0.5163* 0.2399* 0.4882* 0.2157*
CORE24 0.5592* 0.3784* 0.2396* 0.4778* 0.3597* 0.2123* 0.3654* 0.1289
CORE25 0.4759* 0.3578* 0.2879* 0.3862* 0.3009* 0.2256* 0.3050* 0.0873
CORE26 0.6172* 0.4567* 0.4082* 0.4330* 0.3567* 0.1801* 0.3872* 0.1371*
CORE27 0.7316* 0.6392* 0.2359* 0.6233* 0.5605* 0.1534* 0.5210* 0.1938*
CORE28 0.5361* 0.4703* 0.1980* 0.4329* 0.3139* 0.1251 0.3782* 0.1960*
CORE29 0.4510* 0.4613* 0.1714* 0.4332* 0.3323* 0.2055* 0.3356* 0.2245*
CORE30 0.5152* 0.4039* 0.2464* 0.4320* 0.2956* 0.1536* 0.3212* –0.004
CORE31 0.3829* 0.3451* 0.1535* 0.4554* 0.3910* 0.0078 0.4745* 0.0478
CORE32 0.4529* 0.3071* 0.2565* 0.4918* 0.3267* 0.1027 0.4432* 0.0737
CORE33 0.4561* 0.3431* 0.2227* 0.3012* 0.2879* 0.2064* 0.2673* 0.0935
CORE34 0.3507* 0.2773* 0.1902* 0.2776* 0.2213* 0.2714* 0.2562* 0.1728*
* Significant at 1% level or less.
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0.4499* 0.4528* 0.4886* 1
0.4128* 0.4123* 0.4516* 0.3438* 1
0.4076* 0.3633* 0.3851* 0.4373* 0.4152* 1
0.3691* 0.4161* 0.6286* 0.4143* 0.4886* 0.4988* 1
0.7115* 0.3555* 0.3490* 0.3750* 0.4109* 0.3974* 0.4044* 1
0.4514* 0.5128* 0.6561* 0.5171* 0.5091* 0.5570* 0.6271* 0.4262* 1
0.2043* 0.3534* 0.4228* 0.2891* 0.3204* 0.3368* 0.4184* 0.2603* 0.4269*
0.2051* 0.2340* 0.2107* 0.3378* 0.1548* 0.1610* 0.2161* 0.1609* 0.2307*
0.3367* 0.4701* 0.6136* 0.4278* 0.5368* 0.4915* 0.5741* 0.3674* 0.6487*
0.3138* 0.4072* 0.5927* 0.5365* 0.3326* 0.3366* 0.3828* 0.2659* 0.4967*
0.2537* 0.2144* 0.1493* 0.1613* 0.2077* 0.1682* 0.1925* 0.2778* 0.2135*
0.5195* 0.5655* 0.5884* 0.5733* 0.5834* 0.5616* 0.5511* 0.4844* 0.7383*
0.7602* 0.4114* 0.3978* 0.4602* 0.4920* 0.4477* 0.3571* 0.6761* 0.5200*
0.3467* 0.4447* 0.3383* 0.3320* 0.3179* 0.3347* 0.3018* 0.3553* 0.4691*
0.4371* 0.5103* 0.4523* 0.4631* 0.3780* 0.3929* 0.4074* 0.4343* 0.5158*
0.4446* 0.5301* 0.5766* 0.5500* 0.5243* 0.6579* 0.5124* 0.4488* 0.7090*
0.4034* 0.4078* 0.4527* 0.3925* 0.6349* 0.4522* 0.5115* 0.4079* 0.5132*
0.2840* 0.4438* 0.4228* 0.4387* 0.3616* 0.3949* 0.3503* 0.2862* 0.4744*
0.4231* 0.4622* 0.3969* 0.3727* 0.3703* 0.4140* 0.3381* 0.3975* 0.5102*
0.2798* 0.3379* 0.3698* 0.4860* 0.2085* 0.2666* 0.2745* 0.2166* 0.3921*
0.3793* 0.2989* 0.3850* 0.5403* 0.2774* 0.4085* 0.2760* 0.3146* 0.3988*
0.3039* 0.3761* 0.3214* 0.2884* 0.3080* 0.3131* 0.3600* 0.3435* 0.4075*
0.6004* 0.3117* 0.3050* 0.2971* 0.3607* 0.2902* 0.3374* 0.5932* 0.3513*
DOI: 10.3310/hta18340 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 34
157
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Brazier et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TABLE 41 Correlation analysis: CORE-OM items (IAPT) (continued )
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CORE18 CORE19 CORE20 CORE21 CORE22 CORE23 CORE24 CORE25
CORE18 1
CORE19 0.2199* 1
CORE20 0.4430* 0.1711* 1
CORE21 0.2861* 0.3249* 0.4708* 1
CORE22 0.1612* 0.1701* 0.2236* 0.1565* 1
CORE23 0.4538* 0.2942* 0.6327* 0.4855* 0.2794* 1
CORE24 0.3092* 0.2144* 0.4206* 0.3990* 0.2826* 0.6498* 1
CORE25 0.2837* 0.1604* 0.3757* 0.2912* 0.2675* 0.4866* 0.4177* 1
CORE26 0.3598* 0.2343* 0.4709* 0.3833* 0.2485* 0.5559* 0.4648* 0.5708*
CORE27 0.4827* 0.2526* 0.6466* 0.4965* 0.2058* 0.7647* 0.5310* 0.4741*
CORE28 0.3887* 0.2122* 0.5046* 0.3764* 0.2245* 0.5487* 0.4436* 0.3229*
CORE29 0.3415* 0.1607* 0.4521* 0.3464* 0.3448* 0.4980* 0.3640* 0.4985*
CORE30 0.2484* 0.1294 0.4448* 0.3391* 0.2287* 0.5400* 0.4832* 0.4852*
CORE31 0.1962* 0.2624* 0.3098* 0.3527* 0.0298 0.3844* 0.3130* 0.2648*
CORE32 0.2190* 0.3737* 0.3640* 0.4741* 0.2116* 0.4800* 0.4221* 0.2712*
CORE33 0.2070* 0.1621* 0.3005* 0.2844* 0.2970* 0.3942* 0.3920* 0.6118*
CORE34 0.2296* 0.1444* 0.3386* 0.2798* 0.3467* 0.4478* 0.5295* 0.2902*
* Significant at 1% level or less.




0.4513* 0.5511* 0.4015* 1
0.5270* 0.5196* 0.4411* 0.4524* 1
0.2498* 0.4380* 0.1864* 0.2921* 0.2563* 1
0.4006* 0.4900* 0.2740* 0.3437* 0.3648* 0.4227* 1
0.5283* 0.3898* 0.3766* 0.4000* 0.4115* 0.2139* 0.2116* 1
0.3464* 0.3301* 0.3848* 0.2802* 0.3269* 0.0746 0.2348* 0.3134* 1
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TABLE 42 Correlation analysis: SF-6D and CORE-OM items (IAPT)
CORE1 CORE2 CORE3 CORE4 CORE5 CORE6 CORE7 CORE8
SF-6D –0.4949* –0.4812* –0.1438* –0.5205* –0.4724* –0.1390* –0.4257* –0.5498*
sfphysical 0.2498* 0.2379* 0.1178 0.3253* 0.3470* 0.0118 0.2812* 0.4231*
sfrole 0.4244* 0.4045* 0.1359* 0.3957* 0.3272* 0.0828 0.3287* 0.2186*
sfsocial 0.4453* 0.4538* 0.1161 0.4682* 0.3959* 0.0631 0.4125* 0.3085*
sfpain 0.1690* 0.1571* 0.003 0.2271* 0.2085* 0.1411* 0.1376* 0.6958*
sfmental 0.5891* 0.5936* 0.1700* 0.5450* 0.4639* 0.1418* 0.5074* 0.2303*
sfvital 0.3894* 0.3326* 0.1069 0.4663* 0.4933* 0.1046 0.3710* 0.2796*
CORE18 CORE19 CORE20 CORE21 CORE22 CORE23 CORE24 CORE25
SF-6D –0.4254* –0.2323* –0.4989* –0.4330* –0.0853 –0.4989* –0.3533* –0.2833*
sfphysical 0.2701* 0.1730* 0.2725* 0.2805* –0.0106 0.2805* 0.1795* 0.064
sfrole 0.2751* 0.1422* 0.4092* 0.3557* 0.1075 0.3643* 0.2077* 0.2276*
sfsocial 0.2517* 0.2426* 0.4611* 0.4438* 0.1154 0.4446* 0.2849* 0.2387*
sfpain 0.2730* 0.056 0.2514* 0.1943* 0.0647 0.1922* 0.1523* 0.095
sfmental 0.4099* 0.2773* 0.5405* 0.4124* 0.1239 0.6109* 0.4238* 0.3708*
sfvital 0.3413* 0.2037* 0.3761* 0.4145* 0.0172 0.3931* 0.2549* 0.1981*
sfmental, mental health; sfpain, pain; sfphysical, physical functioning; sfrole, role limitation; sfsocial, social functioning;
sfvital, vitality.
* Significant at 1% level or less.
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CORE9 CORE10 CORE11 CORE12 CORE13 CORE14 CORE15 CORE16 CORE17
–0.3102* –0.4313* –0.5809* –0.4618* –0.3789* –0.4018* –0.4148* –0.3247* –0.5203*
0.1475* 0.2781* 0.3913* 0.2831* 0.2354* 0.1919* 0.2532* 0.1463* 0.2541*
0.2227* 0.3744* 0.4677* 0.3548* 0.2843* 0.2662* 0.3109* 0.1955* 0.4290*
0.2795* 0.4187* 0.5628* 0.3930* 0.2944* 0.3117* 0.3864* 0.2867* 0.4674*
0.1444* 0.1478* 0.2564* 0.1776* 0.2264* 0.1649* 0.1708* 0.1661* 0.1943*
0.3959* 0.4927* 0.5679* 0.4947* 0.4198* 0.4767* 0.4952* 0.3662* 0.6194*
0.2040* 0.3452* 0.3980* 0.4126* 0.2539* 0.3345* 0.3005* 0.1929* 0.3986*
CORE26 CORE27 CORE28 CORE29 CORE30 CORE31 CORE32 CORE33 CORE34
–0.3975* –0.5234* –0.3771* –0.3498* –0.2722* –0.3244* –0.3067* –0.2838* –0.2307*
0.1921* 0.2826* 0.2313* 0.1525* 0.0719 0.2192* 0.1621* 0.1241 0.0892
0.3269* 0.4033* 0.2373* 0.3001* 0.2738* 0.2439* 0.2452* 0.2085* 0.1972*
0.3572* 0.4839* 0.2878* 0.2446* 0.3186* 0.2745* 0.3084* 0.2892* 0.2074*
0.1422* 0.1695* 0.2319* 0.1910* 0.0308 0.0535 0.0741 0.102 0.1539*
0.4538* 0.6532* 0.4117* 0.4456* 0.4026* 0.4301* 0.4039* 0.3317* 0.2755*
0.2825* 0.4413* 0.2596* 0.2795* 0.1908* 0.3407* 0.3221* 0.1961* 0.1288
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TABLE 43 Correlation analysis: SF-6D and GHQ-12 score and items (EMPIRIC)
GHQ-12
total GHQ1 GHQ2 GHQ3 GHQ4 GHQ5 GHQ6 GHQ7 GHQ8 GHQ9 GHQ10 GHQ11 GHQ12
GHQ-12 total 1
GHQ1 0.6177* 1
GHQ2 0.7001* 0.4239* 1
GHQ3 0.5000* 0.3230* 0.2150* 1
GHQ4 0.5874* 0.3291* 0.3321* 0.4482* 1
GHQ5 0.7653* 0.4983* 0.5495* 0.2417* 0.4080* 1
GHQ6 0.7475* 0.4171* 0.4690* 0.3255* 0.3501* 0.6113* 1
GHQ7 0.7471* 0.5352* 0.4896* 0.4609* 0.4094* 0.5532* 0.4693* 1
GHQ8 0.6686* 0.3629* 0.3703* 0.2572* 0.4096* 0.5083* 0.5726* 0.4691* 1
GHQ9 0.8489* 0.4695* 0.5855* 0.3071* 0.4963* 0.6727* 0.6233* 0.6164* 0.5682* 1
GHQ10 0.7879* 0.3924* 0.4899* 0.2733* 0.3990* 0.5154* 0.5888* 0.4873* 0.5366* 0.6539* 1
GHQ11 0.7334* 0.3683* 0.4224* 0.3824* 0.4066* 0.4435* 0.5046* 0.4559* 0.5183* 0.5291* 0.7034* 1
GHQ12 0.7648* 0.3834* 0.4755* 0.4534* 0.4813* 0.5136* 0.5093* 0.5831* 0.5271* 0.6484* 0.5317* 0.5340* 1
SF-6D –0.2593* –0.2038* –0.1396 –0.2456* –0.1999* –0.2712* –0.1738 –0.1707 –0.2146* –0.2783* –0.0888 –0.1197 –0.2386*
Physical functioning 0.0875 0.081 0.0163 0.2052* 0.0951 0.0878 0.0734 0.0564 0.0562 0.0388 0.0222 0.0472 0.0419
Role limitation 0.2433* 0.2016* 0.1524 0.2572* 0.1990* 0.2325* 0.2011* 0.1316 0.1883* 0.2121* 0.0972 0.1625 0.1915*
Social functioning 0.1777* 0.1689 0.1001 0.127 0.147 0.2144* 0.0691 0.1396 0.1246 0.2174* 0.0567 0.068 0.1573
Pain 0.1063 0.1169 0.0923 0.1758 0.1262 0.1686 0.0599 0.0657 0.1217 0.0947 –0.0466 0.0096 0.1143
Mental health 0.1829* 0.1476 0.1251 0.0398 0.1828* 0.166 0.0627 0.0892 0.1668 0.2612* 0.037 0.0764 0.2076*
Vitality 0.2970* 0.2850* 0.1601 0.1900* 0.1571 0.2212* 0.2030* 0.2198* 0.2198* 0.2427* 0.2261* 0.2150* 0.2247*
GHQ: 1, concentrate; 2, problem sleeping; 3, felt useful; 4, felt capable of decision-making; 5, strain; 6, could not overcome difficulties; 7, enjoyed normal activities; 8, able to face problems;
9, unhappy/depressed; 10, lost confidence; 11, felt worthless; 12, happy all things considered.






































TABLE 44 Summary performance statistics: best-fitting OLS, Tobit and response-level mapping models – EQ-5D and
HADS (AHEAD)
Independent variables Observed EQ-5D
Predicted EQ-5D
OLS Tobit RLM
HADS-T + age HADS-T + age HADS-T
Mean 0.6118 0.6118 0.6058 0.7480
SD 0.262 0.115 0.110 0.023
Minimum –0.126 0.333 0.327 0.697
Maximum 1 0.917 0.866 0.852
R2 0.193 – –
Pseudo-R2 – 0.932 –
RMSE 0.188 0.189 0.201
BIC 1 33 –
EQ-5D range n EQ-5D OLS RMSE Tobit RMSE RLM RMSE
< 0.3 59 0.1816 0.5495 0.368 0.5453 0.364 0.7372 0.556
0.3–0.599 34 0.4186 0.5254 0.124 0.5219 0.122 0.7349 0.316
0.6–0.699 52 0.6709 0.6002 0.099 0.5959 0.099 0.7483 0.077
0.7–0.799 34 0.7402 0.655 0.105 0.6474 0.103 0.7564 0.025
0.8–1 107 0.8408 0.6655 0.179 0.6575 0.184 0.7554 0.086
HADS-D n EQ-5D OLS RMSE Tobit RMSE RLM RMSE
Non-case/possible≤ 10 147 0.6931 0.6816 0.160 0.6731 0.161 0.7621 0.147
Probable case > 10 139 0.5258 0.5379 0.218 0.5347 0.218 0.7332 0.259
RLM, response-level mapping.
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TABLE 45 Summary performance statistics: best-fitting OLS, Tobit and response-level mapping models – EQ-5D and
HADS (POPMACT)
Independent variables Observed EQ-5D
Predicted EQ-5D
OLS Tobit RLM
HADS-D and -A HADS-D and -A HADS-D and -A
Mean 0.5039 0.5039 0.5008 0.5480
SD 0.319 0.157 0.156 0.129
Minimum –0.594 0.149 0.129 0.261
Maximum 1 1.016 0.915 0.795
R2 0.242 –
Pseudo-R2 – 0.405 –
RMSE 0.227 0.227 0.230
BIC 150 230 –
EQ-5D range n EQ-5D OLS RMSE Tobit RMSE RLM RMSE
≤ 0 33 –0.1245 0.4021 0.527 0.3977 0.522 0.4660 0.591
0.001–0.199 60 0.1295 0.4423 0.313 0.4395 0.310 0.4975 0.368
0.2–0.299 64 0.263 0.4324 0.178 0.4296 0.178 0.4879 0.225
0.3–0.599 90 0.4242 0.4449 0.103 0.4421 0.106 0.4973 0.111
0.6–0.699 57 0.6699 0.532 0.159 0.5319 0.157 0.5797 0.116
0.7–0.799 45 0.7374 0.5421 0.203 0.5395 0.202 0.5813 0.157
0.8–0.899 103 0.8382 0.586 0.259 0.5829 0.257 0.6172 0.221
0.9–1 23 1 0.7295 0.272 0.7157 0.284 0.7100 0.290
HADS-D n EQ-5D OLS RMSE Tobit RMSE RLM RMSE
Non-case/possible≤ 10 210 0.622 0.6375 0.220 0.6341 0.220 0.6564 0.218
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TABLE 46 Summary performance statistics: Tobit models (IAPT)
Independent variables Observed SF-6D
Predicted SF-6D
PHQ-9 GAD-7 CORE items
Mean 0.6193 0.6191 0.6191 0.6191
SD 0.126 0.091 0.078 0.107
Minimum 0.301 0.425 0.482 0.367
Maximum 0.929 0.857 0.832 0.888
RMSE 0.070 0.079 0.054
SF-6D range SF-6D PHQ-9 RMSE GAD-7 RMSE CORE items RMSE
< 0.4 0.3610 0.492 0.131 0.5313 0.170 0.4582 0.101
0.4–0.499 0.4690 0.5589 0.093 0.5695 0.101 0.497 0.046
0.5–0.599 0.5587 0.5691 0.053 0.5869 0.056 0.5682 0.047
0.6–0.699 0.6386 0.6354 0.051 0.625 0.054 0.6442 0.047
0.7–0.799 0.7444 0.687 0.066 0.6745 0.079 0.7081 0.053
0.8–1 0.8552 0.7377 0.119 0.7098 0.145 0.7789 0.080
PHQ-9 cut-offs SF-6D PHQ-9 RMSE GAD-7 RMSE CORE items RMSE
None/mild 0.7272 0.7272 0.073 0.6932 0.085 0.7155 0.061
Moderate 0.6501 0.6475 0.071 0.6481 0.079 0.6507 0.053
Severe 0.5634 0.564 0.068 0.5777 0.076 0.5676 0.051
TABLE 47 Summary performance statistics: response-level mapping models (IAPT)
Independent variables Observed SF-6D
Predicted SF-6D
PHQ-9 GAD-7 CORE items
Mean 0.6193 0.6631 0.5672 0.6783
SD 0.126 0.073 0.009 0.067
Minimum 0.301 0.558 0.559 0.555
Maximum 0.929 0.813 0.587 0.888
RMSE 0.084 0.103 0.089
SF-6D range SF-6D PHQ-9 RMSE GAD- 7 RMSE CORE items RMSE
< 0.4 0.3610 0.5858 0.225 0.5593 0.198 0.6054 0.244
0.4–0.499 0.4690 0.6165 0.148 0.5626 0.094 0.6145 0.146
0.5–0.599 0.5587 0.6217 0.066 0.5634 0.023 0.6431 0.086
0.6–0.699 0.6386 0.6768 0.057 0.5676 0.071 0.6955 0.063
0.7–0.799 0.7444 0.7173 0.053 0.5736 0.171 0.7281 0.044
0.8–1 0.8552 0.7443 0.111 0.5766 0.279 0.7594 0.096
PHQ-9 cut-offs SF-6D PHQ-9 RMSE GAD- 7 RMSE CORE items RMSE
None/mild 0.7272 0.7567 0.087 0.5765 0.161 0.7416 0.077
Moderate 0.6501 0.6929 0.083 0.5701 0.105 0.7029 0.083
Severe 0.5634 0.6133 0.083 0.5623 0.080 0.6429 0.097
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Ordinary least squares regression results
























0.8659* (0.041) 0.8638* (0.059) 1.0264* (0.059) 1.1872* (0.073)
Observations 286 286 286 286 286
R2 0.161 0.133 0.065 0.156 0.193
Adjusted R2 0.155 0.130 0.062 0.153 0.187
RMSE 0.194 0.198 0.212 0.194 0.188
SE, standard error.
* p < 0.01.
TABLE 49 Regression analysis: EQ-5D and HADS (POPMACT)
OLS
variables








HADS-D –0.0245* (0.003) –0.0323* (0.003)
HADS-A –0.0168* (0.004) –0.0319* (0.003)
HADS-T –0.0210* (0.002)
Constant 1.0161* (0.048) 0.8663* (0.035) 0.9554* (0.050) 1.0366* (0.045)
Observations 475 475 475 475
R2 0.242 0.212 0.155 0.240
Adjusted R2 0.239 0.210 0.154 0.238
RMSE 0.227 0.233 0.245 0.228
SE, standard error.
* p < 0.01.
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and -A + age (SE)
HADS-D −0.0107* (0.001) −0.0118*
(0.001)
−0.0110* (0.001)
HADS-A −0.0048* (0.001) −0.0079* (0.001) −0.0050* (0.001)
HADS-T −0.0081* (0.001)
Age −0.0008* (0.000)
Constant 0.7945* (0.019) 0.7437*
(0.013)
0.7229* (0.020) 0.8095* (0.018) 0.8355* (0.023)
Observations 286 286 286 286 286
R2 0.305 0.273 0.094 0.283 0.326
Adjusted R2 0.301 0.271 0.0909 0.280 0.319
RMSE 0.059 0.061 0.067 0.059 0.057
SE, standard error.
* p < 0.01.
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SF-6D PHQ-9 items (significant
variables) (SE)
PHQ-9 total −0.0108*** (0.001)
Little interest −0.0583*** (0.021) −0.0546*** (0.019)
−0.0638** (0.025) −0.0536** (0.021)
−0.0974*** (0.028) −0.0832*** (0.023)
Feeling down 0.0003 (0.027)
0.0155 (0.029)
0.0248 (0.031)
Sleep problems −0.0190 (0.022)
−0.0358 (0.023)
−0.0169 (0.023)
Tired −0.0034 (0.024) −0.0101 (0.023)
−0.0343 (0.025) −0.0392* (0.024)
−0.0681*** (0.025) −0.0702*** (0.024)
Eating problems 0.0082 (0.017)
0.0083 (0.017)
0.0134 (0.017)
Felt bad about self 0.0477*** (0.017) 0.0483*** (0.016)
0.0105 (0.020) 0.0184 (0.019)
0.0263 (0.020) 0.0364* (0.019)
Trouble concentrating −0.0243 (0.018) −0.0271 (0.017)
−0.0476** (0.020) −0.0469** (0.019)








0.0230* (0.013) 0.0219* (0.013)
0.0183 (0.015) 0.0186 (0.015)
−0.0209 (0.019) −0.0188 (0.019)
Affected activities −0.0506** (0.020) −0.0536*** (0.018)
−0.0951*** (0.023) −0.0975*** (0.022)
−0.1530*** (0.026) −0.1527*** (0.024)
Constant 0.7878*** (0.012) 0.8026*** (0.026) 0.7967*** (0.023)
Observations 394 394 394
R2 0.364 0.516 0.508
Adjusted R2 0.362 0.476 0.484
RMSE 0.078 0.070 0.070
SE, standard error.
***p < 0.01; **p < 0.05; *p < 0.1.
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SF-6D GAD-7 items (significant variables)
(SE)
GAD-7 total −0.0118*** (0.001)
Anxious/nervous −0.0782*** (0.028) −0.0790*** (0.027)
−0.0925*** (0.031) −0.0957*** (0.030)
−0.1057*** (0.032) −0.1115*** (0.031)
Uncontrollable
worry
−0.0075 (0.030) 0.0013 (0.025)
0.0130 (0.035) 0.0187 (0.027)
−0.0390 (0.040) −0.0286 (0.028)
Worry too much 0.0224 (0.037)
0.0181 (0.041)
0.0358 (0.045)






Irritable −0.0416* (0.024) −0.0341 (0.023)
−0.0608** (0.026) −0.0587** (0.024)




Affected activities 0.0033 (0.025) −0.0034 (0.024)
−0.0563** (0.028) −0.0664** (0.026)
−0.0907*** (0.031) −0.1032*** (0.029)
Constant 0.7777*** (0.014) 0.8025*** (0.031) 0.8008*** (0.026)
Observations 394 394 394
R2 0.273 0.383 0.371
Adjusted R2 0.271 0.342 0.351
RMSE 0.085 0.079 0.080
SE, standard error.
***p < 0.01; **p < 0.05; *p < 0.1.
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SF-6D PHQ-9 and GAD-7 items
(significant variables) (SE)
PHQ-9 total −0.0086*** (0.001)
GAD-7 total −0.0038*** (0.001)
Little interest −0.0549*** (0.020) −0.0490*** (0.018)
−0.0559** (0.023) −0.0483** (0.021)
−0.0824*** (0.025) −0.0746*** (0.023)
Sleep problems −0.0193 (0.022)
−0.0374 (0.023)
−0.0149 (0.023)
Tired −0.0012 (0.024) −0.0112 (0.022)
−0.0284 (0.025) −0.0397* (0.023)
−0.0638** (0.025) −0.0704*** (0.024)
Eating problems 0.0027 (0.017)
0.0101 (0.017)
0.0103 (0.017)
Felt bad about self 0.0425** (0.017) 0.0446*** (0.016)
0.0132 (0.019) 0.0182 (0.018)
0.0312 (0.019) 0.0373** (0.019)
Trouble concentrating −0.0180 (0.018) −0.0238 (0.017)
−0.0330 (0.020) −0.0377** (0.018)
−0.0513** (0.021) −0.0478** (0.019)
Slow movement/speech 0.0035 (0.013)
0.0147 (0.016)
0.0051 (0.019)
Suicidal/self-harm thoughts 0.0235* (0.013) 0.0229* (0.013)
0.0171 (0.015) 0.0186 (0.015)
−0.0184 (0.019) −0.0144 (0.018)
Affected activities −0.0382* (0.020) −0.0417** (0.018)
−0.0790*** (0.023) −0.0801*** (0.022)
−0.1317 *** (0.026) −0.1341*** (0.025)
Anxious/nervous −0.0517** (0.022) −0.0493** (0.021)
−0.0583** (0.024) −0.0554** (0.023)








NIHR Journals Library www.journalslibrary.nihr.ac.uk












Constant 0.8037*** (0.014) 0.8364*** (0.029) 0.8303*** (0.026)
Observations 394 394 394
R2 0.376 0.538 0.524
Adjusted R2 0.373 0.487 0.497
RMSE 0.077 0.067 0.068
SE, standard error.
***p < 0.01; **p < 0.05; *p < 0.1.







CORE-OM mean −0.0099* (0.001)
CORE-OM functioning −0.0086 (0.011)
CORE-OM risk 0.0101 (0.008)




Constant 0.8165* (0.014) 0.8453* (0.016) 0.8263* (0.014)
Observations 394 394 394
R2 0.373 0.418 0.409
Adjusted R2 0.372 0.412 0.407
RMSE 0.077 0.075 0.075
SE, standard error.
* p < 0.01.
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TABLE 55 Regression analysis results: SF-6D and CORE-OM items (IAPT)
Dimensions Items (item number below) SF-6D CORE items (SE) SF-6D CORE significant items (SE)
Well-being Felt OK 0.0415** (0.017) 0.0385*** (0.013)
4 0.0603*** (0.021) 0.0558*** (0.016)
0.0705*** (0.027) 0.0643*** (0.021)
0.0368 (0.034) 0.0490* (0.027)
Felt like crying 0.0260 (0.025) 0.0439** (0.022)
14 0.0255 (0.022) 0.0337* (0.020)
−0.0070 (0.023) 0.0045 (0.020)
−0.0111 (0.025) 0.0023 (0.020)








Symptoms Tense/anxious −0.0251 (0.020) −0.0312* (0.016)
11 −0.0434** (0.020) −0.0429*** (0.016)
−0.0816*** (0.023) −0.0713*** (0.016)
−0.1089*** (0.026) −0.0988*** (0.018)
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TABLE 55 Regression analysis results: SF-6D and CORE-OM items (IAPT) (continued )









Physical problems (pains/aches) −0.0383** (0.017) −0.0454*** (0.014)
8 −0.0694*** (0.017) −0.0591*** (0.014)
−0.0873*** (0.016) −0.0882*** (0.014)
−0.1370*** (0.016) −0.1373*** (0.013)

























DOI: 10.3310/hta18340 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 34
173
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Brazier et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TABLE 55 Regression analysis results: SF-6D and CORE-OM items (IAPT) (continued )
Dimensions Items (item number below) SF-6D CORE items (SE) SF-6D CORE significant items (SE)




Felt able to cope 0.0211 (0.016) 0.0148 (0.014)
7 0.0006 (0.017) 0.0005 (0.015)
0.0007 (0.021) 0.0081 (0.019)
0.0711*** (0.025) 0.0704*** (0.020)
Happy with actions 0.0061 (0.018) 0.0045 (0.014)
12 0.0522** (0.020) 0.0551*** (0.016)
0.0173 (0.025) 0.0213 (0.020)
0.0437 (0.028) 0.0272 (0.023)




















Been irritable −0.0292 (0.024) −0.0307 (0.020)
29 −0.0580** (0.024) −0.0624*** (0.020)
−0.0363 (0.024) −0.0434** (0.020)
−0.0124 (0.027) −0.0301 (0.022)
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TABLE 55 Regression analysis results: SF-6D and CORE-OM items (IAPT) (continued )
Dimensions Items (item number below) SF-6D CORE items (SE) SF-6D CORE significant items (SE)
















Felt threatened 0.0438** (0.018) 0.0399*** (0.015)
22 0.0363 (0.023) 0.0390** (0.018)
0.0223 (0.026) 0.0112 (0.020)
0.0084 (0.036) −0.0045 (0.028)
Constant 0.7671*** (0.051) 0.6885*** (0.030)
Observations 394 394
R2 0.714 0.609
Adjusted R2 0.576 0.574
RMSE 0.054 0.062
SE, standard error.
***p < 0.01; **p < 0.05; *p < 0.1.
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Appendix 4 Chapter 5 appendices
TABLE 56 Keyword search strategies
First iteration searches




4. 1 or 3 or 2
5. quality of life.ti.




4. 1 or 3 or 2
5. exp Mental Disorders/
6. 4 or 5
7. quality of life.ab,ti.
8. "Quality of Life"/
9. 8 or 7
10. 6 and 9
11. qualitative research/
12. qualitative.tw.
13. 11 or 12
14. 10 and 13



























































28. 27 and 22
1. opportunit$.ti.
























































24. 22 or 21 or 23 or
2024 and 19
continued
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Second iteration searches
Multiple database searches (ASSIA, CINAHL, PsycINFO, Web of Science) – QoL terms, January 2010
ASSIA
((TI=(mental health)) or(TI=(mental$ ill$)) or
(TI=(mental$ disorder$))) and(TI=(quality of
life))
(((TI=(mental health)) or(TI=(mental$ ill$) or AB=(mental$ ill$)) or(TI=
(mental$ disorder$) or AB=(mental$ disorder$)) or (DE=("psychiatric
disorders" or "adjustment disorder" or "affective disorders" or
"organic mood syndrome" or "restlessness" or "seasonal affective
disorders" or "akathisia" or "alexithymia" or "anxiety disorders" or
"acute stress disorder" or "combat disorders" or "generalized anxiety
disorders" or "panic disorders" or "nocturnal panic disorder" or
"stage fright" or "phobias" or "acrophobia" or "agoraphobia" or
"animal phobias" or "anthropophobia" or "claustrophobia" or
"dental phobia" or "dysmorphophobia" or "erotophobia" or "school
phobia" or "snake phobia" or "social phobia" or "spider phobia" or
"weight phobia" or "posttraumatic stress disorder" or "chronic
posttraumatic stress disorder" or "combat related posttraumatic stress
disorder" or "postabortion syndrome" or "separation anxiety" or
"childhood separation anxiety" or "attachment disorders" or
"behaviour disorders" or "attention deficit disorder" or "attention
deficit hyperactivity disorder" or "compulsive buying" or "compulsive
foraging behaviour" or "conduct disorders" or "disruptive behaviour
disorders" or "head banging" or "oppositional defiant disorder" or
"cenesthopathy" or "character disorders" or "chronic psychiatric
disorders" or "communication disorders" or "autism" or "infantile
autism" or "selective mutism" or "confusional states" or "conversion
disorder" or "delusional disorders" or "capgras syndrome" or "cotard
s syndrome" or "fregoli syndrome" or "litigious delusional disorders"
or "demonomania" or "cacodemonomania" or "emotional disorders"
or "impulse control disorders" or "insanity" or "koro" or "mania" or
"hypomania" or "mass psychogenic illness" or "mental illness" or
"neuroticism" or "psychoticism" or "movement disorders" or
"neuroleptic malignant syndrome" or "neuroses" or
"depersonalization disorder" or "dissociative disorders" or
"hypochondriasis" or "neurasthenia" or "obsessive compulsive
neuroses" or "transference neuroses" or "personality disorders" or
"antisocial personality disorder" or "avoidant personality disorders" or
"borderline personality disorder" or "dependent personality" or
"depressive personality disorders" or "gender identity disorder" or
"histrionic personality disorder" or "identity crisis" or "kleptomania"
or "multi impulsive personality disorder" or "multiple personality
disorder" or "narcissistic personality disorder" or "passive aggressive
personality disorder" or "sadistic personality disorder" or "schizotypal
personality disorders" or "selfdefeating personality disorder" or
"pervasive developmental disorders" or "asperger s syndrome" or
"autistic spectrum disorders" or "childhood disintegrative disorder" or
"heller s syndrome" or "rett syndrome" or "pica" or "coprophagia"
or "psychogenic aspects" or "psychogenic polydipsia" or "psychoses"
or "affective psychoses" or "anhedonia" or "bipolar affective
disorder" or "cycloid psychosis" or "depression" or "childhood
depression" or "death depression" or "delusional depression" or
"maternal depression" or "melancholia" or "parental depression" or
"paternal depression" or "postnatal depression" or "refractory
depression" or "vascular depression" or "paranoid states" or
"alcoholic psychoses" or "korsakoff s syndrome" or "mood
incongruent psychoses" or "paranoia" or "querulous paranoia" or
"shared paranoid disorder" or "folie a deux" or "puerperal
psychosis" or "schizophrenia" or "catatonia" or "chronic
schizophrenia" or "paranoid schizophrenia" or "paraphrenia" or
"schizophreniform disorder" or "unipolar disorders" or "psychotic
mood disorders" or "schizoaffective disorder" or "somatoform
disorders" or "body dysmorphic disorder" or "briquet s syndrome" or
"somatization disorders" or "thought disorder"))) and((TI=(quality of
life) or AB=(quality of life)) or(DE="quality of life"))) and((TI=qualitative
or AB=qualitative) or(DE="qualitative research") or(DE="qualitative
methods") or(DE="qualitative data") or(DE="qualitative analysis"))
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Second iteration searches
CINAHL
S6 S4 and S5
S5 TI quality of life
S4 S1 or S2 or S3
S3 TI mental* disorder*
S2 TI mental* ill*
S1 TI mental health
S13 S9 and S12
S12 S10 or S11
S11 (MH "Qualitative Studies+")
S10 TI qualitative or AB qualitative
S9 S5 and S8
S8 S6 or S7
S7 (MH "Quality of Life+")
S6 TI quality of life or AB quality of life
S5 S1 or S2 or S3 or S4
S4 (MH "Mental Disorders+")
S3 TI mental* disorder* or AB mental* disorder*
S2 TI mental* ill* or AB mental* ill*





4. 1 or 2 or 3
5. quality of life.ti.




4. exp mental disorders/
5. 1 or 2 or 3 or 4
6. quality of life.tw.
7. exp "quality of life"/
8. 6 or 7
9. 5 and 8
10. qualitative.tw.
11. qualitative research/
12. 10 or 11
13. 9 and 12
Web of Science
# 6 284 #5 AND #4
# 5 36,217 ti="quality of life"
# 4 44,097 #3 OR #2 OR #1
# 3 5,600 ti="mental* disorder*"
# 2 10,629 ti="mental* ill*"
# 1 28,355 ti="mental health"
# 20 #19 OR #18 Timespan=All Years
# 19 #16 AND #14 Timespan=All Years
# 18 #15 AND #14 Timespan=All Years
# 17 ti=qualitative Timespan=All Years
# 16 ts=qualitative Timespan=1900-2000
# 15 ts=qualitative Timespan=2001-2010
# 14 #13 OR #12 Timespan=All Years
# 13 #11 AND #4 Timespan=All Years
# 12 #5 AND #4 Timespan=All Years
# 11 #9 OR #8 OR #7 OR #6 Timespan=All Years
# 10 ti="mental health" Timespan=All Years
# 9 ts="quality of life" Timespan=1900-1970
# 8 ts="quality of life" Timespan=1971-1980
# 7 ts="quality of life" Timespan=1981-1990
# 6 ts="quality of life" Timespan=1991-2000
# 5 ts="quality of life" Timespan=2001-2010
# 4 #3 OR #2 OR #1 Timespan=All Years
# 3 ts="mental* disorder*" Timespan=All Years
# 2 ts="mental* ill*" Timespan=All Years
# 1 Title=(mental health) Timespan=All Years
Hand-searching and citation searching using key references identified as being of potential relevance through
experts and through first iteration searches.
continued
TABLE 56 Keyword search strategies (continued)
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Third iteration searches
Multiple database searches (ASSIA, CINAHL, MEDLINE, PsycINFO, Web of Science) – quasi or indirectly related
QoL terms, April 2010
ASSIA
(TI=(recovery or (lived experience) or (subjective
experience)) or TI=(coping or adaptation or (life
functioning)) or TI=((life changes) or (life
satisfaction) or wellbeing) or TI=(well being)) and
(TI=((mental health) or (mental$ ill$) or (mental$
disorder$)))
((TI=(recovery or (lived experience) or (subjective experience)) or TI=
(coping or adaptation or (life functioning)) or TI=((life changes) or (life
satisfaction) or wellbeing) or TI=((well being) or lifestyle)) or(AB=
(recovery or (lived experience) or (subjective experience)) or AB=
(coping or adaptation or (life functioning)) or AB=((life changes) or
(life satisfaction) or wellbeing) or AB=((well being) or lifestyle)) or
((DE="recovery") or(DE="personal experiences") or
(DE="experiences") or(DE="life experiences") or(DE="coping") or
(DE="coping strategies") or(DE=("adaptation" or "cognitive
adaptation")) or(DE="adaptability") or(DE="life changes") or(DE="life
changes") or(DE=("wellbeing" or "emotional wellbeing" or "social
wellbeing" or "spiritual wellbeing" or "subjective wellbeing")) or(DE=
("psychological wellbeing" or "sense of coherence")) or
(DE="lifestyle"))) and((TI=(mental health)) or(TI=(mental$ ill$) or AB=
(mental$ ill$)) or(TI=(mental$ disorder$) or AB=(mental$ disorder$)) or
(DE=("psychiatric disorders" or "adjustment disorder" or "affective
disorders" or "organic mood syndrome" or "restlessness" or
"seasonal affective disorders" or "akathisia" or "alexithymia" or
"anxiety disorders" or "acute stress disorder" or "combat disorders"
or "generalized anxiety disorders" or "panic disorders" or "nocturnal
panic disorder" or "stage fright" or "phobias" or "acrophobia" or
"agoraphobia" or "animal phobias" or "anthropophobia" or
"claustrophobia" or "dental phobia" or "dysmorphophobia" or
"erotophobia" or "school phobia" or "snake phobia" or "social
phobia" or "spider phobia" or "weight phobia" or "posttraumatic
stress disorder" or "chronic posttraumatic stress disorder" or "combat
related posttraumatic stress disorder" or "postabortion syndrome" or
"separation anxiety" or "childhood separation anxiety" or
"attachment disorders" or "behaviour disorders" or "attention deficit
disorder" or "attention deficit hyperactivity disorder" or "compulsive
buying" or "compulsive foraging behaviour" or "conduct disorders"
or "disruptive behaviour disorders" or "head banging" or
"oppositional defiant disorder" or "cenesthopathy" or "character
disorders" or "chronic psychiatric disorders" or "communication
disorders" or "autism" or "infantile autism" or "selective mutism" or
"confusional states" or "conversion disorder" or "delusional
disorders" or "capgras syndrome" or "cotard s syndrome" or "fregoli
syndrome" or "litigious delusional disorders" or "demonomania" or
"cacodemonomania" or "emotional disorders" or "impulse control
disorders" or "insanity" or "koro" or "mania" or "hypomania" or
"mass psychogenic illness" or "mental illness" or "neuroticism" or
"psychoticism" or "movement disorders" or "neuroleptic malignant
syndrome" or "neuroses" or "depersonalization disorder" or
"dissociative disorders" or "hypochondriasis" or "neurasthenia" or
"obsessive compulsive neuroses" or "transference neuroses" or
"personality disorders" or "antisocial personality disorder" or
"avoidant personality disorders" or "borderline personality disorder"
or "dependent personality" or "depressive personality disorders" or
"gender identity disorder" or "histrionic personality disorder" or
"identity crisis" or "kleptomania" or "multi impulsive personality
disorder" or "multiple personality disorder" or "narcissistic personality
disorder" or "passive aggressive personality disorder" or "sadistic
personality disorder" or "schizotypal personality disorders" or
"selfdefeating personality disorder" or "pervasive developmental
disorders" or "asperger s syndrome" or "autistic spectrum disorders"
or "childhood disintegrative disorder" or "heller s syndrome" or "rett
syndrome" or "pica" or "coprophagia" or "psychogenic aspects" or
"psychogenic polydipsia" or "psychoses" or "affective psychoses" or
"anhedonia" or "bipolar affective disorder" or "cycloid psychosis" or
"depression" or "childhood depression" or "death depression" or
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Third iteration searches
"delusional depression" or "maternal depression" or "melancholia"
or "parental depression" or "paternal depression" or "postnatal
depression" or "refractory depression" or "vascular depression" or
"paranoid states" or "alcoholic psychoses" or "korsakoff s syndrome"
or "mood incongruent psychoses" or "paranoia" or "querulous
paranoia" or "shared paranoid disorder" or "folie a deux" or
"puerperal psychosis" or "schizophrenia" or "catatonia" or "chronic
schizophrenia" or "paranoid schizophrenia" or "paraphrenia" or
"schizophreniform disorder" or "unipolar disorders" or "psychotic
mood disorders" or "schizoaffective disorder" or "somatoform
disorders" or "body dysmorphic disorder" or "briquet s syndrome" or
"somatization disorders" or "thought disorder"))) and((TI=qualitative
or AB=qualitative) or(DE="qualitative research") or(DE="qualitative
methods") or(DE="qualitative data") or(DE="qualitative analysis"))
CINAHL
S17 S12 and S16
S16 S13 or S14 or S15
S15 TI mental* disorder*
S14 TI mental* ill*
S13 TI mental health
S12 S1 or S2 or S3 or S4 or S5 or S6 or S7 or
S8 or S9 or S10 or S11
S11 TI lifestyle
S10 TI well being
S9 TI wellbeing
S8 TI life satisfaction
S7 TI life change*
S6 TI life functioning
S5 TI adaptation
S4 TI coping
S3 TI subjective experience*
S2 TI lived experience
S1 TI recovery
S30 S21 and S26 and S29
S29 S27 or S28
S28 (MH "Qualitative Studies+")
S27 TI qualitative or AB qualitative
S26 S22 or S23 or S24 or S25
S25 (MH "Mental Disorders+")
S24 TI mental* disorder* or AB mental* disorder*
S23 TI mental* ill* or AB mental* ill*
S22 TI mental health
S21 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11
or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20
S20 (MH "Life Style Changes")
S19 (MH "Life Style")
S18 (MH "Psychological Well-Being")
S17 (MH "Personal Satisfaction")
S16 (MH "Attitude to Life")
S15 (MH "Life Change Events")
S14 (MH "Adaptation, Psychological")
S13 (MH "Coping")
S12 (MH "Life Experiences")
S11 (MH "Recovery")
S10 TI lifestyle or AB lifestyle
S9 TI wellbeing or AB wellbeing or TI well being or AB well being
S8 TI life satisfaction or AB life satisfaction
S7 TI life change* or AB life change*
S6 TI life functioning or AB life functioning
S5 TI adaptation or AB adaptation
S4 TI coping or AB coping
S3 TI subjective experience* or AB subjective experience*
S2 TI lived experience or AB lived experience


























12. Life Change Events/
13. personal satisfaction/
continued
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15. 12 or 14 or 13




17. exp Mental Disorders/
18. mental health.ti.
19. 18 or 16 or 15
20. 19 or 17
21. qualitative research/
22. qualitative.tw.
23. 21 or 22

















15. 12 or 13 or 14






















22. exp mental disorders/
23. 19 or 20 or 21 or 22
24. qualitative.tw.
25. qualitative research/
26. 24 or 25
27. 18 and 23 and 26
Web of Science
# 25 #24 OR #23 OR #22 OR #21 OR #20 OR
#19 OR #18 OR #17 OR #16 OR #15
# 24 #14 AND #10
# 23 #14 AND #9
# 22 #14 AND #8
# 21 #14 AND #7
# 20 #14 AND #6
# 19 #14 AND #5
# 18 #14 AND #4
# 17 #14 AND #3
# 16 #14 AND #2
# 15 #14 AND #1
# 14 #13 OR #12 OR #11
# 13 ti="mental* disorder*"
# 12 ti="mental* ill*"
# 11 ti="mental health"
# 10 ti="well being"
# 9 ti=wellbeing
# 17 #16 AND #15 AND #11 Timespan=2009-2010
# 16 ts=qualitative Timespan=2009-2010
# 15 #14 OR #13 OR #12 Timespan=2009-2010
# 14 ts="mental* disorder*" Timespan=2009-2010
# 13 ts="mental* ill*" Timespan=2009-2010
# 12 ti="mental health" Timespan=2009-2010
# 11 #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR
# 1 Timespan=2009-2010
# 10 ts=wellbeing Timespan=2009-2010
# 9 ts="life satisfaction" Timespan=2009-2010
# 8 ts="life change*" Timespan=2009-2010
# 7 ts="life functioning" Timespan=2009-2010
# 6 ts=adaptation Timespan=2009-2010
# 5 ts=coping Timespan=2009-2010
# 4 ts="subjective experience*" Timespan=2009-2010
# 3 ts="subjective experience" Timespan=2009-2010
# 2 ts="lived experience" Timespan=2009-2010
# 1 ts=recovery Timespan=2009-2010
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Third iteration searches
# 8 ti="life satisfaction"
# 7 ti="life change*"
# 6 ti="life functioning"
# 5 ti=adaptation
# 4 ti=coping
# 3 ti="subjective experience*"
# 2 ti="lived experience"
# 1 ti=recovery
Fourth iteration searches
Hand-searching and citation searching using key references identified as being of potential relevance through
experts and through third iteration searches.
QoL, quality of life.
TABLE 56 Keyword search strategies (continued)
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Studies identified through experts and web searching
No relevant
studies identified
Firdt search iteration Second search iteration Third search iteration Fourth search iteration
Search activity
End of search activity
Link indicating results of
one search activity informing
scope of another search activity
in next search iteration 





































TABLE 57 Summary of qualitative review studies
First author and year
Affiliation
of first
author Country Participants Recruited from Diagnosis/mental health problem












Schizophrenia n = 27; schizoaffective disorder n = 7; bipolar disorder
n = 4; depression n = 9; PTSD n = 4; anxiety disorder n = 4; borderline
personality disorder n = 4; don’t know/no response n = 5
Fisher (1998)210 Nursing Canada n = 24 Acute inpatients Diagnoses included major depression; bipolar disorder; affective
disorder; depression/anxiety; schizoaffective disorder; psychosis;
sociopathic personality disorder





Canada 4 males Poster campaign Schizophrenia or other psychotic disorder

















Outpatients Schizophrenia – DSM-IV diagnostic criteria





Via occupational therapists No diagnosis – ‘enduring mental health problems’
Michalak (2006)207,218 Psychiatry Canada 12 males
23 females
Outpatients and inpatients Bipolar disorder

























































































































































































































































































































































































































































































Appendix 5 Chapter 6 appendices
DRAFT TOPIC GUIDE 4 MARCH 2010
Objectives
l How/if quality of life is affected by mental health difficulties
l To establish the domains of quality of life that are important to people with mental health problems
Introduction
l Introduce self
l Aims: What affects quality of life for people with mental health difficulties?
l Proposed structure of interview (start with own perceptions – warn questions will be deliberately
vague, give reason – will move on to areas highlighted in previous research if not already discussed –
complete and give opinions on current QoL questionnaires)
l Stress that we are interested in what is important to them (not about what is important to quality of life
more generally); there are no right or wrong answers, it is their perspective that we are interested in
l They are not obliged to answer; if they don't want to talk about a subject, to please say so, and will
move on
l They can stop the recording of the interview at any time
l They can stop the interview at any time if they do not wish to continue
l Interview confidential and anything used will be completely anonymous
Interview
SECTION A
Explore quality of life from their own perspective without giving any prompts
Background
Tell me a bit about yourself
l How do they spend their time?
l How is their health (mental and physical)
Quality of Life
What are the things that make life good/bad for you?
l Prompts if primary question does not work (example probing questions, don’t expect to ask
them all)
¢ What is important/unimportant to you?
¢ What would you change to make your life better?
¢ What would make your life worse?
¢ Has anything stopped/enabled you doing the things you want to do?
¢ Has there been a time in your life when you feel your life was better/worse than it is now? What is
it about these times that has made a difference?
¢ What do you think are the most important of the things you have mentioned and why?
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What do you/don't you enjoy?
Mental Health (pick up on anything said in response to above questions – use their terminology when
referring to mental health difficulties)
l Does (their mental health) affect the different areas of their life
l Directly (e.g. symptoms/medication) and/or indirectly (relationships/activities/stigma etc.)
SECTION B
Domains from literature review and EQ-5D and SF-36
Once their own perceptions have been exhausted introduce concepts that research has indicated might be
important to people with mental health difficulties that have not already been explored. Explore how each
helps and hinders. Explore what it is about this aspect of their life that is important to them; give
suggestions if person unable to explain further e.g. Work: being active, meeting people, money,
self-esteem, purpose, structure, routine etc.
Relationships – being with people, having a partner/friends, socialising, support
Work/occupation/study (include voluntary etc.)
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